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Abstract 
Myeloproliferative neoplasms (MPNs) are hyperproliferative disorders affecting the number of 
circulating cells within the peripheral blood. Previous research has identified the same JAK2 point 
mutation in three different MPNs; polycythaemia vera (PV), essential thrombocythaemia (ET) and 
myelofibrosis (MF). The JAK2V617F mutation is thought to be the driver of malignant transformation 
however, elucidating the mechanisms in which one mutation can result in three different cancers is still 
a challenge to researchers. The JAK1/2 inhibitor ruxolitinib has been successfully used to alleviate 
disease-related symptoms and reduce splenomegaly in MPN patients. Furthermore, it has been 
suggested that STAT1, a direct downstream target of JAK2 activation, is the genetic modifier involved in 
the development of the malignant phenotypes, with increased STAT1 activity producing an ET-like 
phenotype, whereas lower STAT1 activity produces a PV-like phenotype. 
This report will investigate the effect of JAK2 inhibition by ruxolitinib on cellular proliferation and 
expression of downstream JAK/STAT targets in PV and ET representative cell lines (SET2 and HEL 
respectively. Cells were treated with 1 µM ruxolitinib and proliferation and cell viability were assessed 
by growth curve analysis, MTS and Trypan Blue assays.  Mass spectrometry was used to identify 
molecules of significance with respect to JAK2 signalling in ET through differential expression upon 
ruxolitinib treatment. Following this, Western Blot and Q-RT-PCR was performed on molecules of 
interest. Ruxolitinib was also investigated as a dual agent alongside IFN-α, a STAT1 activator, and 
fludarabine, a STAT1 inhibitor, to investigate the specific role of STAT1 in both PV and ET and possible 
synergistic effects of two treatments currently used with MPN patients. 
Results show that ruxolitinib had a similar effect on cell proliferation and viability in both SET2 and HEL 
cells. Protein and mRNA expression of known JAK2 downstream signalling targets were shown to be 
downregulated in response to ruxolitinib treatment in SET2 cells and a selection of molecular chaperone 
genes, transcription factors, cell cycle regulators and genes involved in antigen presentation were 
affected by ruxolitinib treatment. Treatment of SET2 and HEL cells with a combination of IFN-α and 
ruxolitinib showed a similar pattern as treatment with ruxolitinib alone with respect to cell proliferation 
and viability, suggesting this combination may not be the most effective treatment for PV and ET. 
Combination treatment of fludarabine and ruxolitinib resulted in a much greater decrease in 
proliferation and viability in both cell lines compared to ruxolitinib treatment alone, proposing a new 
potential treatment combination for this subset of MPNs.   
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1. Introduction 
1.1. Myeloproliferative Neoplasms: An Overview 
Myeloproliferative neoplasms (MPNs) are a group of rare haematopoietic disorders of the bone marrow 
characterised by the increased number of circulating mature myeloid cells (Vardiman, et al., 2009). All 
haematopoietic cells differentiate from one type of blood cell, the haematopoietic stem cell (HSC) 
(Birbrair & Frenette, 2016). These stem cells can undergo asymmetric cell division to produce one stem 
cell and one differentiated cell of either the lymphoid or myeloid lineage (Orkin, 2000). Figure 1 
illustrates the diverse maturation lineages possibly undertaken by HSCs and consequent development of 
differentiated mature haematopoietic cells. 
 
 
Figure 1: Diagram of the haematopoiesis process showing the differentiation and maturation of a haematopoetic stem cell 
into the distinct lineages. Haematopoetic stem cells can divide by asymmetric division and produce one stem cell and one cell 
destined to differentiate into a mature cell of one of the haematopoetic lineages; myeloid or lymphoid progenitors. Further 
differentiation and maturation of progenitor cells produces a wide range of mature haematopoetic cells with various functions 
in the innate and adaptive immune response, thrombosis and oxygen transportation. (OpenStax College, 2013).  
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As the name suggests, MPNs are proliferative disorders of cells within the myeloid lineage. MPNs are 
sub-divided into two types: classical MPNs and non-classical MPNs, with the latter affecting a smaller 
population of people. Classical MPNs include chronic myeloid leukaemia (CML), polycythaemia vera 
(PV), essential thrombocythemia (ET) and myelofibrosis (MF) (Tefferi & Vardiman, 2008). CML is a 
disorder resulting in the unregulated growth of granulocytes (neutrophils, eosinophils and basophils) 
within the myeloid linage and their subsequent accumulation within the bone marrow and peripheral 
blood. Conversely, both PV and ET are hyperproliferative disorders which affect primarily the red blood 
cells and platelets respectively, while MF is the development of scar tissue within the bone marrow 
which inhibits the development and maturation of other haematopoetic cells. MF can be idiopathic 
(primary MF (PMF)) or develop secondary to PV or ET (secondary MF or post-PV/post-ET MF) (Tefferi & 
Vardiman, 2008).  
 
1.2. Philadelphia-chromosome negative MPNs 
Since the discovery of the Philadelphia chromosome (Ph) in myeloid stem cells of CML patients (Nowell 
& Hungerford, 1960), classical MPNs have been further subdivided into Ph+ and Ph-. The Philadelphia 
chromosome is the genetic abnormality relating to the translocation between chromosomes 9 and 22, 
creating a fusion gene (BCR-ABL). This translocation leads to the translation of a mutant tyrosine kinase 
within myeloid stem cells and constituent activation of proliferative signalling. As such, the development 
of therapeutic agents has been targeted to the presence of this mutated protein and success in the 
treatment of CML followed in the form of the small molecule tyrosine kinase inhibitor, Imatinib 
(Buchdunger, et al., 1996). In contrast, the genetic mutations underpinning the development of the 
three Ph- MPNs is more complicated than previously understood, as mutations within JAK, CALR and 
MPL have all been linked to MPN pathogenesis, making it difficult to develop targeted therapeutic 
strategies for these disorders.  
 
The prevalence of PV within the Europe is estimated at 0.4-2.8 per 100,000 people per year while ET and 
MF prevalence is estimated at 0.4-1.7 and 0.1-1 per 100,000 people per year respectively (Moulard, et 
al., 2014). Although these disorders are relatively rare within the population, ET and PV are associated 
with an increased risk of thrombotic events such as heart attack and stroke, which are a major cause of 
early morbidity and mortality (Marchioli, et al., 2005) (Barbui, et al., 2011). Quality of life in patients is 
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drastically decreased due to cytokine-mediated constitutional symptoms including pruritus, headaches 
and fatigue, coupled with symptoms arising from abnormally high numbers of circulating blood cells 
such as splenomegaly and cardiovascular disease. In addition, all three MPNs have the potential to 
progress to acute myeloid leukaemia, due to the underlying nature of the disease or sometimes due to 
treatments for the initial disease (Chen & Mullally, 2014) (Björkholm, et al., 2011). The risk of 
transformation to MF or AML, as a result of clonal evolution of the two disorders, is the cause of the 
majority of deaths associated with MPNs (Marchioli, et al., 2005) and can promote additional symptoms 
such as anaemia and thrombocytopenia, due to fibrosis suppressing the bone marrow function. 
 
The phenotypic relationship between the three Ph- MPNs was first noted by William Dameshek in a 
1951 editorial of Blood, where he commented on the existence of pancytosis and elements of bone 
marrow fibrosis in PV patients, at that time thought to affect the proliferation of erythroid cells only 
(Dameshek, 1951). Advances in molecular and genetic technology have allowed for the better 
understanding of MPN pathology as clonal disorders arising from a multipotent myeloid progenitor 
(Delhommeau, et al., 2007) (Fialkow, et al., 1981). One of the main findings in this field of haematology 
came in 2005 when four independent research groups identified the same point mutation within the 
JAK2 gene in 95% of patients with PV and 50-60% of patients with ET and MF (James, et al., 2005) 
(Kralovics, et al., 2005) (Levine, et al., 2005) (Baxter, et al., 2005). 
  
1.3. The JAK2V617F Mutation 
Janus kinases (JAK) are a family of four non-receptor tyrosine kinases, named JAK1-3 and TYK2. These 
serine-threonine protein kinases transduce extracellular signals following cytokine receptor activation to 
regulate several haematopoietic processes such as cellular proliferation, differentiation, cell migration 
and apoptosis (Wilks, et al., 1991) (Ihle, et al., 1995). JAK proteins are comprised of seven homology 
domains (JH1-7), with the catalytically active domain, JH1, at the C-terminus and a pseudokinase 
domain, JH2, directly following (Kawamura, et al., 1994), as shown in Figure 2A. With respect to JAK2, 
the JH2 domain contains an activation loop which binds to the JH1 catalytic domain to negatively 
regulate the activity of the JAK2 protein (Feng, et al., 1997). Residue V617 is thought to reside within the 
activation loop of the pseudo kinase domain and translocations at this point may disrupt the 
interactions between the JH2 loop and the JH1 catalytic domain, which negatively regulate the protein’s 
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kinase activity. The location of residue 617 and interactions of the wild-type JAK2 the JAK2V617F mutant 
with the JH1 domain are illustrated in Figure 2B and 2C. The V617F mutation leads to constitutively 
active JAK2 and ligand-independent JAK/STAT signalling (Chen & Mullally, 2014). Constituent activation 
of downstream signalling pathways including the RAS/MAPK, P-I3K and Akt pathways have also been 
seen in JAK2V617F-positive cells (James, et al., 2005). As a result, JAK2V617F clones are capable of 
cytokine-independent growth and hypersensitivity to cytokine signals. It is estimated that 25-30% of PV 
and MF patients and 2-4% of ET patients are homozygous for JAK2V617F (Baxter, et al., 2005) (James, et 
al., 2005) (Levine, et al., 2005) (Kralovics, et al., 2005). 
 
Figure 2: Location of the JAK2V617F mutation in relation to the JAK2 gene domains and protein’s tertiary structure. (A) JAK2 
contains seven homology domains including the JH1 kinase domain and JH2 pseudokinase domain. (B) Interaction between JH1 
and JH2 domains of JAK2 occur to inhibit JH1 activation. (C) The X-ray crystal structures of wild-type JH2 and JH2 V617F solved 
by the Hubbard laboratory (Constantinescu, 2014) 
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1.4. JAK2-STAT Signalling 
JAK2 mediates extracellular cytokine signals via Type II receptors, including erythropoietin receptor 
(EpoR), thrombopoietin receptor (TpoR, also known as MPL) and receptors for the granular-macrophage 
colony stimulating factor receptor (GM-CSF), which form homodimers and heterodimers with other 
members of the JAK family and possess varying affinities for cytokine and growth factor ligands (Brooks, 
et al., 2014). The JAK2-STAT signalling pathway is illustrated in the figure below (Figure 3).   
 
 
Figure 3: The JAK2/STAT signalling pathway. JAK/STAT signalling pathway illustrating the transduction of extracellular 
signalling instigated by erythropoietin (EPO). The binding of the EPO ligand to EpoR recruits JAK2 monomers to the intracellular 
domains of the receptor. JAK2 monomers auto-phosphorylate and recruit STAT proteins which are then phosphorylated by the 
active JAK2. STAT proteins activate several other intracellular signalling pathways, including MAPK/ERK and P-I3K pathways. 
STAT proteins also translocate to the nucleus to initiate target gene transcription. SOCS proteins are one of many JAK/STAT 
targets and they function to negatively regulate the activity of JAK proteins. Diagram adapted from (Ostojic, et al., 2012). 
 JAK2  JAK2 
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Upon ligand binding and subsequent receptor dimerization, the Type II receptors’ intracellular domains 
recruit and bind JAK2 proteins. Two JAK2 monomers auto-phosphorylate one another at receptor-borne 
tyrosine residues, resulting in the formation of phosphotyrosine-based docking sites for SH2 domain-
containing targets, such as signal transducers and activators of transcription (STATs) and members of 
the MAPK/ERK pathway (Argetsinger, et al., 2004) (Ihle, et al., 1995). In the case of STAT proteins, JAK2 
causes tyrosine phosphorylation of STAT monomers, which then homo- or heterodimerise with other 
STATs and undergo conformational changes that allow nuclear localisation through the Ran nuclear 
import pathway. STAT dimers then bind to palindromic base sequences within the DNA and 
consequently initiate target gene transcription (Stark & Darnell, 2012) (Hebenstreit, et al., 2005).  
 
This signalling pathway is negatively controlled by suppressors of cytokine signals (SOCS), proteins 
whose gene sequences are targeted by STAT proteins, resulting in a negative feedback loop. SOCS 
proteins bind to active JAK2 monomers and inhibit their catalytic activity (Krebs & Hilton, 2001). SOCS1 
and SOCS3 are negative regulators of the JAK2/STAT pathway (Greenhalgh & Hilton, 2001) and work by 
degrading JAK2 through the E3 ubiquitin ligase ECS complex (Frantsve, et al., 2001) (Ungureanu, et al., 
2002). SOCS1 and SOCS3 directly bind to JAK2’s catalytic domain to inhibit kinase activity (Ungureanu, et 
al., 2002) (Nicholson, et al., 1999) whereas SOCS3 can also indirectly affect JAK2 by binding to cytokine 
receptors such as EpoR (Sasaki, et al., 2000). Since JAK/STAT signalling plays a central role in 
haematopoiesis, dysregulation of this pathway has been implicated in a wide range of haematological 
malignancies such as chronic myeloid leukaemia, T-acute lymphoblastic leukaemia and B-cell leukaemia 
(Tefferi & Vardiman, 2008), with the JAK2V617F mutation being identified in AML, other MPNs and 
myelodysplastic syndromes (James, et al., 2005) (Levine, et al., 2005) (Tono, et al., 2005) (Steensma & 
Tefferi, 2008) (McLornan, et al., 2006).  
 
1.5. Key signalling molecules in the pathogenesis of Ph- MPNs 
Since the JAK2V617F mutation accounts for 95% of PV cases, and 50-60% of ET and MF cases, this 
mutation cannot be assumed as the genetic modifier in the development of these MPNs. It has been 
discovered that the remaining 5% of PV patients exhibit mutations within exon 12 of JAK2, while 
mutations within MPL and CALR account for the majority of non-JAK2 mutant ET and MF cases 
(Passamonti, et al., 2011) (Rumi, et al., 2014) (Rumi, et al., 2013).  
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Myeloproliferative leukaemia protein, encoded by the MPL oncogene, is the receptor for 
thrombopoietin (TPO) which regulates megakaryopoiesis (Kaushansky, 1995). TPO initiates 
megakaryocyte colony forming unit (CFU-MKs) maturation by activation of three major signalling 
pathways: MAPK, P-I3K and JAK/STAT (Rojnuckarin, et al., 1999) (Geddis, et al., 2001) (Drachman, et al., 
1995). Signalling through MPL has been shown to activate JAK2, STAT1, STAT3 and STAT5 (Sattler, et al., 
1995) (Bacon, et al., 1995) (Drachman, et al., 1995). Furthermore, differential expression of STAT1 has 
been observed when comparing PV and ET-like phenotypes in mice models of MPNs and as such, 
increased expression of STAT1 is associated with an ET phenotype (Chen, et al., 2010). Conversely, 
STAT5 has been shown to have a key role in the development of PV-like phenotype in mice models and 
loss of STAT5 expression prevents the development of JAK2V617F+ MPNs (Yan, et al., 2012). STAT5 
phosphorylation is strongly associated with JAK2 activation and signal transduction and research 
demonstrates that constitutive activation of STAT5 in erythroid progenitors induced the formation of 
endogenous (EPO-independent) erythroid colonies (EEC), a hallmark of the PV phenotype but also seen 
in ET patients (Garçon, et al., 2006) (Mondet, et al., 2015).  
 
Calreticulin is a chaperone protein encoded by the CALR gene. The protein functions to prevent the 
export of misfolded proteins from the endoplasmic reticulum (ER) by binding to their N-glycosylated 
sites (Michalak, et al., 2009). Active cytokine receptor are highly N-glycosylated (Royer, et al., 2005) 
(Albu & Constantinescu, 2011) and therefore the association between aberrant MPL and JAK/STAT 
signalling and CALR mutations in the pathogenesis of Ph-MPNs was discovered (Chachoua, et al., 2016). 
Mutant CALR has been shown to induce constituent, ligand-independent activation of the TPO receptor 
MPL, which leads to the direct dimerization of JAK2 and subsequent JAK2/STAT signalling (Chachoua, et 
al., 2016). Overall, dysregulation of the JAK2/STAT pathway is thought to be fundamental for the 
development of Ph-negative MPNs and as such, current therapeutic approaches are moving towards 
JAK2 inhibition.  
 
1.6. Current therapeutic strategies for Ph- MPNs 
At present, the first treatment option for PV patients is phlebotomy, used to decrease the number of 
circulating blood cells and help alleviate symptoms caused by the increased peripheral blood volume. 
However, limitations include no change in the molecular pathogenesis of the disease and the inability to 
15 
 
control pruritus or splenomegaly. Failure of phlebotomy to successfully alleviate symptoms usually 
results in the use of hydroxyurea (HU) therapy, a chemotherapeutic agent used to suppress bone 
marrow function. Use of HU has been linked to an increased risk of progression to leukaemia but is still 
effective at controlling haematocrit and normalising white blood cell counts in patients that need 
cytoreductive therapy (Björkholm, et al., 2011) (Nielsen & Hasselbalch, 2003) (Harrison, et al., 2005) 
(Cortelazzo, et al., 1995). Figure 4 shows the current treatment algorithm for PV, as of this year. 
 
For ET patients, HU is the first-line therapeutic agent, followed closely by anagrelide, a platelet-
modifying drug considered less effective than HU but not associated with risk of leukaemogenesis 
(Barosi, et al., 2013). Interferon therapy may also be used to treat PV and ET (this topic will be discussed 
in greater detail in Section 1.8). PV and ET patients who are resistant or intolerant to HU are considered 
high-risk for the development of complications. High-risk patients also include those over 60 years of 
age and who have a history of thrombotic events or presence of cardiovascular events. Low dose aspirin 
is recommended, particularly in this group to reduce risk of thrombotic complications. Figure 5 shows 
the most recent treatment algorithm for ET. 
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Figure 4: Current treatment algorithm for polycythaemia vera. Flow chart containing information on the current treatment of PV upon differentiating patients into high- and 
low-risk disease based on history of thrombosis and advanced age. (Tefferi, et al., 2018).  
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Figure 5: Current treatment algorithm for essential thrombocythaemia. Flow chart containing information on the current treatment of PV upon differentiating patients into 
high-, intermediate-, low- and very low-risk disease based on history of thrombosis, advanced age and presence of JAK2 or MPL mutations (Tefferi, et al., 2018)  
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1.7. JAK2 Inhibition by Ruxolitinib 
Currently, the small molecule JAK1/2 inhibitor ruxolitinib is being used for the treatment of high-risk PV 
and ET patients with limited success in clinical practice. Ruxolitinib was first approved by the FDA for the 
treatment of MF based on the two COMFORT studies in which the drug has proven to be significantly 
more effective in reducing spleen volume by an average of 32% and improving disease-related 
symptoms by ≥50% in 46% of patients compared to a placebo in which symptom improvement was only 
5% and placebo-treated patients also experienced weight loss and spleen volume increases by 8.1% 
(COMFORT-I) (Verstovsek, et al., 2012). In comparison to best available therapy (BAT)(COMFORT-II) 
(Harrison, et al., 2012), 28% of patients achieved ≥35% reduction in spleen volume when treated with 
ruxolitinib compared to no patients within the BAT group, making ruxolitinib a more effective treatment 
for MF patients who are not suitable candidates for allogenic stem cell transplantation (Harrison, et al., 
2016). Recently, studies have shifted to investigate the use of ruxolitinib in treating PV and ET patients 
who have intolerance or resistance to HU (Verstovsek, et al., 2014) (Verstovsek, et al., 2017) 
(Verstovsek, et al., 2014) (Verstovsek, et al., 2016). These studies show that ruxolitinib successfully 
reduced splenomegaly and improved disease-related symptoms such as pruritus, bone pain and night 
sweats. Haematocrit and platelet count was also reduced in each respective disease (Verstovsek, et al., 
2014) (Verstovsek, et al., 2014).  
 
Ruxolitinib has also been compared to BAT in HU-resistant or intolerant ET patients in the MAJIC trial 
(Harrison, et al., 2017). Results demonstrate that ruxolitinib was not superior to BAT with respect to 
complete or partial haematological response, but was superior with respect to molecular responses, 
which was only seen in ruxolitinib-treated patients. Ruxolitinib treatment is not currently approved for 
the treatment of ET and more research is needed to fully support its use as a routine therapy in ET 
management. With respect to PV, ruxolitinib has been shown to be superior to BAT in reducing 
splenomegaly, controlling haematocrit and improving disease-related symptoms as shown in the 
RESPONSE trials (Vannucchi, et al., 2015) (Verstovsek, et al., 2016) (Verstovsek, et al., 2014). As a result, 
ruxolitinib is the now the second-line therapy in PV after failure of HU (resistance or intolerance) (Barosi, 
et al., 2010) (Barosi, et al., 2009), with its use supported by the RESPONSE studies (Vannucchi, et al., 
2015) (Verstovsek, et al., 2016) (Passamonti, et al., 2017).  
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Despite its clinical success, clonal burden and risk of leukaemic transformation are still unaffected by 
ruxolitinib treatment (Mesa et al, 2016) and many studies also associate its use with an increased risk of 
haematological complications such as anaemia, thrombocytopenia, bleeding and increase risk of 
opportunistic infections (Verstovsek, et al., 2014) (Verstovsek, et al., 2012) (Verstovsek, et al., 2014) 
(Harrison, et al., 2012) (Harrison, et al., 2016), possibly due to adverse immunosuppressive effects 
(Schönberg, et al., 2015) (Yajnanarayana, et al., 2015). Complete remission such as that seen in Ph-
positive CML patients treated with Imatinib is unlikely to be achieved in Ph-negative MPNs and a much 
more complex, multi-target approach may have to be administered. Furthermore, drug resistance and 
reduced sensitivity is also a challenge with prolonged use of JAK2 inhibitors (Koppikar, et al., 2012). If 
new and improved therapeutic strategies are to be developed for malignancies involving mutated JAK2, 
it is important that we gain a more comprehensive understanding of the global cellular signalling and 
the significance of JAK2 signalling in the pathogenesis of MPNs.  
 
1.8. Interferon-alpha therapy in MPNs 
Interferons (IFN) are signalling cytokines made and released by host cells in response to the presence of 
pathogens or tumour cells. Type-I interferons are a class of interferons known to be induced directly by 
viral infections, in contrast to Type-II IFNs which are synthesised after T- and natural killer (NK) cell 
antigen recognition (Welsh, et al., 2012). They play a major role in promoting antigen presentation via 
the upregulation of antigen-presentation genes and consequently induce the activation of T and B cells 
in response to pathogenic or tumour-associated antigens. IFNs also activate NK cells and macrophages 
to destroy infected or transformed cells. IFN-α is a Type-I IFN that activates JAK1 and TYK2, therefore 
recruiting and activating STAT1 and STAT2 (Ivashkiv & Donlin, 2014). IFN-α has been shown to cause 
elongation of the G2 and S phases of the cell cycle to inhibit the proliferation of malignant cells 
(Katayama, et al., 2007) (Yin, et al., 2015). IFN-α is also known to cause cell cycle arrest in the G1 phase 
(Falchi, et al., 2015). Figure 6 shows a selection of anti-tumour mechanisms initiated by IFN-α. 
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Figure 6: Biological mechanisms of interferon-alpha. IFN-α is known to affect several biological processes that contribute to its 
anti-tumour effects in haematological malignancies (Talpaz, et al., 2015) 
 
Interferon alpha-2a (IFN-α) therapy has been used to treat MPNs for more than 30 years (Bellucci, et al., 
1988) (Ludwig, et al., 1985) (Cimino, et al., 1993), however reports of high rates of short-term adverse 
reaction and long-term resistance limited its use to rare cases (Bellucci, et al., 1988) (Kiladjian, et al., 
2011) (Kiladjian, et al., 2008) (Geyer & Mesa, 2014) (Hasselbalch, et al., 2011). The use of IFN-α in the 
treatment of ET was first introduced due to the increasing incidence of ET in young adults, with a slightly 
higher frequency in females (Landgren, et al., 2008). With younger patients needing to receive 
treatment for many years, this increases their risk for treatment-related side effects. In addition, 
pregnancies in women affected by ET may suffer foetal complications due to elevated platelet counts 
such as recurrent abortions, foetal growth restriction, stillbirth and placental abruption and maternal 
complications such as bleeding and thrombotic events (Vantroyen & Vanstraelen, 2002). To reduce 
these complications, the use of antiplatelet drugs or cytoreductive agents is often considered however, 
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there have been controversies regarding the use of hydroxyurea during pregnancy and suggestions of 
potential teratogenic effects (abortion, congenital malformations, intrauterine growth restrictions) 
(Vantroyen & Vanstraelen, 2002). 
 
More recently, the use of IFN-α in treating PV and ET has been reported in multiple studies and phase II 
trials (Bellucci, et al., 1988) (Kiladjian, et al., 2011) (Stein & Tiu, 2013) (Kiladjian, et al., 2008) (Kiladjian, 
et al., 2006) (Quintás-Cardama, et al., 2009). Results of the phase II trials have shown IFN-α to be 
effective in eliminating the risk of thrombotic events, reducing the risk of MF and AML transformation, 
and inducing complete haematological response in 75-95% and complete molecular response in 15-20% 
of participants, marked by an inability to detect JAK2V617F clones (Quintás-Cardama, et al., 2009) 
(Quintás-Cardama, et al., 2013) (Stauffer Larsen, et al., 2013) (Mascarenhas, et al., 2014), overcoming 
known limitations of the JAK2 inhibitor ruxolitinib. IFN-α is the only treatment to date able to induce this 
level of response in such a significant proportion of patients and is currently used to treat younger 
patients based on lack of leukemogenicity (Mesa, et al., 2017) (Vannucchi, et al., 2015). IFN-α has also 
been shown to reduce symptoms and splenomegaly and decrease red blood cell, white blood cell and 
platelet counts in MPN patients (Falchi, et al., 2015).  
 
In consideration of this evidence, IFN-α therapy is not without its downfalls as its use has been 
associated with serious side effects such as risk of depression, exacerbation of autoimmune diseases, 
neuropathy, hypothyroidism, retinitis and myelosuppression (Kiladjian, et al., 2008) (Samuelsson, et al., 
2006) (Gowin, et al., 2012). Toxicity was one major limitation to the use of IFN-α as a viable therapy for 
MPNs, as shown by the phase II trials, and a resulting PEGylated isoform of IFN-α has been synthesised 
which seems to be better tolerated than the previous isoform due to its increased half-life within the 
body. Furthermore, PEGylated IFN-α has been approved by regulating agencies for MPN treatment due 
to its decreased toxicity and has been proven to reduce MPN tumour burden (Kiladjian, et al., 2008) 
(Quintás-Cardama, et al., 2009) (Them, et al., 2015) (Stauffer Larsen, et al., 2013). In comparison to the 
current first-line therapy, there was no significant difference in overall response rate in PV and ET 
patients when comparing PEGylated IFN-2α and HU (Mascarenhas, et al., 2016).  
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Due to PEGylated IFN-α’s continued association with myelosuppression and non-haematologic toxicity 
leading to 15-20% of PV and ET patients discontinuing treatment (Masarova, et al., 2017) (Kiladjian, et 
al., 2008) (Samuelsson, et al., 2006) (Gowin, et al., 2012), a mono-PEGylated isoform (ropeginterferon 
alpha-2b) was synthesised. Advantages of this new isoform include the administration to patients 
decreased to every 2 weeks and that has produced overall response rates of 90% and complete 
molecular response in 21% of patients in the phase I/II PEGIN-VERA study (Gisslinger, et al., 2015).  
Phase III trial comparing ropeginterferon-α 2b to HU showed no significant difference in the two 
therapies in terms of complete haematological response (Gisslinger, et al., 2016) however, it has been 
shown that MPN patients treated with HU have a higher risk of secondary malignancies compared to 
those treated with IFN-α (Hansen, et al., 2017). 
 
The exact mechanism of action of IFN-α is currently unknown, however it appears to involve the 
preferential targeting and depletion of JAK2V617F malignant clones via a direct pro-apoptotic 
mechanism (Kiladjian, et al., 2011) (Chawla-Sarkar, et al., 2003) (Bekisz, et al., 2010) (Gugliotta, et al., 
1989). It is known that Type-I interferons such as IFN-α can inhibit the proliferation of cancer cells and 
increase the cytotoxic activity of NK cells and T-cells (Paul, et al., 2015). As a pleiotropic agent, the 
efficacy of IFN-α is likely due to a multitude of biological properties including enhancing the immune 
system (Biron, 2001) (Burchert, et al., 2010) (Burchert, et al., 2015) and direct effects of the drug on 
malignant stem cells. More recently, the role of inflammation in cancer promotion supports the role of 
IFN-α in MPN therapy (Hasselbalch, 2013). The presence of additional non-driver mutations may result 
in the resistance of JAK2V617F mutants to IFN-α therapy, as reported previously (e.g. TET2 mutations), 
therefore using a combined therapy may be most useful to fully eradicate MPN clones. Despite the 
toxicity of IFN-α, it has been recently shown that MPN patients treated with HU have a greater risk of 
secondary malignancies compared to those treated with IFN-α (Hansen, et al., 2017) however it has 
been speculated that factors such as length of treatment, age and follow up period differences may 
have influenced the outcomes of this report.  
 
1.9. Combination of ruxolitinib and IFN-α in MPN treatment 
There is limited research investigating the effect of a combinational treatment of ruxolitinib and IFN-α 
despite a generous amount of evidence suggesting that both have a significant effect on alleviating 
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disease-related symptoms and improving haematocrit. One case study reported use of the two drugs in 
combination in a PV patient resistant to HU (Bjørn, et al., 2013). The study explains how the patient 
achieved complete haematological remission and normalisation of haematocrit within 4 weeks of 
treatment. 10-month follow up showed the JAK2V617F allele burden was reduced from 90% to 28% 
(Bjørn, et al., 2013) (Bjørn, et al., 2014). Furthermore, the RUXOPeg clinical trial is recruiting patients 
with primary MF to investigate the effects of PEGylated IFN-α 2a in combination with ruxolitinib in PMF 
patients (ClinicalTrials.gov Identifier: NCT02742324). In addition, a recent ad-hoc analysis was published 
comparing ruxolitinib and IFN-2α therapy in PV patients (Kiladjian, et al., 2018). Results indicated that 
ruxolitinib was superior to IFN with respect to haematocrit control and tolerance. Patients initially 
treated with IFN-2α before crossover to ruxolitinib treatment had reduced splenomegaly and improved 
blood counts after crossover. Rates of adverse effects decreased after the crossover, however an 
increase in infections was noted after induction of ruxolitinib (Kiladjian, et al., 2018).The exact 
mechanism by which IFN-α is able to improve disease-related symptoms and quality of life is not yet 
elucidated and evidence suggests that ruxolitinib in combination with IFN-α treatment may be superior 
to single treatment with either agent. A small clinical trial has complimented this theory by evaluating 
the use of IFN-a and ruxolitinib. The results show how patients displayed marked improvements in 
symptoms such as major reductions in splenomegaly and improved haematocrit. The authors suggest 
that combination therapies should be applied in the future (Bose & Verstovsek, 2017). 
 
1.10. Fludarabine treatment in MPNs 
Fludarabine is a STAT1 inhibitor used to treat chronic lymphocytic leukaemia (CLL), AML and some 
subtypes of Hodgkin’s lymphoma (Egle, et al., 2018) (Zhang, et al., 2017) (Jackson, 2004). As an 
adenosine nucleoside analogue, fludarabine works by inhibiting DNA synthesis by competing with dATP 
as an alternative substrate and directly inhibiting DNA polymerases (Chun, et al., 1991) (Brockman, et 
al., 1977). Fludarabine is negatively charged at physiological pH and therefore acts as a pro-drug that is 
dephosphorylated before entering cells by facilitated transport (Barrueco, et al., 1987) (Plunkett, et al., 
1980). Inside the cell, it is then re-phosphorylated to the triphosphate state, which is the major 
intracellular metabolite form of fludarabine and the only known metabolite to have cytotoxic activity. 
Mono- and diphosphate forms also exist in low concentrations within the cells (Ross, et al., 1993) 
(Plunkett, et al., 1993). Fludarabine triphosphate has also been shown to inhibit DNA primase, leading to 
inefficient synthesis of RNA primers required for the initiation of lagging strand synthesis (Catapano, et 
24 
 
al., 1993) (Parker & Cheng, 1987) and ribonuclease reductase, resulting in a reduction of deoxynuclease 
pools within the cell (Parker, et al., 1988). Figure 7 shows the chemical structures of deoxyadenosine, a 
naturally occurring purine, and fludarabine and illustrates the similarities in structure between both 
purine analogues.  
 
Figure 7: Chemical structures of deoxyadenosine and fludarabine. Deoxyadenosine, the naturally occurring purine, and 
fludarabine have chemically similar structures and thus compete for the active sites of many enzymes involved in DNA synthesis 
and replication such as DNA polymerase, DNA primase and ribonuclease reductase. Image from (Sigmond & Peters, 2005). 
 
Fludarabine treatment was approved in the US for medical use in 1991 (Oncology, 1991) and is part of 
the WHO’s List of Essential Medicines, a list of the most effective and safe medicine needed in a health 
system (World Health Organsation, 2015). Fludarabine has been shown to be superior to chlorambucil 
(an alkylating agent) in the treatment of a multitude of haematological malignancies (Leblond, et al., 
2013) (Rai & Hollweg, 2011) (Gandhi & Plunkett, 2002) and is also currently used in combination with 
cyclophosphamide, mitoxantrone, dexamethasone and rituximab (Thompson, et al., 2016) (Zinzani, et 
al., 2015) (Manoukian, et al., 2010) (Ma, et al., 2004). With respect to MPNs, fludarabine has been used 
in the treatment of elderly patients with MF (Matsubara, et al., 2016). Disadvantages of its use include 
side effects such as nausea, fever, pruritus, shortness of breath, with some severe side effects including 
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cytopenia and lung inflammation; some of these symptoms are dissimilar to the MPN symptoms 
themselves (Ding, et al., 2008). 
 
It has been previously reported that fludarabine induces cell cycle arrest and apoptosis and is thought to 
act primarily through p53 activation (Baran-Marszak, et al., 2004). Since STAT1 has been shown to 
interact with p53 (Townsend, et al., 2004), fludarabine is able to inhibit the cytokine-induced activation 
of STAT1 and consequent target gene transcription (Frank, et al., 1999).  
 
1.11. Combination of ruxolitinib and fludarabine in MPN treatment 
Fludarabine has been previously used in combination with busulfan to decrease splenomegaly in 
patients with myeloid malignancies, including MF and AML prior to haematopoetic stem cell 
transplantation as the presence of splenomegaly has been associated with delayed engraftment, graft 
failure and poor survival (Gooptu, et al., 2018) (Khalil, et al., 2018) (Matsubara, et al., 2016). At present, 
there are no studies investigating a direct combinational treatment of ruxolitinib and fludarabine on the 
treatment of any myeloid malignancies, however one study has explored the use of ruxolitinib prior to a 
fludarabine/busulfan conditioning regiment as preparation for haematopoetic stem cell transplantation 
in MF patients. The outcome of this study confirmed that ruxolitinib was able to reduce splenomegaly 
and symptoms prior to conditioning and pre-treatment with ruxolitinib did not appear to negatively 
impact post-transplant outcomes (Gupta, et al., 2016).  
 
1.12. Summary  
To summarise the differences in these hyperproliferative MPNs, Table I outlines the disease phenotypes 
investigated in this study, their current treatment options and the cell lines representative of these 
diseases.   
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Table I: MPN disease phenotype summary information. Information on the MPN disease phenotypes examined in this study, their molecular aberrations and frequency of 
disease in the populations, current treatment options numbered from first-line, low risk treatment option and increasing to high-risk patient options or options for non-responsive 
patients. Details of the cell lines representative of each disease phenotype and pertinent details are also included.  
Type of MPN Molecular aberrations Treatment  Cell line used 
in this study 
Origin of cell line 
Essential 
thrombocythaemia 
JAK2V617F (50-60% of cases) 
MPL exon 10 (3-4% of cases), 
CALR (15-25% of cases) 
nonmutated JAK2/CALR/MPL 
(10% of cases) (Imai, et al., 
2017) (Nangalia, et al., 2013) 
(Rotunno, et al., 2014), 
(Pardanani, et al., 2006) 
(Rumi, et al., 2014) 
1. Aspirin once daily  
2. Aspirin twice daily 
3. Hydroxyurea (HU) and 
aspirin once daily 
4. HU and aspirin twice daily 
5. For HU resistant or 
unresponsive patients: 
pegylated IFN-α or busulfan 
and aspirin daily 
SET2 established from peripheral 
blood of a 71-year old female 
with ET at megakaryoblastic 
transformation, carries 
JAK2V617F mutation 
(Quentmeier, et al., 2006) 
(Uozumi, et al., 2000) 
Polycythaemia vera JAK2V617F (95-96% of cases)  
JAK2 exon 12 mutations (4-
5% of cases) (Rumi, et al., 
2014) 
1. Phlebotomy and aspirin daily  
2. Phlebotomy and aspirin 
twice daily  
3. Phlebotomy and aspirin and 
HU 
4. For HU resistant or 
unresponsive patients: 
ruxolitinib, pegylated IFN-α 
or busulfan and aspirin daily 
HEL established from peripheral 
blood of a 30-year old man 
with erythroleukemia (AML 
M6) in relapse (after 
treatment for Hodgkin 
lymphoma), carries JAK2V617F 
mutation (Quentmeier, et al., 
2006) (Martin & 
Papayannopoulou, 1982) 
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This report will investigate the effects of JAK2 inhibition by ruxolitinib on cell proliferation and 
expression of downstream JAK/STAT signalling targets in ET- and PV-representative cell lines to elucidate 
the role of JAK2 signalling in the pathogenesis of these hyperproliferative MPNs. Ruxolitinib will also be 
used in combination with IFN-α, a STAT1 activator, and fludarabine, a selective STAT1 inhibitor, in both 
cell lines to investigate the role of STAT1 in the pathogenesis of each disease phenotype and identify 
potential molecular advantages of a dual therapy in the treatment of Ph- MPNs.  
 
1.13. Aims and Objectives 
The aims of this study were to investigate the effect of JAK2 inhibition via ruxolitinib on downstream 
signalling targets in cell lines representative of ET and PV (SET2 and HEL respectively) to help 
differentiate between the two disorders. In addition, a combination of ruxolitinib and IFN-α or 
fludarabine was used to investigate the effects of a dual agent therapy compared to ruxolitinib alone 
and evaluate the role of STAT1 in the pathogenesis of MPNs. The global proteome of SET2 cells was also 
investigated to identify key downstream targets of JAK2 which could be of interest to disease 
pathogenesis and progression. This was achieved via several objectives:  
1. Investigate the effects of JAK2 inhibition by ruxolitinib on the proliferation of HEL and SET2 cells 
using MTS proliferation assays, Trypan Blue exclusion assays and growth curves  
2. Examine the effect of ruxolitinib on the expression of downstream signalling targets SET2 cells using 
Q-RT-PCR, Western Blotting and mass spectrometry 
3. Evaluate the effects of IFN-α, a STAT1 activator, and fludarabine, a selective STAT1 inhibitor, as a 
single and dual-agent therapy in combination with ruxolitinib in SET2 and HEL cells and measure the 
effects of combinational treatment on cellular proliferation and viability. 
This report contains 3 hypotheses, as described below:  
1. H0. Ruxolitinib will have no effect on cellular proliferation, viability or expression of downstream 
JAK2 targets in SET2 and HEL cells.   
H1. Ruxolitinib will negatively affect cellular proliferation and viability. Expression of 
downstream JAK2 targets will also be decreased in SET2 and HEL cells treated with ruxolitinib.  
2. H0. The combination of ruxolitinib and IFN-α or fludarabine will have no effect on SET2 and HEL cells 
and will not be superior to ruxolitinib treatment alone with respect to proliferation and viability. 
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H1. Ruxolitinib in combination with IFN-α or fludarabine will have a synergistic effect and be a 
more effective at inhibiting cellular proliferation and decreasing viability in SET2 and HEL cells.  
3. H0. There will be no difference between the two cell lines, SET2 and HEL, in their response to 
ruxolitinib and a combination of ruxolitinib and IFN-α or fludarabine considering cell proliferation 
and viability. 
H1. Treatment with ruxolitinib and dual treatment with IFN-α or fludarabine will have distinct 
cellular responses within SET2 and HEL cells, allowing better insights into the molecular and 
genetic pathogenesis of each disease phenotype.  
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2. Materials and Methods 
All reagents, instrumentation, software and kits were supplied by Thermo Fisher Scientific (Paisley, UK), 
Sigma-Aldrich (Dorset, UK) or Bio-Rad Laboratories Ltd. (Hertfordshire, UK) unless specified otherwise. 
SET2 and HEL cells were incubated in NuAire TripleRed Laboratory Technology incubator 
(Buckinghamshire, UK). All statistical analysis was performed using GraphPad Prism v 7.04 (GraphPad 
Software Inc., California, USA). 
 
2.1. Cell Culture 
All cell culture was performed in a Class II MSC safety cabinet (NuAire LabGard ES NU-540 Class II, Type 
A2 Biosafety Cabinet). All cabinets and equipment were cleaned with 70% (v/v) industrial methylated 
spirits (IMS) made in distilled water prior to use. All cells were cultured at 37°C with 5% CO₂. Ruxolitinib 
and fludarabine powders (Selleckchem.com) were dissolved in sterile DMSO to create a final 
concentration of 25 and 50 mM respectively. Human Recombinant Interferon Alpha (IFN-α) 2A (Stem 
Cell Technologies) powder was dissolved in sterile Dulbecco Phosphate Buffered Saline (DPBS) (Lonza 
BioWhittaker) supplemented with 0.1% FBS to a concentration of 1 mg/ml. From these stock solutions, 
each treatment was further diluted using cell culture media to the required experimental 
concentrations. Cell viability was assessed to be greater than 95% before experiments were set up.  
 
2.1.1. Cell lines and treatments 
The SET2 cell line is a JAK2V617F+ line, established from the peripheral blood of a 71-year-old female 
with essential thrombocythaemia at the megakaryoblastic leukaemic transformation stage. Like the 
SET2 cell line, the polycythaemia vera-representative cell line (human erythroleukemia; HEL) also carries 
the JAK2V617F mutation. This line was established from the peripheral blood of a 30-year-old male with 
acute myeloid leukaemia subtype M6 (erythroleukemia), according to the French American British 
system and World Health Organisation classification. Both cell lines were purchased from DMSZ. SET2 
and HEL cells were treated with 1 µM ruxolitinib and cultured for up to 72 hours to investigate the 
effects of JAK2 inhibition on cell proliferation and viability.  
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1 µM ruxolitinib was chosen as this concentration has shown to have significant effects on cell 
proliferation and gene expression in previous studies (Waibel, et al., 2013) (Mazzacurati, et al., 2015) 
(Meyer, et al., 2015). Furthermore, it has been previously shown that the maximum concentration of 
ruxolitinib detected in the plasma of patients treated with currently licensed doses of ruxolitinib is 1 µM, 
as determined by mass spectrometry (Shilling, et al., 2010). IFN-α was used at a concentration of 1 
µg/ml in this study, whereas current literature shows that at a concentration of 2 µg/ml, the treatment 
is able to inhibit proliferation of HEL cells by 41%  while the number of patient-derived EECs was 
reduced by 90% with this concentration (Verger, et al., 2018). In contrast, an in vivo study of IFN- α use 
report the maximum serum concentration at 0.0186 pg/ml (Costa, et al., 2018). With respect to 
fludarabine, this molecule has previously been used as a synergistic drug to treat patients with relapsed 
leukaemias, including AML, and has been shown to achieve the most significant drug synergism with 
cytarabine at a concentration of 10 µM (Avramis, et al., 1998) (Gandhi, et al., 1998).  
 
2.1.2. Culture of cell lines 
Cell culture media for both cell lines was RPMI 1640 media supplemented with 25 mM HEPES and 2 mM 
L-glutamine (Lonza BioWhittaker), with 100 I.U./ml penicillin and 100 µg/ml streptomycin at 1% (v/v) 
also added to the media. Foetal bovine serum (FBS) (Gibco) was added to SET2 media at a 20% (v/v) 
whereas 10% (v/v) FBS was added to HEL media. Cells were maintained at a concentration of 0.5-1x10⁵ 
cells per ml and both cell lines were grown in suspension culture. After 48 hours of continued growth, or 
when cells reached 80% confluency, a single cell suspension was made, and cells were sub-cultured with 
fresh media.  
 
2.1.3. Assessment of cell viability 
Cell viability was assessed using the trypan blue exclusion assay. The dye is excluded from live cells as 
they possess an intact membrane however, dead cells do not and so take up the dye. Dead cells are 
therefore stained dark blue, which is visible under the microscope. To assess cell viability, a single cell 
suspension was made, and cells were transferred to a 15 ml centrifuge tube. Cells were collected by 
centrifugation at 1200 rpm (257 xg) for 3 minutes using a bench top centrifuge. The supernatant was 
discarded, and cell pellet resuspended in media pre-warmed to 37°C in a water bath. 50 µl cell 
suspension was removed and diluted 1:1 with Trypan Blue dye. 10 µl of this solution was loaded onto a 
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haemocytometer and cells were counted. The number of live and dead cells in the sample were counted 
and an average cell count was determined by the mean cell count of four 1 mm² areas. The total 
number of cells per ml cell suspension was calculated using the following equation: Cell count per ml = 
Average (mean) cell count x 2 (dilution factor with Trypan Blue) x 10⁴.  
 
2.1.4. Assessment of cell proliferation by MTS assay 
SET2 cells were cultured in media containing 1 µM ruxolitinib (referred to as RUX for the remainder of 
this report), 1 µg/ml IFN-α, 1 µM fludarabine (referred to as FLU) or a combination treatment (n=6) 
(1x10⁴ cells/96-well). Cells were incubated at 37°C 5% CO₂ for 72 hours and then MTS assay was 
performed as per the manufacturer’s instructions using CellTitre 96 Aqueous MTS Reagent solution 
(Promega). 20 µl of MTS solution was added to each well and the plate left to incubate at 37°C in the 
dark for 3 hours before absorbance was read at 490 nm using a Synergy HT microplate reader (Vermont, 
USA). Live and dead cell controls and background fluorescence (media only) were also accounted for 
(n=3 for each). 
 
2.2. Mass Spectrometry  
2.2.1. Protein isolation and quantification  
Cell pellets were collected and lysed in lysis buffer containing 0.5 M triethylammonium bicarbonate 
(TEAB), 0.05% SDS, 6.4 mM sodium pyrophosphate (SP) and 1 mM sodium orthovanadate (SO). Samples 
were sonicated twice for 15 seconds with a 15 second incubation on ice between sonication and then 
centrifuged at 21200 xg for 30 minutes. The lysate containing the total protein was removed and 
quantified by BCA assay (Thermo Fisher Scientific). Samples were made in 1:10 dilutions in lysis buffer 
and Pierce BCA Protein assay kit was used in accordance with the manufacturer’s instructions. The plate 
was incubated at 37°C for 10 mins and the absorbance was read at 562 nm using a plate reader using a 
Synergy HT microplate reader (Vermont, USA).   
 
2.2.2. Solution Digestion of Proteins 
10 µg protein from each sample was made up to 15 µL with 100 mM TEAB. Reduction buffer was made 
with 45 µL 240 mM TCEP (pH 8) and 108 µL 120 mM iodoacetamide (IANH₂), and 85 µL of this buffer was 
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added to each sample. Samples were incubated in the dark for 1 hour at room temperature. 10 µL 0.01 
µg/µL Lys-C was added to each sample and left to digest at 37°C for 4 hours. 10 µL 0.05 µg/µL 
Sequencing Grade Modified Trypsin Porcine (Promega) made in TEAB lysis buffer was added to samples 
and left to digest overnight at 37°C.  
 
2.2.3. Peptide Recovery using Harvard Spin Column  
Samples were acidified using 10% trifluoroacetic acid (TFA) and pH measured between 2-3 using pH 
sticks. 96-well Micro Spin Columns (Harvard Apparatus) were used as per the manufacturer’s 
instructions. Briefly, 50% acetonitrile (AcN) constitution buffer was added to the spin columns. Two 
wash steps were performed before samples were loaded onto the columns. Samples were washed 3 
times within the columns and eluted in 80% AcN solution containing 0.1% TFA. Eluted peptides were 
transferred to 1.5 mL Lo-Bind Eppendorf tubes and lyophilized by vacuum centrifugation for 3.5 hours. 
Peptides were reconstituted in 0.1% acetic acid in HPLC-grade water and loaded onto the LC-MS System.  
 
2.2.4. SWATH-MS analysis 
Data-independent acquisition (DIA) Sequential Window Acquisition of all Theoretical Fragment ions 
(SWATH) mass spectrometry was performed using a 5600 TripleTOF mass spectrometer (ABSciex, 
Warrington, UK) and an Eksigent 1D+ Nano LC systems (Eksigent, Dublin, CA). The LC gradient was 
produced using buffer A (2% AcN and 0.1% formic acid in HPLC water) and buffer B (2% water and 0.1% 
formic acid in AcN) with 0.1% iRT peptide samples of a known m/z ratio spiked-in. 3 µL containing 10 µg 
each sample was injected in triplicate and separated with a linear gradient of 2% buffer B to 35% buffer 
B over 180 min at a flow rate of 0.3 μl/min. Spectra autocalibration occurred after acquisition of every 
five samples using dynamic LC–MS and MS/MS acquisitions of 25 fmol β-galactosidase. The mass 
spectrometer was operated in a looped production mode; with the instrument tuned to allow a 
quadrupole resolution of 25 amu per mass selection. 
 
2.2.5. Targeted Data Extraction and Bioinformatics  
Spectral alignment and targeted data extraction of DIA samples were performed with the SWATH 2.0. 
Processing in Peakview (Version 2.2, AB Sciex) using an in-house plasma reference spectral library. 
Resulting SWATH .wiff files were analysed using Markerview (ABSciex). Peptides were identified with 
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99% confidence at a false discovery rate (FDR) below 1% and compared to a pan-human reference 
spectral library for target protein identification. Welch’s t-test was used to detect differences between 
RUX-treated and untreated SET2 samples. The proteomic data set was then ordered by P-value and 
proteins with P-values less than 0.05 and below the FDR were considered for further analysis as this was 
the collection of proteins of interest differentially expressed upon RUX treatment in comparison to 
untreated cells. To identify significantly differentially expressed proteins upon JAK2 inhibition, the 
selected proteins of interest were ordered by fold change and proteins with a fold change>1.5 and 
<1/1.5, when comparing treated samples to untreated samples, were identified. Accession numbers of 
each protein were acquired through Uniprot database and protein-protein interactions were 
determined using the STRING database version 10.2. Volcano plots were produced using GraphPad 
Prism. This workflow allowed us to identify key downstream JAK2 targets which may contribute to the 
ET phenotype in SET2 cells and distinguish potential biomarkers of disease in ET and thus highlight 
future therapeutic targets.  
 
2.3. Western Blotting 
2.3.1. Protein extraction and quantification 
Cell pellets were lysed on ice in lysis buffer containing 50 mM Tris, 150 mM NaCl, 1% NP-40 and 10% 
glycerol with one cOmplete Mini Protease Inhibitor Cocktail tablet (Roche Diagnostics, Mannheim, 
Germany) added per 20 ml lysis buffer. Samples were vortexed briefly before centrifugation at 21130 xg 
for 2 minutes at 4°C. The supernatant containing the protein was then transferred to a clean, chilled 0.5 
mL Eppendorf tube and pellet discarded. Protein was quantified via BCA assay as previously described 
(see Section 2.2.1) 
 
2.3.2. Protein analysis by SDS Polyacrylamide Gel Electrophoresis 
Samples were mixed with 4X NuPAGE LDS sample loading buffer (Invitrogen by Thermo Scientific) in 0.5 
mL Eppendorfs and heated 99°C for 2 minutes on a digital heat block. Two 5-10% Tris-Glycine SDS gels 
were prepared as described previously (Harlow & Lane, 1988). The gels were assembled within the 
electrophoresis tank and the tank filled with SDS running buffer (25 mM Tris, 192 mM Glycine, 0.1% w/v 
SDS). Lysates were loaded onto the gels along with 5 µL Spectra Multicolor Broad Range Protein Ladder 
molecular weight marker (Thermo Fisher Scientific). Proteins were separated by electrophoresis at 100 V 
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for 100 minutes in a Mini-Protean Tetra System electrophoresis tank. Transfer to Trans-Blot Turbo 
Transfer 0.2 µL nitrocellulose membranes was performed using a semi-dry automated transfer system 
(Trans-Blot Turbo Transfer System) as per the manufacturer’s instructions and using Trans Blot Transfer 
Solution (Bio-Rad). Parameters for the automated transfer are as follows: 25 V, 2.5 A, 7 minutes. The 
membrane was blocked for 1 hour at room temperature on a rocker in 5% BSA made in TBS-Tween (20 
mM Tris, 100 mM NaCl, 0.1% Tween, pH 7.5). Primary antibody solution was added to the membrane 
and incubated overnight at 4°C on a rocking platform shaker. Primary antibody concentrations are found 
within Table II.   
 
Table II: Details of Western Blot antibodies used in this report. All primary antibodies were diluted in 2.5% BSA in TBS-Tween.  
Monoclonal 
Primary 
Antibody 
Target 
Dilution Organism 
of origin 
Manufacturer Phosphorylated 
residue 
Antibody 
Clone 
STAT1 1:10,000 Rabbit Cell Signalling Technology - - 
Phospho-
STAT1 
1:1000 Rabbit Cell Signalling Technology Y701 D4A7 
STAT5 1:5000 Rabbit Cell Signalling Technology - - 
HSP70 1:2000 Rabbit Cell Signalling Technology - - 
α-Tubulin  1:10000 Mouse Merck (formerly Sigma 
Aldrich) 
- DM1A 
 
Blots were then washed 5 times for 5 minutes per wash in TBS-Tween. HRP-linked polyclonal secondary 
antibody (Dako) was added at a concentration of 1:10,000 (made in TBS). Incubation of the secondary 
antibody took place at room temperature on a rocking platform shaker for 1 hour. The membrane was 
again washed 5 times for 5 minutes each in TBS-Tween. The Radiance Plus High Sensitivity 
Chemiluminescent HRP Substrate kit (Azure Biosystems) was used as per the manufacturer’s 
instructions, with both kit reagents being mixed at a 1:1 ratio to make the ECL reagent. 0.5 mL reagent 
was then added to the membrane and protein bands were detected using chemiluminescence via the 
ChemiDoc Gel Imaging System. The protein of interest was identified using a molecular weight marker 
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which was run in the first lane of each gel. Densitometry analysis was performed using ImageLab 6.0 
software (Bio-Rad) and showed the relative density of each protein in each sample to quantify the 
expression of target protein. Target protein expression was normalized to the expression of α-tubulin in 
each sample. 
   
2.4. Q-RT-PCR 
2.4.1. RNA Isolation 
Total RNA was isolated from cells using an RNA Mini-Prep kit (Zymo Research) as per the manufacturer’s 
instructions. Briefly, cells were lysed in buffer before being transferred to a spin column and filtered by 
centrifugation. 0.8% (v/v) ethanol was added to the filtrate before being passed through another filtered 
spin column. Samples were washed before incubation with RNAse-Free DNAse (Qiagen) for 15 minutes 
at room temperature. Cells were washed twice, and RNA was eluted in RNAse-free water. The 
concentration of RNA in each sample was measured using a Nanodrop 1000 Spectrophotometer and 
One Viewer software (Thermo Scientific). 
 
2.4.2. RNA to cDNA conversion 
1000 µg RNA from each sample was diluted in nuclease-free water and reverse transcribed using the 
iScript cDNA synthesis kit (Bio-Rad) as per the manufacturer’s instructions. 15 µL isolated RNA was 
mixed with 1 µL MMLV reverse transcriptase (RT) and 4 µL 5x reaction mix containing both oligo(DT) and 
random hexamer primers in 0.2 mL Eppendorf tubes (20 µL total volume). For each sample, a negative 
control was made using 1 µL nuclease-free water in place of the reverse transcriptase. A no-template 
control containing 15 µL RNAse-free water was also made. All samples were placed on a SureCycler 8800 
thermocycler (Agilent Technologies Ltd., Cheadle, UK) with parameters as follows (see Table III). After 
reverse transcription, all samples were stored at -20°C.  
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Table III: Thermal cycler parameters for reverse transcription of RNA. 
RT Step Temperature (°C) Time (minutes) 
Priming 25 5 
Reverse Transcription 46 20 
RT Inactivation 95 1 
Storage 4 ∞ 
 
2.4.3. Q-RT-PCR  
Samples were diluted 1:50 with molecular-grade water and SYBR Green forward and reverse primers 
were made to 10 mM, also with molecular-grade water. Primers were then combined with SensiFast 
SYBR Lo-ROX Master mix (Bioline) at a 1:11 ratio respectively. 5.5 µL of SYBR Green/primer solution was 
added to each well along with 90 µg cDNA (suspended in 4.5 µL) to give a total volume of 10 µL per well. 
Each SYBR Green reaction was performed in duplicate on a 96-well PCR plate. The plate was centrifuged 
at 100 xg for 1 minute before being loaded onto the StepOnePlus Real-Time qPCR System (Applied 
Biosystems). qPCR conditions were input into the StepOne Software (v2.3) and were: 95°C for 10 
minutes then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. A dissociation curve was added to 
each reaction to determine the accuracy of primers used. Dissociation curve parameters were: 95°C for 
15 seconds, 60°C for 1 minute and +0.3°C/second increasing temperature up to 95°C. The cycle 
threshold (CT) values for each sample were normalised to GAPDH CTs and the comparative CT method 
(2-ΔΔCT) was used to calculate the relative quantities of target mRNAs. A list of primer sequences can be 
found in Table IV.  
 
Table IV: List of primer sequences used in this report. Forward and reverse primer sequences used in Q-RT-PCR experiments. 
Gene Primer Sequences (5’-3’) 
STAT1 F: ATCAGGCTCAGTCGGGGAATA 
R: TGGTCTCGTGTTCTCTGTTCT 
STAT3 F: GGTACATCATGGGCTTTATC 
R: TTTGCTGCTTTCACTGAATC 
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STAT5B F: ATGGGACTCAGTAGATCTTG 
R: CTTCAGTAAAACCCATCTTCC 
SOCS1 F: TTTTCGCCCTTAGCGTGAAG 
R: CATCCAGGTGAAAGCGGC 
SOCS3 F: AGCAGCGATGGAATTACCTGGAAC 
R: TCCAGCCCAATACCTGACACAGAA 
HSP90AB1 F: AGAAATTGCCCAACTCATGTCC 
R: ATCAACTCCCGAAGGAAAATCTC 
HSPA8 F: ACCTACTCTTGTGTGGGTGTT 
R: GACATAGCTTGGAGTGGTTCG 
HSPA5B F: CATCACGCCGTCCTATGTCG 
R: CGTCAAAGACCGTGTTCTCG 
HLA-A F: CTTGTAAAGTGTGAGACAGC 
R: CTTCAAGTCACAAAGGGAAG 
CALR F: AGTTCCGGCAAGTTCTACGG 
R: ACAGAGCATAAAAGCGTGCAT 
CANX F: GGCCAAGCATCATGCCATCT 
R: TGATCCAGGTTGAGTTCTGGT 
MCL1 F: TGCTTCGGAAACTGGACATCA 
R: TAGCCACAAAGGCACCAAAAG 
IRF1 F: CTGTGCGAGTGTACCGGATG 
R: ATCCCCACATGACTTCCTCTT 
DDX3X F: ACGAGAGAGTTGGCAGTACAG 
R: ATAAACCACGCAAGGACGAAC 
ISG15 F: CGCAGATCACCCAGAAGATCG 
R: TTCGTCGCATTTGTCCACCA 
TAP-1 F: CTGGGGAAGTCACCCTACC 
R: CAGAGGCTCCCGAGTTTGTG 
GAPDH F: TGCACCACCAACTGCTTAGC 
R: GGCATGGACTGTGGTCATGAG 
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2.5. Statistical Analysis 
Results are presented as mean ± standard deviation (SD). To assess statistical analysis of growth curves 
and Trypan Blue exclusion assays comparing each treatment (ruxolitinib alone and the combination of 
ruxolitinib and IFNα or fludarabine) over 72 hours, a two-way analysis of variance (ANOVA) was 
performed with subsequent Bonferroni post-hoc analysis test. MTS assays comparing ruxolitinib alone 
with untreated cells were analysed by unpaired T-tests, whereas MTS assay results assessing the 
combination of ruxolitinib with IFNα or fludarabine were assessed by one-way ANOVA with Tukey’s 
multiple comparison post-hoc test. For RNA expression analysis by Q-RT-PCR, unpaired T-test were 
performed for 24-hour experiments whereas for 72-hour experiments, two-way ANOVA with 
Bonferroni’s post-hoc test was performed as expression was normalised to the expression of each target 
of untreated cells at 24 hours. Differential protein expression analysed by Western Blot and SWATH-MS 
was also analysed by unpaired T-tests. For mass spectrometry experiments, Welch’s T-test was 
performed for comparison of differential protein expression in SET2 cells upon 24-hour ruxolitinib 
treatment. All of this statistical analysis was performed in GraphPad Prism v5.0. Results were considered 
statistically significant when the P value was less than or equal to 0.05. Stars representing p values are 
indicated as follows: p>0.05 not significant; p<0.05 *; p<0.01 **; p<0.001 ***; p<0.0001.   
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3. Results 
3.1. The effect of 1µM RUX on cellular proliferation and viability 
To investigate the effect of RUX on SET2 and HEL, cells were seeded at a density of 2.5x10⁴ cells/ml in 6-
well plates. Cells were grown in the presence or absence of 1 µM RUX and cultured for a total of 72 
hours at 37°C 5% CO₂. Every 24 hours, a single cell suspension was made and 50 µL was removed for 
counting. Cells were mixed at a 1:1 (v/v) ratio with Trypan Blue and counted as per Section 2.1.3.
 
Figure 8: A) SET2 and B) HEL cells grown in the presence or absence of 1 µM RUX over 72 hours and cells counted at 24-hour 
intervals (n=4). Each point represents the mean of the biological repeats with error bars indicating the standard deviation. Two-
way ANOVA: SET2: p<0.0001. HEL: p=0.0135.  
A 
B 
** 
**** 
** 
**** 
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Figure 8 shows the total number of SET2 and HEL cells at each time point when treated with 1 µM RUX 
or vehicle control (DMSO). The graph illustrates that cellular proliferation is negatively affected by RUX 
treatment in both cell lines. Two-way ANOVA repeated measures analysis of SET2 results shown in 
Figure 8A shows a significant difference in cell proliferation between treated and untreated SET2 cells 
(p<0.0001). A similar pattern was observed with HEL cells in Figure 8B (p=0.0135). Bonferroni multiple 
comparisons analysis indicates no significant differences comparing treated to untreated cells at 24 
hours however a statistically significant difference at 48 and 72 hours was observed in SET2 cells (p<0.01 
and p<0.0001 respectively). In HEL cells, Bonferroni multiple comparison showed the same pattern, with 
no significant difference in cell proliferation at 24 hours but a significant difference at 48 and 72 hours 
(p<0.01 and p<0.0001 respectively).   
 
Alongside the production of growth curves, the sample of cells removed for counting at each time point 
were subject to Trypan Blue exclusion assay to assess cell viability in SET2 and HEL cell treated with 1 
µM RUX. The Trypan Blue data shown below in Figure 9 is coupled with the growth curve data shown in 
Figure 8.  
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Figure 9: A) SET2 and B) HEL cells grown in the presence or absence of 1 µM RUX over 72 hours and cells viability determined 
by Trypan Blue every 24 hours (n=4). Each bar represents the mean of the biological repeats with error bars indicating the 
standard deviation. Two-way ANOVA: SET2: p=0.0001. HEL: p<0.0001.  
 
A 
B 
* **** 
**** 
** **** 
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Trypan Blue exclusion assay results shown in Figure 9 illustrate that the viability of both SET2 and HEL 
cells was decreased with RUX treatment after 24, 48 and 72 hours compared to untreated cells. Two-
way ANOVA repeated measures analysis shows a significant difference in cell proliferation between 
treated and untreated SET2 cells (p=0.0001), shown in Figure 9A. A similar pattern was observed with 
HEL cells in Figure 9B (p<0.0001). Bonferroni multiple comparisons analysis of SET2 results indicates no 
significant differences comparing treated to untreated cells at 24 hours however a statistically significant 
difference was observed at both 48 and 72 hours in SET2 cells (p<0.01 and p<0.0001 respectively). In 
HEL cells, Bonferroni multiple comparison showed a significant decrease in cellular proliferation at all 
three time-points (p<0.05, p<0.0001 and p<0.0001 respectively), suggesting that HEL cells may be more 
sensitive to ruxolitinib treatment.   
 
Cell proliferation was also determined by MTS assay. 1x10⁴ cells were grown in a 96-well plate in the 
presence or absence of 1 µM RUX and cultured for 72 hours at 37°C 5% CO₂.  
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Figure 10: Cell proliferation in A) SET2 and B) HEL cells determined by MTS assay 72 hours post-treatment with 1 µM RUX, 
normalised to untreated controls (n=6 and n=7 respectively). Each bar represents the mean of the biological repeats with error 
bars indicating the standard deviation. Unpaired T-test: SET2: p<0.0001. HEL: p<0.0001. 
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**** 
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Figure 10 shows the percentage proliferation of SET2 and HEL cells treated with 1 µM RUX or VC 
(DMSO), with results normalized to the VC, determined by MTS assay. This experiment shows that 
cellular proliferation is negatively affected by RUX treatment in both SET2 (Figure 10A) and HEL cells 
(Figure 10B). Unpaired T-Tests were performed and show a significant decrease in cell proliferation was 
observed when comparing RUX-treated cells to untreated cells in both cell lines after 72 hours (SET2: 
p<0.0001. HEL: p<0.0001.) 
 
3.2. The effect of 1 µM ruxolitinib on global protein expression in ET  
To investigate the changes in global protein expression upon JAK2 inhibition with RUX, Sequential 
Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra (SWATH-MS) was performed in 
SET2 cells subject to 1µM ruxolitinib treatment and cultured for 24 hours. SWATH-MS generates a digital 
proteomic map of the biological sample is then compared to an existing pan-human database for 
protein identification. SWATH-MS was performed in triplicate on ruxolitinib-treated cells to identify 
molecules of importance to JAK2 with respect to the global signalling pathways in ET. Three biological 
repeats of SET2 cells treated with 1 µM RUX and cultured for 24 hours were processed for SWATH-MS 
analysis, as per Section 2.2. HEL cell samples were not analysed by SWATH-MS due to problems with cell 
viability when conducting this experiment. 
 
During mass spectrometry analysis, 4467 proteins were identified at a 99% confidence and 1% false 
discovery rate. Figure 11 below shows the volcano plot of proteins differentially expressed 24-hours 
after ruxolitinib treatment in SET2 cells and identified through mass spectrometry analysis.  
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Figure 11: Volcano plot of the clustering of differentially expressed proteins in SET2 cells upon treatment with and without 1 
µM RUX for 24 hours, identified by SWATH-MS (n=3). Each plot indicates a different protein identified by mass spectrometry. 
Red dotted lines indicate the cut-off points for the proteins considered up- and downregulated in response to RUX, with fold 
change values of greater than 1.5 and less than 0.667. The horizontal red dotted line indicates the cut-off point for protein 
expression to be significantly altered by RUX treatment, as determined by Welch’s T-test (p<0.05).  
 
To investigate changes in protein expression in SET2 cells in response to RUX treatment, the 4467 
proteins identified to be differentially expressed were stratified to highlight significantly up- and 
downregulated proteins. Upregulated proteins were considered as those with a fold change of greater 
than 1.5 whereas downregulated proteins had a fold change of less than 1/1.5 (0.667) with respect to 
untreated cells. Further stratification was required to select only the proteins with significant changes in 
expression when comparing treated to untreated cells (p<0.05, as determined by Welch’s two-tailed t-
test).  
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Of the 4467 proteins identified to be differentially expressed in response to RUX treatment, 305 proteins 
were recognised as significantly downregulated in response to RUX. A comprehensive list of all 
significantly downregulated proteins, as determined by Welch’s T-test, can be found below in Table V.  
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Table V: List of significantly downregulated proteins in SET2 cells upon 1 µM RUX treatment for 24 hours, detected by SWATH-MS. Details of all significantly downregulated 
proteins in SET2 cells in response to 24hr RUX treatment. Information on the protein and associated UniProt ID, function (as described within the UniProt database), fold change 
and p-values comparing treated to untreated cells, as determined by Welch’s T-test, are included.  
Uniprot 
ID 
Protein 
Identity  
Protein Name Function p-value Fold 
Change 
Q8N0X7 SPG20 Spartin  May be implicated in endosomal trafficking, or microtubule dynamics, or 
both. Participates in cytokinesis 
0.00075 0.663 
Q9Y2K7 KDM2A Lysine-specific demethylase 
2A 
Important in the histone code as it specifically demethylates 'Lys-36' of 
histone H3 
0.04307 0.661 
P46060 RAGP1 Ran GTPase-activating protein 
1 
Converts cytoplasmic GTP-bound RAN to GDP-bound RAN, which is 
essential for RAN-mediated nuclear import and export 
6.75E-
06 
0.66 
Q9UHD1 CHRD1 Cysteine and histidine-rich 
domain-containing protein 1  
Inhibits the kinase activity of ROCK2 and regulates centrosome 
duplication. Also acts as co-chaperone for HSP90. 
7.90E-
05 
0.659 
Q02809 PLOD1 Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 1  
Catalyses the hydroxylation of lysine residues in collagen alpha chains as 
part of a complex with PLOD1, P3H3 and P3H4. Also required for normal 
assembly and cross-linking of collagen fibrils 
0.00059 0.658 
P67809 YBOX1 Nuclease-sensitive element-
binding protein 1 
Regulates splice site selection by binding to splice sites in pre-mRNA. Also 
binds to and stabilizes cytoplasmic mRNA 
1.90E-
07 
0.657 
P62266 RS23 40S ribosomal protein S23  Component of the ribosome, a large ribonucleoprotein complex 
responsible for the synthesis of proteins in the cell  
0.00035 0.657 
Q5UIP0 RIF1 Telomere-associated protein 
RIF1  
Regulates the activity of TP53BP1 that promotes non-homologous end 
joining mediated repair of double stranded DNA breaks in response to 
DNA damage 
3.02E-
06 
0.655 
Q92925 SMRD2 SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin 
subfamily D member 2 
Chromatin remodelling protein involved in complexes to change 
chromatin structure and DNA-histone contacts within the nucleosome 
Also controls the transcriptional activation and repression of chromatin 
remodelling genes 
0.00527 0.655 
Q0VDF9 HSP7E Heat shock 70 kDa protein 14 Component of the ribosome-associated complex (RAC) involved in 
folding or maintaining nascent polypeptides in a folded state 
0.00874 0.653 
O00571 DDX3X ATP-dependent RNA helicase 
DDX3X 
Multifunctional protein involved in several steps of gene expression, for 
example transcription, translation, mRNA maturation and export 
6.78E-
08 
0.651 
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Q13232 NDK3 Nucleoside diphosphate 
kinase 3 
Synthesises nucleoside triphosphates. Also plays a role in haematopoiesis 
by inhibiting granulocyte differentiation and inducing apoptosis 
0.00264 0.651 
Q96SL4 GPX7 Glutathione peroxidase 7  Protects against oxidative DNA damage and double-strand breaks 0.01012 0.651 
P39656 OST48 Dolichyl-
diphosphooligosaccharide--
protein glycosyltransferase 48 
kDa subunit 
Required for efficient N-glycosylation. Essential subunit of the N-
oligosaccharyl transferase (OST) complex 
0.00011 0.65 
Q9BQ67 GRWD1 Glutamate-rich WD repeat-
containing protein 1 
Binds to histones to regulate chromatin dynamics and maintain 
minichromosome loading at replication origins by promoting the opening 
of chromatin 
0.00012 0.65 
O00182 LEG9 Galectin-9  Binds galactosides. Acts as an eosinophil chemoattractant. Also inhibits 
angiogenesis 
0.0402 0.649 
O95456 PSMG1 Proteasome assembly 
chaperone 1 
Chaperone protein which promotes assembly of the 20S proteasome as 
part of a heterodimer with PSMG2 
0.00013 0.648 
Q8IY22 CMIP C-Maf-inducing protein  Plays a role in T-helper 2 signalling 0.00876 0.648 
Q96SB4 SRPK1 SRSF protein kinase 1  Involved in the regulation of splicing and phosphorylation of SR splicing 
factors. Also controls the distribution of splicing factors in the nucleus of 
interphase cells and the reorganization of nuclear speckles during 
mitosis  
0.03978 0.648 
Q9BX40 LS14B Protein LSM14 homolog B Controls mRNA translation 0.00817 0.647 
P57088 TMM33 Transmembrane protein 33 Helps regulate the tubular endoplasmic reticulum (ER) network. 
Suppresses the RTN3/4-induced formation of the ER tubules. Positively 
regulates PERK-mediated and IRE1-mediated unfolded protein response 
signalling 
0.03094 0.647 
P62633 CNBP Cellular nucleic acid-binding 
protein  
Single-stranded DNA-binding protein that specifically binds to the sterol 
regulatory element (SRE). Involved in cholesterol balance in mammalian 
cells by lowering levels of low-density lipoprotein receptor and enzymes 
in the cholesterol biosynthesis pathway 
2.03E-
08 
0.644 
P07919 QCR6 Cytochrome b-c1 complex 
subunit 6, mitochondrial  
Component of the ubiquinol-cytochrome c reductase complex (complex 
III or cytochrome b-c1 complex), which is part of the mitochondrial 
respiratory chain 
0.03901 0.643 
Q15843 NEDD8 NEDD8  Ubiquitin-like protein which plays an important role in cell cycle control 0.04136 0.643 
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Q9UN86 G3BP2 Ras GTPase-activating 
protein-binding protein 2 
Probable scaffold protein that may be involved in mRNA transport 1.30E-
08 
0.642 
Q96KB5 TOPK Lymphokine-activated killer T-
cell-originated protein kinase  
Protein that phosphorylates MAP kinase p38. Seems to be active only in 
mitosis but may also be involved in the activation of lymphoid cells 
0.00957 0.642 
Q8WXE9 STON2 Stonin-2 Adapter protein involved in endocytic machinery and synaptic vesicle 
recycling. May also facilitate the uncoating of clathrin-coated vesicles 
0.02954 0.642 
Q8TDB6 DTX3L E3 ubiquitin-protein ligase 
DTX3L 
E3 ubiquitin-protein ligase which, in association with ADP-
ribosyltransferase PARP9, plays a role in DNA damage repair and in 
interferon-mediated antiviral responses 
0.00061 0.641 
P49327 FAS Fatty acid synthase An acyl carrier protein that catalyses the formation of long-chain fatty 
acids from acetyl-CoA, malonyl-CoA and NADPH 
7.42E-
13 
0.639 
O43156 TTI1 TELO2-interacting protein 1 
homolog  
Involved in the cellular resistance to DNA damage stresses. May 
participate in the proper folding of newly synthesized PIKKs with the TTT 
complex and HSP90. Promotes the maintenance, assembly and 
stabilisation of mTORC1 and 2 complexes which regulate cellular growth 
and survival in response to hormone and nutrient signals 
0.00061 0.638 
Q00341 VIGLN Vigilin Potentially involved in cell sterol metabolism by protecting cells from 
over-accumulating cholesterol 
0.00123 0.638 
Q9UHI6 DDX20 Probable ATP-dependent RNA 
helicase DDX20 
Part of the SMN complex that catalyses the assembly of small nuclear 
ribonucleoproteins (snRNPs), the building blocks of the spliceosome. 
0.00048 0.637 
O60427 FADS1 Fatty acid desaturase 1  Involved in the catalysis of highly unsaturated fatty acids from precursor 
polyunsaturated fatty acids 
0.00378 0.637 
Q14558 KPRA Phosphoribosyl 
pyrophosphate synthase-
associated protein 1 
Seems to play a negative regulatory role in 5-phosphoribose 1-
diphosphate synthesis 
0.0337 0.637 
O94966 UBP19 Ubiquitin carboxyl-terminal 
hydrolase 19 
Deubiquitinating enzyme that regulates the degradation of various 
proteins 
0.02221 0.636 
Q8NHQ9 DDX55 ATP-dependent RNA helicase 
DDX55 
Probable ATP-binding RNA helicase 0.0414 0.636 
P26358 DNMT1 DNA (cytosine-5)-
methyltransferase 1  
Methylates CpG residues. Maintains the methylation pattern in newly 
synthesised DNA strands by associating with DNA replication sites in S 
phase. This is essential for epigenetic inheritance 
7.14E-
06 
0.635 
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O14933 UB2L6 Ubiquitin/ISG15-conjugating 
enzyme E2 L6 
Catalyses the covalent attachment of ubiquitin or ISG15 to other 
proteins. 
1.18E-
05 
0.633 
Q8TB61 S35B2 Adenosine 3'-phospho 5'-
phosphosulfate transporter 1  
Controls the transport of adenosine 3'-phospho 5'-phosphosulfate (PAPS) 
from the cytosol to the Golgi 
0.00077 0.633 
Q99873 ANM1 Protein arginine N-
methyltransferase 1  
The main enzyme that controls the monomethylation and asymmetric 
dimethylation of histone H4 'Arg-4', a specific tag for epigenetic 
transcriptional activation 
0.00014 0.632 
Q99653 CHP1 Calcineurin B homologous 
protein 1  
Calcium-binding protein involved in a number of cellular processes: 
regulation of vesicular trafficking; gene transcription; co-factor in cellular 
pH control; mediates the association between microtubules and 
membrane-bound organelles of the ER and Golgi apparatus; inhibits 
rRNA transcription 
0.00312 0.632 
Q14807 KIF22 Kinesin-like protein KIF22  Involved in spindle formation and subsequent movements of 
chromosomes during mitosis and meiosis by binding to microtubules and 
DNA  
0.05361 0.632 
P55209 NP1L1 Nucleosome assembly protein 
1-like 1  
May be involved in modulating chromatin formation and contribute to 
regulation of cell proliferation. 
0.00017 0.631 
Q9NR30 DDX21 Nucleolar RNA helicase 2 Senses the transcriptional status of RNA polymerase (Pol) I and II. Also 
promotes ribosomal RNA (rRNA) processing and transcription from 
polymerase II (Pol II)  
8.33E-
10 
0.63 
P11940 PABP1 Polyadenylate-binding protein 
1  
Binds the poly(A) tail of mRNA. May be involved in cytoplasmic 
regulatory processes such as pre-mRNA splicing 
1.83E-
06 
0.628 
P56182 RRP1 Ribosomal RNA processing 
protein 1 homolog A 
Plays a critical role in the generation of 28S rRNA. 2.65E-
05 
0.628 
O00232 PSD12 26S proteasome non-ATPase 
regulatory subunit 12 
Component of the 26S proteasome. Important in maintaining protein 
homeostasis by removing proteins whose functions are no longer 
required and moving misfolded or damaged proteins 
0.00094 0.627 
Q5TA45 INT11 Integrator complex subunit 
11  
Involved in the transcription of small nuclear RNA U1 and U2 0.01202 0.627 
Q9NRW3 ABC3C DNA dC-dU-editing enzyme 
APOBEC-3C 
DNA deaminase (cytidine deaminase) that may play a role in the 
epigenetic regulation of gene expression through the process of active 
DNA demethylation 
0.0194 0.627 
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Q6UB35 C1TM Monofunctional C1-
tetrahydrofolate synthase, 
mitochondrial  
Thought to provide the missing metabolic reaction linking the 
mitochondria and the cytoplasm in one-carbon folate metabolism 
4.24E-
07 
0.626 
Q99615 DNJC7 DnaJ homolog subfamily C 
member 7 
Acts as recycling co-chaperone to HSP70 and HSP90 in folding of steroid 
receptors 
0.00248 0.626 
Q9Y314 NOSIP Nitric oxide synthase-
interacting protein 
Negatively regulates nitric oxide production by inducing the translocation 
of NOS1 and NOS3 to the actin cytoskeleton and inhibiting their activity  
0.00625 0.626 
O75607 NPM3 Nucleoplasmin-3  May act as a chaperone 0.0002 0.625 
P46783 RS10 40S ribosomal protein S10 Component of the 40S ribosomal subunit 0.01142 0.621 
Q5PRF9 SMAG2 Protein Smaug homolog 2  Transcriptional repressor protein. Overexpression inhibits the 
transcriptional activities of AP-1, p53/TP53 and CDKN1A 
0.05348 0.619 
P08195 4F2 4F2 cell-surface antigen heavy 
chain 
Required by light chain amino-acid transporters. Involved in the transport 
of large neutral amino acids 
0.0043 0.618 
P12004 PCNA Proliferating cell nuclear 
antigen 
Helps control DNA replication by increasing DNA polymerase delta's 
processability during elongation of the leading strand. Plays a key role in 
DNA repair and damage response pathways 
3.12E-
09 
0.614 
Q01650 LAT1 Large neutral amino acids 
transporter small subunit 1 
Sodium-independent, high-affinity transport of large neutral amino acids. 
Involved in cellular amino acid uptake 
0.04554 0.614 
Q9BVJ6 UT14A U3 small nucleolar RNA-
associated protein 14 
homolog A 
May be required for ribosome biogenesis 0.00106 0.613 
P24941 CDK2 Cyclin-dependent kinase 2 Serine/threonine-protein kinase involved cell cycle control at the point of 
G1-S transition/ Promotes DNA synthesis and regulates G2 progression 
0.0002 0.61 
Q15397 PUM3 Pumilio homolog 3 Inhibits the poly(ADP-ribosyl)ation activity of PARP1 and the degradation 
of PARP1 by CASP3 following genotoxic stress 
0.00032 0.61 
Q9NRN7 ADPPT L-aminoadipate-
semialdehyde 
dehydrogenase-
phosphopantetheinyl 
transferase 
Catalyses the post-translational modification of target proteins by 
phosphopantetheine. 
0.0045 0.609 
P57678 GEMI4 Gem-associated protein 4  Catalyses the assembly of small nuclear ribonucleoproteins (snRNPs), 
essential components of the spliceosome 
0.00788 0.609 
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Q9UKD2 MRT4 mRNA turnover protein 4 
homolog 
Component of the ribosome assembly machinery 7.28E-
05 
0.608 
Q8TF42 UBS3B Ubiquitin-associated and SH3 
domain-containing protein B  
Inhibits the downregulation and degradation of receptor tyrosine kinases 
and promotes the accumulation of activated target receptors on the cell 
surface 
0.01355 0.608 
Q9UNL2 SSRG Translocon-associated protein 
subunit gamma  
Part of a complex that binds calcium to the ER membrane and regulates 
the retention of ER resident proteins 
0.006 0.606 
P78346 RPP30 Ribonuclease P protein 
subunit p30 
Part of the ribonuclease P complex that generates mature tRNA 
molecules by cleaving their 5'-ends 
0.03405 0.606 
P40429 RL13A 60S ribosomal protein L13a Component of the GAIT (gamma interferon-activated inhibitor of 
translation) complex which mediates translation inhibition in the 
inflammation processes 
2.34E-
05 
0.605 
Q13685 AAMP Angio-associated migratory 
cell protein  
Plays a role in angiogenesis and cell migration 0.00096 0.604 
Q9NY61 AATF Protein AATF  General inhibitor of histone deacetylase HDAC1 and therefore involved in 
cell cycle progression 
0.01019 0.604 
P23921 RIR1 Ribonucleoside-diphosphate 
reductase large subunit  
Provides the precursors for DNA synthesis. Catalyses the biosynthesis of 
deoxyribonucleotides from the corresponding ribonucleotides. 
2.10E-
06 
0.602 
Q8NCA5 FA98A Protein FAM98A  Involved in skeletal homeostasis by stimulating PRMT1-induced protein 
arginine methylation 
0.01081 0.601 
Q9HCN4 GPN1 GPN-loop GTPase 1  Small GTPase required for nuclear import of RNA polymerase II  0.01265 0.601 
O95714 HERC2 E3 ubiquitin-protein ligase 
HERC2 
Regulates ubiquitin-dependent retention of repair proteins on damaged 
chromosomes 
0.00069 0.6 
P35625 TIMP3 Metalloproteinase inhibitor 3  Creates a complex with metalloproteinases and binds to their catalytic 
zinc cofactor, irreversibly inactivating them 
0.00443 0.6 
P68402 PA1B2 Platelet-activating factor 
acetylhydrolase IB subunit 
beta  
Inactivates platelet activating factor (PAF) and involved in lipid 
metabolism and positive regulation of macroautophagy 
0.01239 0.598 
Q9NZA1 CLIC5 Chloride intracellular channel 
protein 5  
Inserts into membranes and forms ion channels with poor selectivity. 
May also transport chloride ions 
0.00391 0.597 
Q12899 TRI26 Tripartite motif-containing 
protein 26 
Regulates IFN-beta production and antiviral response downstream of 
pattern-recognition receptors (PRRs). Also encourages nuclear IRF3 
ubiquitination and proteasomal degradation 
0.02327 0.595 
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Q99496 RING2 E3 ubiquitin-protein ligase 
RING2 
Plays a central role in histone code and gene regulation by mediation of 
monoubiquitination of 'Lys-119' of histone H2A (H2AK119Ub)  
0.00108 0.593 
Q13501 SQSTM Sequestosome-1  Receptor required for selective macroautophagy. Bridges the link 
between polyubiquitinated cargo and autophagosomes 
8.36E-
05 
0.592 
P60602 ROMO1 Reactive oxygen species 
modulator 1  
Promotes the production of reactive oxygen species (ROS) necessary for 
cell proliferation. May be involved in the induction of oxidative DNA 
damage and replicative senescence.  
0.01431 0.592 
P46013 KI67 Antigen KI-67 Important in the maintenance of individual mitotic chromosomes 
dispersed in the cytoplasm following nuclear envelope disassembly 
6.42E-
05 
0.591 
Q8WV99 ZFN2B AN1-type zinc finger protein 
2B 
Regulates the translocation and ubiquitin-mediated proteasomal 
degradation of nascent proteins at the ER, controlling protein 
homeostasis 
0.00595 0.591 
P57721 PCBP3 Poly(rC)-binding protein 3 Single-stranded nucleic acid binding protein that binds to oligo dC 0.00417 0.59 
O00566 MPP10 U3 small nucleolar 
ribonucleoprotein protein 
MPP10  
Component of the 60-80S U3 small nucleolar ribonucleoprotein (U3 
snoRNP). Required for cleaving during pre-18S rRNA processing 
0.03856 0.589 
O43716 GATC Glutamyl-tRNA(Gln) 
amidotransferase subunit C, 
mitochondrial  
Promotes the formation of correctly charged Gln-tRNA(Gln) through the 
transamination of misacylated Glu-tRNA(Gln) in the mitochondria during 
mitochondrial translation 
0.02098 0.587 
Q8IWZ3 ANKH1 Ankyrin repeat and KH 
domain-containing protein 1 
May function as a scaffolding protein that associates with the abnormal 
phenotype of leukaemia cells. Isoform 2 is thought to possess 
antiapoptotic effects and regulate caspase activity 
0.00158 0.585 
Q13422 IKZF1 DNA-binding protein Ikaros  Transcription regulator of hematopoietic cell differentiation. Regulates 
transcription through association with both HDAC-dependent and HDAC-
independent complexes. 
0.01651 0.585 
P61289 PSME3 Proteasome activator 
complex subunit 3  
Subunit of the 11S REG-gamma proteasome regulator. Involved in the 
promotion of ubiquitination and proteasomal degradation of p53/TP53, 
resulting in inhibited apoptosis 
2.05E-
06 
0.584 
P52732 KIF11 Kinesin-like protein KIF11  Motor protein required for establishing a bipolar spindle during mitosis 2.96E-
07 
0.583 
Q14331 FRG1 Protein FRG1  May function in the regulation of pre-mRNA splicing or assembly of rRNA 
into ribosomal subunits. 
0.00781 0.583 
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P30305 MPIP2 M-phase inducer 
phosphatase 2  
Dose-dependently induces mitotic progression through its tyrosine 
protein phosphatase activity. Required for G2/M progression during the 
cell cycle 
0.04785 0.583 
P42224 STAT1 Signal transducer and 
activator of transcription 1-
alpha/beta 
Mediates the cellular response to interferons, cytokines and other 
growth factors 
7.36E-
08 
0.582 
O95793 STAU1 Double-stranded RNA-binding 
protein Staufen homolog 1 
Binds double-stranded RNA and tubulin and forms cross-links between 
the cytoskeleton and RNA components to affect the positioning of 
mRNAs and stimulate their translation 
0.00175 0.582 
Q92598 HS105 Heat shock protein 105 kDa  Acts as a nucleotide-exchange factor for HSPA1A and HSPA1B chaperone 
proteins, promoting the release of ADP and stimulating client/substrate 
protein release. Also inhibits HSPA8 and HSC70 activity 
5.07E-
08 
0.581 
Q9UI30 TR112 Multifunctional 
methyltransferase subunit 
TRM112-like protein 
Acts as an activator of both rRNA/tRNA and protein methyltransferases 2.80E-
05 
0.58 
Q9P287 BCCIP BRCA2 and CDKN1A-
interacting protein  
Isoform 2/alpha is particularly important for the regulation of 
microtubule anchoring and stability, and spindle architecture and 
orientation during interphase. May promote cell cycle arrest by 
enhancing the inhibition of CDK2 activity by CDKN1A. 
0.00078 0.58 
Q9H4B7 TBB1 Tubulin beta-1 chain Major component of microtubules 0.00832 0.579 
Q14444 CAPR1 Caprin-1 Regulates the transport and translation of mRNAs of proteins involved in 
proliferation and migration 
4.67E-
10 
0.578 
Q9Y5A9 YTHD2 YTH domain-containing family 
protein 2 
Regulates RNA stability, processing and degradation by binding N6-
methyladenosine (m6A)-containing RNAs 
0.00351 0.575 
P62310 LSM3 U6 snRNA-associated Sm-like 
protein LSm3 
Binds specifically to the 3'-terminal U-tract of U6 snRNA 0.00382 0.574 
Q03518 TAP1 Antigen peptide transporter 1 Involved in the transport of antigens from the cytoplasm to the 
endoplasmic reticulum for association with MHC class I molecules 
0.00089 0.573 
Q9Y3D7 TIM16 Mitochondrial import inner 
membrane translocase 
subunit TIM16 
Regulates ATP-dependent protein translocation into the mitochondrial 
matrix 
0.02513 0.573 
P49005 DPOD2 DNA polymerase delta 
subunit 2  
Component of Pol-delta3 and Pol-delta4 (DNA polymerase 
complexes)and is involved in lagging strand synthesis and repair  
0.00029 0.572 
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Q07864 DPOE1 DNA polymerase epsilon 
catalytic subunit A 
Participates in DNA repair and in chromosomal DNA replication. 0.02186 0.572 
Q5K651 SAMD9 Sterile alpha motif domain-
containing protein 9  
May play a role in the inflammatory response to tissue injury and the 
control of extra-osseous calcification, acting as a downstream target of 
TNF-alpha signalling. May be involved in endosome fusion 
0.05455 0.572 
Q9Y289 SC5A6 Sodium-dependent 
multivitamin transporter 
Transports pantothenate, biotin and lipoate in the presence of sodium 0.01021 0.57 
O14662 STX16 Syntaxin-16  SNARE protein involved in vesicular transport from the late endosomes 
to the trans-Golgi network 
0.02708 0.569 
Q13907 IDI1 Isopentenyl-diphosphate 
Delta-isomerase 1  
Part of the isoprenoid biosynthesis pathway 0.0012 0.568 
P17844 DDX5 Probable ATP-dependent RNA 
helicase DDX5 
Regulates pre-mRNA splicing and transcription. Transcriptional 
coactivator for p53. Also involved in p53’s response to DNA damage and 
apoptosis 
8.81E-
10 
0.567 
P37198 NUP62 Nuclear pore glycoprotein 
p62 
Essential component of the nuclear pore complex. Plays a role in the M 
phase of the cell cycle by regulating centrosome segregation, centriole 
maturation and spindle orientation 
0.01731 0.565 
Q8NB16 MLKL Mixed lineage kinase domain-
like protein 
Pseudokinase that plays a key role in TNF-induced necroptosis, a 
programmed cell death process. 
0.03507 0.565 
P01033 TIMP1 Metalloproteinase inhibitor 1 Forms one-to-one complexes with target metalloproteinases and binds 
to their catalytic zinc cofactor, irreversibly inactivating them 
0.00041 0.564 
Q9NQT8 KI13B Kinesin-like protein KIF13B  Associated with the reorganisation of the cortical cytoskeleton. Regulates 
axon formation 
0.01251 0.562 
O14579 COPE Coatomer subunit epsilon  Cytosolic protein complex that binds to dilysine motifs and reversibly 
associates with Golgi non-clathrin-coated vesicles, which further mediate 
biosynthetic protein transport from the ER, via the Golgi up to the trans 
Golgi network  
0.00031 0.56 
Q6DD88 ATLA3 Atlastin-3  Involved in endoplasmic reticulum tubular network biogenesis 0.01071 0.56 
Q9H2J4 PDCL3 Phosducin-like protein 3 Acts as a chaperone for the angiogenic VEGF receptor KDR/VEGFR2, 
controlling its abundance and inhibiting its ubiquitination and 
degradation. 
0.0002 0.559 
P17813 EGLN Endoglin Vascular endothelium glycoprotein that plays an important role in the 
regulation of angiogenesis. Acts as TGF-beta coreceptor and is involved in 
3.12E-
05 
0.558 
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the TGF-beta/BMP signalling cascade that ultimately leads to the 
activation of SMAD transcription factors  
Q16850 CP51A Lanosterol 14-alpha 
demethylase  
Catalyses C14-demethylation of lanosterol to convert into zymosterol in 
the cholesterol biosynthesis pathway  
3.51E-
05 
0.558 
Q53GQ0 DHB12 Very-long-chain 3-oxoacyl-
CoA reductase 
Catalyses the second of four reactions within the long-chain fatty acids 
elongation cycle 
0.00204 0.558 
Q9NP97 DLRB1 Dynein light chain roadblock-
type 1  
Acts as a motor for the intracellular retrograde motility of vesicles and 
organelles along microtubules 
0.02364 0.557 
Q7Z7L1 SLN11 Schlafen family member 11  Inhibitor of DNA replication that promotes cell death in response to DNA 
damage. Acts as a guardian of the genome by killing cells with defective 
replication 
0.02595 0.554 
Q6PD62 CTR9 RNA polymerase-associated 
protein CTR9 homolog  
Component of the PAF1 complex which has multiple functions during 
transcription by RNA polymerase II. Involved in haematopoiesis and 
histone modification e.g. ubiquitination of histone H2B and methylation 
on histone H3 'Lys-4' 
0.00042 0.553 
Q9NY65 TBA8 Tubulin alpha-8 chain  Major component of microtubules 0.00984 0.552 
Q9UBC5 MYO1A Unconventional myosin-Ia  Involved in directing the movement of organelles along actin filaments 0.01681 0.551 
Q9NVP2 ASF1B Histone chaperone ASF1B  Histone chaperone that facilitates histone deposition, exchange and 
removal during nucleosome assembly and disassembly 
0.00071 0.548 
Q13627 DYR1A Dual specificity tyrosine-
phosphorylation-regulated 
kinase 1A  
Involved in the signalling pathway which regulates nuclear functions of 
cellular proliferation. Also modulates alternative splicing by 
phosphorylating SRSF6 splice factor 
0.00469 0.543 
Q9Y6A5 TACC3 Transforming acidic coiled-
coil-containing protein 3 
Plays a role in the microtubule-dependent coupling of the nucleus and 
the centrosome 
0.0532 0.542 
O75794 CD123 Cell division cycle protein 123 
homolog 
Required for S phase entry of the cell cycle 0.00686 0.541 
Q9UL25 RAB21 Ras-related protein Rab-21  Regulates cell adhesion and migration by regulation of integrin 
internalisation and recycling 
0.01728 0.54 
Q9ULX3 NOB1 RNA-binding protein NOB1  May play a role in mRNA degradation. 8.83E-
05 
0.538 
Q05397 FAK1 Focal adhesion kinase 1  Non-receptor protein-tyrosine kinase that has a critical function in many 
cellular processes, including regulating cell migration, adhesion, 
0.00712 0.537 
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reorganization of the actin cytoskeleton, cell cycle progression, 
proliferation and apoptosis 
P34931 HS71L Heat shock 70 kDa protein 1-
like 
Molecular chaperone involved in a multitude of cellular processes 
including protecting the proteome from stress, folding and transport of 
newly synthesized polypeptides and activates the proteolysis of 
misfolded proteins 
0.01529 0.536 
P98179 RBM3 RNA-binding protein 3 Enhances global protein synthesis at both physiological and mild 
hypothermic temperatures. Promotes the phosphorylation of translation 
initiation factors 
1.22E-
05 
0.527 
Q05639 EF1A2 Elongation factor 1-alpha 2 Promotes GTP-dependent binding of aminoacyl-tRNA to the A-site of 
ribosomes during protein biosynthesis 
0.00667 0.525 
Q92667 AKAP1 A-kinase anchor protein 1, 
mitochondrial  
Binds to type I and II regulatory subunits of protein kinase A and 
stabilises them to the mitochondrial outer membrane. 
0.04689 0.525 
Q9ULW3 ABT1 Activator of basal 
transcription 1  
Could be a novel TATA-binding protein (TBP) which can function as a 
basal transcription activator 
0.05047 0.525 
O75153 CLU Clustered mitochondria 
protein homolog  
Involved in mitochondrial biogenesis. Binds to and regulates the 
transport or translation of mRNAs of nuclear-encoded mitochondrial 
proteins in the cytoplasm 
2.27E-
09 
0.524 
Q5SYB0 FRPD1 FERM and PDZ domain-
containing protein 1  
Involved in protein localisation to membranes and regulates G-protein 
coupled receptor signalling through stabalisation of membrane-bound 
GPSM1 
0.01212 0.524 
Q13283 G3BP1 Ras GTPase-activating 
protein-binding protein 1 
Unwinds partial DNA and RNA duplexes. ATP- and magnesium-dependent 1.18E-
07 
0.522 
P41227 NAA10 N-alpha-acetyltransferase 10  Catalytic subunit of NatA complex which has alpha acetyltransferase 
activity  
0.00863 0.522 
O75494 SRS10 Serine/arginine-rich splicing 
factor 10 
Functions as a repressor of pre-mRNA splicing in its dephosphorylated 
form. Required for splicing repression in M-phase cells and after heat 
shock 
0.00014 0.521 
Q5VWQ8 DAB2P Disabled homolog 2-
interacting protein 
Scaffold protein involved in the reduction of G1 phase cyclin levels, 
resulting in G0/G1 cell cycle arrest. Also involved in multiple intracellular 
processes such as apoptosis, cell survival, angiogenesis, cell migration 
and maturation 
0.05331 0.521 
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Q9Y6H1 CHCH2 Coiled-coil-helix-coiled-coil-
helix domain-containing 
protein 2 
Transcription factor involved in oxygen response. Activates the 
transcription of COX4I2 (cytochrome c oxidase) under hypoxic conditions  
0.00278 0.52 
Q96D46 NMD3 60S ribosomal export protein 
NMD3 
Adapter protein for XPO1/CRM1-mediated export of the 60S ribosomal 
subunit  
0.00603 0.52 
Q9NRZ9 HELLS Lymphoid-specific helicase Required for de novo or maintenance DNA methylation. May be involved 
in the formation and organization of heterochromatin, which 
consequently regulates transcription and mitosis 
0.00462 0.519 
P15104 GLNA Glutamine synthetase Plays an essential role in the metabolism of nitrogen by catalysing the 
condensation of glutamate and ammonia to form glutamine 
3.69E-
06 
0.518 
O75676 KS6A4 Ribosomal protein S6 kinase 
alpha-4  
Required for the mitogen- or stress-induced phosphorylation of the 
CREB1, ATF1 and RELA transcription factors, thus contributes to gene 
activation by histone phosphorylation and regulation of inflammatory 
genes 
0.01988 0.518 
Q9BRT9 SLD5 DNA replication complex GINS 
protein SLD5 
Initiates DNA replication and progression of DNA replication forks 0.00318 0.517 
Q30154 DRB5 HLA class II histocompatibility 
antigen, DR beta 5 chain  
Binds antigens produced as a result of endocytosis of antigen presenting 
cells (APC). Presents these antigens on the cell surface for recognition by 
T-cells 
0.01429 0.516 
O15091 MRRP3 Mitochondrial ribonuclease P 
protein 3  
Removes the 5'-extranucleotides from tRNA precursor via its 
endonucleolytic activity 
0.02412 0.515 
Q9UBV2 SE1L1 Protein sel-1 homolog 1 Important in endoplasmic reticulum-associated degradation (ERAD) and 
involved in ubiquitin-dependent degradation of misfolded ER proteins 
0.0028 0.513 
Q9NVE7 PANK4 Pantothenate kinase 4  Regulates intracellular CoA concentration 0.01189 0.511 
Q969Z3 Mar-02 Mitochondrial amidoxime 
reducing component 2 
As a component of the benzamidoxime prodrug-converting complex 
required to reduce N-hydroxylated prodrugs, such as benzamidoxime 
0.03071 0.511 
Q9H223 EHD4 EH domain-containing protein 
4  
ATP- and membrane-binding protein involved in the control of 
membrane reorganization and tubulation upon ATP hydrolysis. Also 
involved in early endosomal transport 
1.78E-
05 
0.509 
Q13112 CAF1B Chromatin assembly factor 1 
subunit B 
Part of a complex thought to assist in the assembly of histone octamers 
onto replicating DNA, therefore mediating chromatin assembly in DNA 
replication and repair 
0.00149 0.506 
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Q9Y4C8 RBM19 Probable RNA-binding protein 
19  
Plays a role in embryo pre-implantation development 0.03056 0.505 
P49642 PRI1 DNA primase small subunit  Polymerase enzyme that synthesizes small RNA primers for the Okazaki 
fragments that form during DNA replication 
0.0002 0.503 
O94919 ENDD1 Endonuclease domain-
containing 1 protein  
Acts as a DNase and RNase  0.01993 0.499 
Q8IWR0 Z3H7A Zinc finger CCCH domain-
containing protein 7A 
May be a specific regulator of miRNA biogenesis. 0.01438 0.498 
Q96GD4 AURKB Aurora kinase B  Serine/threonine-protein kinase that forms part of the chromosomal 
passenger complex that regulates mitosis 
0.04832 0.496 
P13693 TCTP Translationally-controlled 
tumour protein 
Involved in calcium binding and microtubule stabilization. 9.88E-
07 
0.495 
O95478 NSA2 Ribosome biogenesis protein 
NSA2 homolog  
Involved in the biogenesis and quality control of pre-60S ribosomal 
subunits 
1.17E-
06 
0.493 
Q92643 GPI8 GPI-anchor transamidase Involved in glycolipid biosynthesis by mediating GPI anchoring in the ER 0.00548 0.493 
Q9NYY8 FAKD2 FAST kinase domain-
containing protein 2, 
mitochondrial  
Plays an important role in assembly of the mitochondrial large ribosomal 
subunit  
0.00193 0.492 
Q8WWK9 CKAP2 Cytoskeleton-associated 
protein 2 
Stabilises microtubules. Also involved in regulating p53/TP53-dependent 
aneuploidy and cell death 
0.00197 0.492 
O14802 RPC1 DNA-directed RNA 
polymerase III subunit RPC1  
Largest and catalytic core component of RNA polymerase III which 
synthesizes 5S rRNA and tRNAs. Catalyses the transcription of DNA to 
RNA 
0.00761 0.49 
Q8TDN6 BRX1 Ribosome biogenesis protein 
BRX1 homolog  
Required for biogenesis of the 60S ribosomal subunit 0.00136 0.489 
Q6UW68 TM205 Transmembrane protein 205  Involved in the resistance to cisplatin in cancerous cells 0.0048 0.489 
Q9HA92 RSAD1 Radical S-adenosyl 
methionine domain-
containing protein 1, 
mitochondrial  
May be involved in porphyrin cofactor biosynthesis 0.02223 0.489 
Q16625 OCLN Occludin  Important in the formation and regulation of the tight junction 
paracellular permeability barriers by inducing adhesion when expressed 
in cells lacking tight junctions 
0.03281 0.488 
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O00264 PGRC1 Membrane-associated 
progesterone receptor 
component 1 
Component of a progesterone-binding protein complex  0.00123 0.487 
Q96R06 SPAG5 Sperm-associated antigen 5  Essential mitotic spindle component required for chromosomal 
segregation and alignment, anaphase progression and maintenance of 
spindle pole structure 
0.00762 0.487 
Q8NG66 NEK11 Serine/threonine-protein 
kinase Nek11 
Involved in the G2/M checkpoint response to DNA damage. Controls 
degradation of CDC25A (M-phase inducer phosphate 1). 
0.00269 0.485 
Q9C037 TRIM4 E3 ubiquitin-protein ligase 
TRIM4 
Controls 'Lys-63'-linked polyubiquitination of DDX58 innate immune 
receptor which enhances IFN induction 
0.02397 0.484 
P52292 IMA1 Importin subunit alpha-1  Functions as an adapter protein for nuclear receptor KPNB1, which is 
involved in the Ran nuclear import pathway 
2.27E-
08 
0.482 
Q6NYC1 JMJD6 Bifunctional arginine 
demethylase and lysyl-
hydroxylase JMJD6 
Dioxygenase that regulates RNA splicing by mediating the activity of 
U2AF2/U2AF65 
0.00473 0.482 
Q9NZQ3 SPN90 NCK-interacting protein with 
SH3 domain 
Has an important role in stress fibre formation induced by active 
diaphanous protein homolog 1 (DRF1) 
0.01564 0.479 
O15496 PA2GX Group 10 secretory 
phospholipase A2 
Catalyses the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-
phosphoglycerides 
0.03072 0.479 
P40692 MLH1 DNA mismatch repair protein 
Mlh1  
Heterodimerizes with PMS2 to form MutL alpha which is involved in the 
DNA mismatch repair system 
0.00091 0.477 
P78316 NOP14 Nucleolar protein 14  Involved in pre-18S ribosomal RNA nucleolar processing and nuclear 
export of 40S pre-ribosomal subunits into the cytoplasm 
0.00012 0.476 
P23258 TBG1 Tubulin gamma-1 chain  Major constituent of microtubules. The gamma chain is found at 
microtubule organizing centres (MTOC) such as the spindle poles or the 
centrosome 
0.00201 0.473 
Q99661 KIF2C Kinesin-like protein KIF2C  Forms the major microtubule plus-end depolymerizing complex in mitotic 
cells when in complex with KIF18B. Important in mitosis for the 
regulation of microtubule turnover at the kinetochore and chromosome 
segregation 
0.00044 0.472 
O60566 BUB1B Mitotic checkpoint 
serine/threonine-protein 
kinase BUB1 beta 
Mitotic checkpoint protein required for progression of mitosis 0.00793 0.472 
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P62847 RS24 40S ribosomal protein S24 Critical role in the processing of pre-rRNA and maturation of 40S 
ribosomal subunits 
4.57E-
05 
0.47 
P36639 8ODP 7,8-dihydro-8-oxoguanine 
triphosphatase 
Antimutagenic protein that acts as a sanitising enzyme for oxidized 
nucleotide pools and suppresses cell dysfunction and death-induced 
oxidative stress. Prevents misincorporation of oxidised purine nucleoside 
triphosphates into DNA  
0.00667 0.468 
Q9NUU7 DD19A ATP-dependent RNA helicase 
DDX19A 
Involved in mRNA export from the nucleus 0.01513 0.465 
P51580 TPMT Thiopurine S-
methyltransferase  
Catalyses the S-methylation of thiopurine drugs. TMPT activity modulates 
the cytotoxic effects of thiopurine pro-drugs 
0.0187 0.465 
Q9BYE9 CDHR2 Cadherin-related family 
member 2  
Plays a role in cell-cell adhesion and contact inhibition in epithelial cells 0.04553 0.465 
Q58FF6 H90B4 Putative heat shock protein 
HSP 90-beta 4  
Chaperonin that promotes the maturation, maintenance and regulation 
of target proteins 
0.00076 0.464 
P09486 SPRC SPARC  Interacts with extracellular matrix proteins and cytokines to regulate cell 
growth 
0.04161 0.464 
O75534 CSDE1 Cold shock domain-containing 
protein E1 
RNA-binding protein involved in translationally coupled mRNA turnover 6.51E-
11 
0.463 
Q9H2D6 TARA TRIO and F-actin-binding 
protein  
Directly binds and stabilises filamentous F-actin to regulate actin 
cytoskeleton organization and cell contraction  
0.0002 0.462 
P61619 S61A1 Protein transport protein 
Sec61 subunit alpha isoform 1 
Important in the insertion of secretory and membrane polypeptides into 
the ER. Required for assembly of membrane and secretory proteins. 
0.02559 0.462 
Q9BZL1 UBL5 Ubiquitin-like protein 5  Positively regulates chaperone gene expression in the mitochondrial 
unfolded protein response. Induction of cellular stress promotes the 
accumulation of UBL-5 
6.12E-
10 
0.461 
Q12834 CDC20 Cell division cycle protein 20 
homolog  
Essential to provide full ubiquitin ligase activity within the anaphase 
promoting complex/cyclosome 
0.00028 0.455 
O75843 AP1G2 AP-1 complex subunit 
gamma-like 2 
Involved in protein sorting in late endosomes or multivesicular bodies 0.00718 0.455 
Q49A26 GLYR1 Putative oxidoreductase 
GLYR1 
Putative oxidoreductase that is recruited on chromatin and promotes 
KDM1B demethylase activity  
0.00153 0.454 
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Q9Y5J9 TIM8B Mitochondrial import inner 
membrane translocase 
subunit Tim8 B  
Imports and inserts of multi-pass transmembrane proteins into the l 
inner membrane of the mitochondria 
0.01069 0.454 
Q9BZX2 UCK2 Uridine-cytidine kinase 2  Phosphorylates uridine and cytidine to uridine monophosphate and 
cytidine monophosphate 
0.00515 0.449 
O14653 GOSR2 Golgi SNAP receptor complex 
member 2  
Involved in transport of proteins from the cis/medial-Golgi to the trans-
Golgi network 
0.01577 0.447 
Q8N9F7 GDPD1 Glycerophosphodiester 
phosphodiesterase domain-
containing protein 1 
Involved in the phospholipid metabolic process. Hydrolyses 
lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and the 
corresponding amines 
0.02574 0.446 
Q9BW19 KIFC1 Kinesin-like protein KIFC1  Required for bipolar spindle formation 0.00327 0.445 
O00165 HAX1 HCLS1-associated protein X-1  Interacts with KCNC3 and the Arp2/3 complex to regulate and reorganise 
the cortical actin cytoskeleton 
0.04004 0.441 
Q9H6U8 ALG9 Alpha-1,2-
mannosyltransferase ALG9  
Involved in the protein glycosylation pathway. Catalyses the transfer of 
mannose from Dol-P-Man to lipid-linked oligosaccharides 
0.0171 0.437 
Q9HAH7 FBRS Probable fibrosin-1  May be a fibrogenic lymphokine involved in fibroblast growth 0.00726 0.436 
Q13895 BYST Bystin Required for the biogenesis of 40S ribosomal subunits and processing of 
20S pre-rRNA precursors 
0.00013 0.432 
O14530 TXND9 Thioredoxin domain-
containing protein 9 
Significantly decreases the ATPase activity of chaperonin TCP1 complex 
to negatively regulate protein folding of actin and tubulin 
3.17E-
07 
0.431 
Q2VIR3 IF2GL Putative eukaryotic 
translation initiation factor 2 
subunit 3-like protein 
Molecular subunit of eukaryotic initiation factor 2 (eIF2), involved in the 
early stages of protein synthesis 
0.00203 0.429 
Q10469 MGAT2 Alpha-1,6-mannosyl-
glycoprotein 2-beta-N-
acetylglucosaminyltransferase  
Involved in protein glycosylation and modification. Catalyses an essential 
step in the conversion of oligo-mannose to complex N-glycans. 
0.01187 0.429 
Q9BV57 MTND 1,2-dihydroxy-3-keto-5-
methylthiopentene 
dioxygenase 
Down-regulates cell migration mediated by MMP14 2.22E-
05 
0.427 
P31350 RIR2 Ribonucleoside-diphosphate 
reductase subunit M2 
Provides the precursors for DNA synthesis. Catalyses the biosynthesis of 
deoxyribonucleotides from the corresponding ribonucleotides. Inhibits 
Wnt signalling 
6.17E-
05 
0.426 
63 
 
O43324 MCA3 Eukaryotic translation 
elongation factor 1 epsilon-1 
Positive modulator of ATM response to DNA damage 0.00119 0.425 
P27635 RL10 60S ribosomal protein L10 Component of the large ribosomal subunit. Plays a role in the formation 
of actively translating ribosomes 
1.29E-
05 
0.424 
Q9HCG8 CWC22 Pre-mRNA-splicing factor 
CWC22 homolog  
Required for nonsense-mediated decay, pre-mRNA splicing and exon-
junction complex assembly. 
0.03759 0.424 
Q9UBI1 COMD3 COMM domain-containing 
protein 3 
Modulates the activity of cullin-RING E3 ubiquitin ligase (CRL) complexes. 
May also be involved in the downregulation of NF-kappa-B activity 
0.00089 0.423 
P01892 1A02 HLA class I histocompatibility 
antigen, A-2 alpha chain  
Involved in the presentation of foreign antigens to the immune system 0.00632 0.418 
Q8IZQ1 WDFY3 WD repeat and FYVE domain-
containing protein 3 
Adapter protein involved in selective macroautophagy by linking proteins 
destined for degradation to the core autophagic machinery members 
0.00505 0.416 
P53350 PLK1 Serine/threonine-protein 
kinase PLK1 
Serine/threonine-protein kinase that performs several important 
functions throughout M phase of the cell cycle, including the regulation 
of centrosome maturation and spindle assembly and removal of cohesins 
from chromosome arms 
1.70E-
05 
0.411 
Q7L7X3 TAOK1 Serine/threonine-protein 
kinase TAO1 
Serine/threonine-protein kinase involved in a number of intracellular 
pathways such as p38/MAPK14 stress-activated MAPK cascade, DNA 
damage response and the regulation of cytoskeleton stability 
0.02141 0.408 
P60520 GBRL2 Gamma-aminobutyric acid 
receptor-associated protein-
like 2  
Ubiquitin-like modifier. Modulates intra-Golgi transport through coupling 
between NSF activity and SNAREs activation. Involved in autophagy 
0.00025 0.404 
Q14CZ7 FAKD3 FAST kinase domain-
containing protein 3, 
mitochondrial  
Required for mitochondrial respiration by increasing the steady-state 
levels and half-lives of some mature mitochondrial mRNAs 
0.00207 0.403 
P33121 ACSL1 Long-chain-fatty-acid--CoA 
ligase 1  
Activates long-chain fatty acids for lipid synthesis and degradation via 
beta-oxidation 
0.03623 0.401 
Q07817 B2CL1 Bcl-2-like protein 1  Potent inhibitor of cell death and inhibits activation of caspases. Also acts 
as a regulator of G2 checkpoint and progression to cytokinesis during 
mitosis 
0.00062 0.398 
Q96PP9 GBP4 Guanylate-binding protein 4  Plays a role in erythroid differentiation. Hydrolyses GTP 0.01673 0.398 
Q01581 HMCS1 Hydroxymethylglutaryl-CoA 
synthase, cytoplasmic 
Enzyme that condenses acetyl-CoA with acetoacetyl-CoA to form HMG-
CoA. This step is involved in mevalonate synthesis 
5.97E-
06 
0.397 
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Q6PL18 ATAD2 ATPase family AAA domain-
containing protein 2  
Transcriptional coactivator of ESR1 (Estrogen receptor alpha) which 
regulates gene expression patterns 
4.05E-
06 
0.396 
Q13509 TBB3 Tubulin beta-3 chain Major constituent of microtubules. TUBB3 plays a critical role in proper 
axon guidance and maintenance 
0.00107 0.393 
Q96EK9 KTI12 Protein KTI12 homolog Chromatin-associated protein which interacts with the Elongator 
complex, a component of the elongating form of RNA polymerase II  
3.58E-
05 
0.392 
Q9BUN8 DERL1 Derlin-1 Part of the endoplasmic reticulum-associated degradation (ERAD) for 
misfolded lumenal proteins. Forms a channel that allows misfolded 
proteins into the cytosol for ubiquitination and degraded by the 
proteasome 
0.00055 0.385 
Q9NQZ5 STAR7 StAR-related lipid transfer 
protein 7, mitochondrial 
Plays a protective role in mucosal tissues by preventing exaggerated 
allergic response 
0.00953 0.382 
P31689 DNJA1 DnaJ homolog subfamily A 
member 1  
Co-chaperone for HSPA8/Hsc70 and HSPA1B for protein transport into 
mitochondria. Also protects cells from apoptosis by negatively regulating 
the translocation of BAX from the cytosol to the mitochondria in 
response to cellular stress 
1.69E-
10 
0.379 
P20290 BTF3 Transcription factor BTF3 Binds to newly synthesised polypeptide chains as they emerge from the 
ribosome and blocks their interaction with the signal recognition particle, 
inhibiting them from being targeted for secretion 
1.62E-
05 
0.379 
P08473 NEP Neprilysin Cleaves a Gly-Phe bond in opioid peptides such as Met- and Leu-
enkephalins, causing their destruction 
0.01377 0.378 
Q9UBB6 NCDN Neurochondrin  Positively regulates the expression of GRM5 and increases its cell surface 
localisation of GRM5 to promote signal transduction within the nervous 
system 
5.41E-
06 
0.374 
Q9H4A5 GLP3L Golgi phosphoprotein 3-like Phosphatidylinositol-4-phosphate-binding protein. Antagonises the 
action of GOLPH3 required for vesicle budding at the Golgi  
0.0044 0.374 
Q9ULJ3 ZBT21 Zinc finger and BTB domain-
containing protein 21  
Acts as a transcription repressor 0.04207 0.371 
P06732 KCRM Creatine kinase M-type Reversibly catalyses the transfer of phosphate between ATP and various 
phosphogens (e.g. creatine phosphate). 
0.05299 0.356 
O43561 LAT Linker for activation of T-cells 
family member 1  
Involved in TCR (T-cell antigen receptor)- and pre-TCR-mediated 
signalling in mature T-cells and during their development 
0.02382 0.354 
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P08243 ASNS Asparagine synthetase 
[glutamine-hydrolysing]  
Part of the amino acid biosynthesis pathway. Involved in the synthesis of 
L-asparagine from L-aspartate 
0.01926 0.35 
P33908 MA1A1 Mannosyl-oligosaccharide 
1,2-alpha-mannosidase IA 
Involved in the maturation of Asn-linked oligosaccharides, as part of 
protein glycosylation  
4.38E-
05 
0.347 
P41440 S19A1 Folate transporter 1  Transporter for the intake of folate 0.04008 0.339 
P22392 NDKB Nucleoside diphosphate 
kinase B 
Major role in the synthesis of nucleoside triphosphates other than ATP. 0.00031 0.338 
Q9NRL2 BAZ1A Bromodomain adjacent to 
zinc finger domain protein 1A 
Component of the ACF complex, an ATP-dependent chromatin 
remodelling complex, that regulates spacing of nucleosomes using ATP to 
generate evenly spaced nucleosomes along the chromatin 
0.00044 0.334 
Q9BU89 DOHH Deoxyhypusine hydroxylase  Plays a role in the post-translational modification of lysine into hypusine 
in the eukaryotic translation initiation factor 5A, essential for its maturity 
and function 
0.00602 0.332 
Q7LGA3 HS2ST Heparan sulphate 2-O-
sulfotransferase 1 
Catalyses the transfer of sulphate to the C2-position of selected 
hexuronic acid residues within the maturing heparan sulphate (HS) which 
is essential for HS to participate in a variety of high-affinity ligand-binding 
interactions and signalling processes 
4.07E-
05 
0.331 
Q92692 NECT2 Nectin-2  Modulates T-cell activation and signalling by co-stimulating or co-
inhibiting T-cell function, depending on the receptor it binds to 
0.00516 0.329 
P04183 KITH Thymidine kinase, cytosolic  Phosphotransferase enzyme that has a key role in the synthesis of DNA.  1.20E-
07 
0.326 
P16070 CD44 CD44 antigen Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix 
interactions through its affinity for HA. Adhesion with HA plays an 
important role in cell migration, tumour growth and progression and 
haematopoiesis 
5.62E-
07 
0.325 
O60232 SSA27 Sjogren 
syndrome/scleroderma 
autoantigen 1 
Antigenic molecule which may play a role in mitosis. Could be a 
centromere-associated protein. May induce anti-centromere antibodies. 
0.00165 0.321 
O43318 M3K7 Mitogen-activated protein 
kinase 7  
Serine/threonine kinase involved in the MAPK signal transduction 
pathway. Mediates signal transduction of TRAF6, various cytokines  
0.0014 0.32 
O14965 AURKA Aurora kinase A Involved in several events during mitosis by association with the 
centrosome and spindle microtubules. Events include establishing mitotic 
0.01501 0.318 
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spindles, centrosome duplication, centrosome separation, chromosomal 
alignment, spindle assembly checkpoint, and cytokinesis 
Q9NPD8 UBE2T Ubiquitin-conjugating enzyme 
E2 T  
Accepts ubiquitin from the E1 complex and catalyses its covalent 
attachment to other proteins.  
0.00024 0.317 
Q5XPI4 RN123 E3 ubiquitin-protein ligase 
RNF123  
Required during G1 phase of the cell cycle for polyubiquitination and 
proteasome-mediated degradation of CDKN1B  
0.01952 0.313 
P02533 K1C14 Keratin, type I cytoskeletal 14  Promotes the self-organisation of KRT5-KRT14 filaments into large 
bundles 
0.03506 0.31 
Q8IYD1 ERF3B Eukaryotic peptide chain 
release factor GTP-binding 
subunit ERF3B  
Involved in translation termination in response to the termination 
codons UAA, UAG and UGA 
1.82E-
05 
0.304 
Q16763 UBE2S Ubiquitin-conjugating enzyme 
E2 
Accepts ubiquitin from the E1 complex and catalyses its covalent 
attachment to other proteins 
0.00011 0.302 
Q15758 AAAT Neutral amino acid 
transporter B(0) 
Sodium-dependent amino acids transporter for a broad range of amino 
acid substrates 
3.24E-
10 
0.299 
Q8NCG7 DGLB Sn1-specific diacylglycerol 
lipase beta  
Catalyses the hydrolysis of diacylglycerol (DAG) to 2-arachidonoyl-
glycerol (2-AG) 
0.02049 0.28 
O95864 FADS2 Fatty acid desaturase 2 Catalyses the biosynthesis of highly unsaturated fatty acids from 
precursor essential polyunsaturated fatty acids in the lipid metabolism 
pathway 
5.18E-
07 
0.277 
P13929 ENOB Beta-enolase Involved in the synthesis of pyruvate from D-glyceraldehyde 3-phosphate 0.01749 0.267 
P04818 TYSY Thymidylate synthase  Mitochondrial protein involved in the dTTP biosynthesis pathway which 
is part of Pyrimidine metabolism 
2.70E-
11 
0.252 
Q9H2V7 SPNS1 Protein spinster homolog 1  Sphingolipid transporter. May be involved in necrotic or autophagic cell 
death 
0.05051 0.245 
Q99595 TI17A Mitochondrial import inner 
membrane translocase 
subunit Tim17-A  
Mediates the translocation of transit peptide-containing proteins across 
the mitochondrial inner membrane as part of the TIM23 complex 
2.90E-
07 
0.224 
Q9ULW0 TPX2 Targeting protein for Xklp2  Spindle assembly factor essential in apoptosis for the assembly of mitotic 
spindles and microtubules 
0.00156 0.197 
Q15004 PAF15 PCNA-associated factor PCNA-binding protein that regulates DNA repair during replication 1.07E-
08 
0.126 
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All significantly downregulated proteins were then mapped using STRING-DB, an online biological 
database of known and predicted protein-protein interactions. The protein map below was generated 
using this web resource and indicates the relationship between proteins to form clusters of similar 
function and structure. In the STRING-DB images, interactions from curated databases and 
experimentally determined interactions are assigned light blue and pink connections respectively while 
predicted interactions through gene neighbourhood, gene fusion or gene co-occurrence relate to green, 
red or dark blue connections respectively. White connections represent protein homology, black 
connections indicate co-expression while yellow connections indicate text mining. Empty nodes indicate 
proteins of unknown 3D structure while filled nodes show proteins with some known or predicted 3D 
structure.   
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Figure 12: Protein network showing the proteins significantly downregulated (fold change <0.667) in response to 1 µM RUX in SET2 cells cultured for 24 hours and detected by SWATH-MS analysis. 
Proteins were mapped using STRING database at high confidence. 305 UNIPROT identification numbers of significantly downregulated proteins were input into the database. Due to slight 
discrepancies between the two databases (UNIPROT and STRING), 3 proteins could not be identified leaving a network of 302 proteins. From this network, the medium interaction score parameter was 
set to high confidence (0.7000) and at this point, nodes with no interactions were removed from the protein network, leaving a total of 118 nodes within the protein map. Protein clusters indicated: 
Red = ribosome biogenesis, blue = translation control, green = DNA replication, purple = mitosis and cell cycle progression, orange = microtubule formation, black = polypeptide folding.  
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Figure 12 shows the protein map generated by STRING, with nodes indicating proteins that were 
downregulated in SET2 cells upon 1 µM RUX treatment for 24 hours. Lines indicate relationships 
between proteins with similar structures and functions. Clustering of nodes shows proteins with strong 
relationships. Of the proteins identified through SWATH-MS, clusters of proteins involved in cell cycle 
progression and DNA replication were shown to be significantly downregulated by RUX treatment, along 
with proteins involved in post-translational processing and ribosome biogenesis. 
 
STRING-DB results indicate that RUX has a significant effect on the overall survival of SET2 cells by 
affecting all pathways involved in the central dogma of biology, starting from the conversion of the 
genetic DNA code into an RNA sequence and eventually into fully folded proteins with specific cellular 
functions. The largest cluster of downregulated proteins were shown to be involved in ribosome 
biogenesis (red cluster) which subsequently affects RNA translation (blue cluster) and cell cycle 
progression. Many proteins involved in the initiation and control of mitosis (purple cluster) were also 
significantly downregulated upon RUX treatment, including DNA replication and microtubule formation 
(green and orange clusters), both of which are vital during the M phase of the cell cycle.  
 
Analysis was then performed on significantly upregulated proteins, of which there were 129. A 
comprehensive list of all significantly upregulated proteins, as determined by Welch’s T-test, is displayed 
below in Table VI.  
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Table VI: List of significantly upregulated proteins in SET2 cells upon 1 µM RUX treatment for 24 hours, detected by SWATH-MS. Details of all significantly upregulated proteins 
in SET2 cells in response to 24hr RUX treatment. Information on the protein and associated UniProt ID, function (as described within the UniProt database), fold change and p-
values comparing treated cells to untreated cells, as determined by Welch’s T-test, are included.  
Uniprot 
ID 
Protein 
Identity  
Protein Name Function p-value Fold 
Change 
Q05469 LIPS Hormone-sensitive 
lipase 
Converts cholesteryl esters to free cholesterol for steroid production in 
steroidogenic tissues 
0.00791 3.91 
P12259 FA5 Coagulation factor V  Central regulator of haemostasis that is an essential co-factor for factor Xa 
prothrombinase activity, resulting in the activation of prothrombin to thrombin 
0.0126 3.84 
Q9H4L5 OSBL3 Oxysterol-binding 
protein-related protein 
3  
Phosphoinositide-binding protein that has a role in regulation of the actin 
cytoskeleton, cell polarity and cell adhesion 
0.03865 3.63 
O00291 HIP1 Huntingtin-interacting 
protein 1 
Involved in clathrin-mediated endocytosis and trafficking. May also induce cell 
death and promote apoptosis through the intrinsic apoptosis pathway 
0.04194 3.23 
P51687 SUOX Sulphite oxidase, 
mitochondrial 
Involved in sulphur metabolism 0.00021 3.19 
Q8IUH4 ZDH13 Palmitoyltransferase 
ZDHHC13 
May play a role in Mg2+ transport 0.04297 3.12 
Q13541 4EBP1 Eukaryotic translation 
initiation factor 4E-
binding protein 1 
Prevents EIF4E assembly into the eIF4F complex. The hypophosphorylated form 
of this protein competes with EIF4G1 and EIF4G3 and strongly binds to EIF4E, 
resulting in translation repression 
2.27E-
05 
3.05 
O43294 TGFI1 Transforming growth 
factor beta-1-induced 
transcript 1 protein 
Regulates the Wnt and TGFB signalling pathways and also coordinates multiple 
protein-protein interactions at the focal adhesion complex and in the nucleus 
0.00954 2.9 
Q99988 GDF15 Growth/differentiation 
factor 15  
Regulates food intake, energy expenditure and body weight in response to 
metabolic and toxin-induced stresses 
0.03523 2.79 
Q3V6T2 GRDN Girdin  Involved in PI3K phosphorylation and downstream signalling. Regulates DNA 
replication and cell proliferation through phosphorylation of AKT1/PKB. Also 
required for maintenance of actin cytoskeleton integrity and cell migration 
0.0492 2.49 
O14907 TX1B3 Tax1-binding protein 3  May regulate several protein-protein interactions by competing for PDZ domain 
binding sites 
0.00475 2.45 
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Q53EL6 PDCD4 Programmed cell death 
protein 4 
Tumour suppressor protein that plays a role in apoptosis. Down-regulates the 
expression of MAP4K1, thus inhibiting events important in invasion 
1.68E-
11 
2.42 
P13224 GP1BB Platelet glycoprotein Ib 
beta chain 
Involved in the production of platelet plugs by binding to von Willebrand factor 0.01271 2.39 
Q9H7N4 SFR19 Splicing factor, 
arginine/serine-rich 19 
May function in pre-mRNA splicing 0.01033 2.37 
Q13885 TBB2A  Tubulin beta-2A chain  The major constituent of microtubules 0.00242 2.24 
Q96AQ6 PBIP1 Pre-B-cell leukaemia 
transcription factor-
interacting protein 1 
Regulates the function of pre-B-cell leukaemia transcription factors (BPXs). 
Inhibits PBX1-HOX complex binding to DNA and blocks the transcriptional 
activity of E2A-PBX1 
0.00128 2.22 
Q9H7C9 AAMDC Mth938 domain-
containing protein 
May play a role in preadipocyte differentiation and adipogenesis 0.00061 2.21 
O95372 LYPA2 Acyl-protein 
thioesterase 2 
Has lysophospholipase activity. Hydrolyses fatty acids from S-acylated cysteine 
residues in proteins such as trimeric G alpha proteins 
0.03141 2.19 
P28289 TMOD1 Tropomodulin-1 Inhibits the elongation and depolymerization of the actin filaments at the 
pointed end. Forms a complex with TM (Tmod/TM) to assist in the formation of 
the short actin protofilament 
0.03973 2.17 
Q9UJW2 TINAG Tubulointerstitial 
nephritis antigen  
Mediates adhesion of proximal tubule epithelial cells via integrins alpha3-beta1 
and alphaV-beta3 
0.02484 2.14 
P42126 ECI1 Enoyl-CoA delta 
isomerase 1, 
mitochondrial 
Involved in lipid metabolism, specifically fatty acid beta-oxidation.   0.03583 2.14 
P62877 RBX1 E3 ubiquitin-protein 
ligase RBX1 
Mediates the ubiquitination and degradation of target proteins, including 
proteins involved in cell cycle progression, signal transduction, transcription 
and transcription-coupled nucleotide excision repair 
0.03774 2.14 
P35612 ADDB Beta-adducin Associated with the membrane cytoskeleton to promote the assembly of the 
spectrin-actin network 
4.79E-
06 
2.13 
Q8WUZ0 BCL7C B-cell CLL/lymphoma 7 
protein family member 
C  
May play an anti-apoptotic role 0.04815 2.12 
P07711 CATL1 Cathepsin L1 Important for the overall degradation of proteins in lysosomes 1.38E-
06 
2.11 
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Q96TC7 RMD3 Regulator of 
microtubule dynamics 
protein 3 
Involved in cellular calcium homeostasis regulation. Thought to be involved in 
the differentiation and apoptosis of keratinocytes 
0.0024 2.06 
Q9H4Z3 PCIF1 Phosphorylated CTD-
interacting factor 1 
Associates with the phosphorylated C-terminal domain of the largest subunit of 
RNAPII to assists in transcription elongation and coupling transcription to pre-
mRNA processing 
0.01038 2.03 
P28676 GRAN Grancalcin  Calcium-binding protein that assists in the adhesion of neutrophils to 
fibronectin. May also assist in the formation of focal adhesions 
0.00017 2.01 
O43924 PDE6D Retinal rod rhodopsin-
sensitive cGMP 3',5'-
cyclic 
phosphodiesterase 
subunit delta  
Regulates the subcellular location and activity of prenylated or palmitoylated 
Ras family members by releasing them from the cell membrane. 
0.0162 2 
Q9H9E3 COG4 Conserved oligomeric 
Golgi complex subunit 
4 
Required for normal Golgi function. Plays a role in SNARE-pin assembly and 
Golgi-to-ER retrograde transport via its interaction with SCFD1 
0.05399 1.99 
P08567 PLEK Pleckstrin Major protein kinase C substrate of platelets 0.00208 1.98 
Q9NZC2 TREM2 Triggering receptor 
expressed on myeloid 
cells 2 
Triggers immune activation of macrophages and dendritic cells by forming a 
receptor signalling complex with TYROBP. May also instigate chronic 
inflammation and production of constitutive chemokines and cytokines 
0.02976 1.97 
Q05823 RN5A  2-5A-dependent 
ribonuclease  
Endoribonuclease involved in the interferon antiviral response by cleavage of 
single-stranded viral RNAs. Also induces apoptosis and inhibits protein synthesis 
through degradation of rRNA 
0.03265 1.97 
P61764 STXB1 Syntaxin-binding 
protein 1  
Interacts with GTP-binding proteins to help regulate synaptic vesicle docking 
and fusion  
0.01496 1.95 
Q92747 ARC1A Actin-related protein 
2/3 complex subunit 
1A 
Probably functions as component of the Arp2/3 complex which is involved in 
regulation of actin polymerization and together with an activating nucleation-
promoting factor (NPF) mediates the formation of branched actin networks 
0.02987 1.94 
P55060 XPO2 Exportin-2  Mediates the export of importin-alpha from the nucleus to the cytoplasm after 
cargo proteins have been released into the nucleoplasm 
0.03491 1.93 
Q92506 DHB8 Oestradiol 17-beta-
dehydrogenase 8 
Involved in oestrogen biosynthesis 0.00025 1.92 
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Q9NWB6 ARGL1 Arginine and 
glutamate-rich protein 
1 
Required for the oestrogen-dependent expression of ESR1 target genes. Can act 
in cooperation with MED1 
0.03753 1.92 
Q9H479 FN3K Fructosamine-3-kinase May initiate a process leading to the deglycation of fructoselysine and of 
glycated proteins 
6.93E-
06 
1.9 
P45954 ACDSB Short/branched chain 
specific acyl-CoA 
dehydrogenase, 
mitochondrial 
Involved in lipid metabolism, specifically mitochondrial fatty acid beta-oxidation 0.00018 1.89 
P42338 PK3CB Phosphatidylinositol 
4,5-bisphosphate 3-
kinase catalytic subunit 
beta isoform 
Activates signalling cascades involved in cell growth, survival, proliferation, 
motility and morphology by recruiting PH domain-containing proteins, such as 
AKT1 and PDPK1, to the membrane  
 
0.00013 1.88 
Q05707 COEA1 Collagen alpha-1(XIV) 
chain  
Plays an adhesive role by integrating collagen bundles 0.0002 1.88 
Q13620 CUL4B Cullin-4B Involved in the mediation of ubiquitination and subsequent proteasomal 
degradation of target proteins as it is a core component of multiple cullin-RING-
based E3 ubiquitin-protein ligase complexes  
7.72E-
05 
1.87 
Q9UL33 TPC2L Trafficking protein 
particle complex 
subunit 2-like protein  
May play a role in vesicular transport from endoplasmic reticulum to Golgi 0.02152 1.87 
Q96ME7 ZN512 Zinc finger protein 512 May be involved in transcriptional regulation 0.00014 1.85 
Q9P0U4 CXXC1 CXXC-type zinc finger 
protein 1 
Transcriptional activator that exhibits a unique DNA binding specificity for CpG 
unmethylated motifs with a preference for CpGG 
0.00566 1.85 
Q9Y5U9 IR3IP Immediate early 
response 3-interacting 
protein 1 
May be implicated in the regulation of apoptosis. May be involved in protein 
transport between endoplasmic reticulum and Golgi apparatus 
0.01369 1.85 
P09871 C1S Complement C1s 
subcomponent 
Serine protease that forms complexes with C1q and C1r to form C1, forming the 
first component of the classical pathway of the complement system 
0.03051 1.85 
Q9Y4F5 C170B Centrosomal protein of 
170 kDa protein B 
Plays a role in microtubule organization 0.04564 1.85 
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Q13469 NFAC2 Nuclear factor of 
activated T-cells, 
cytoplasmic 2  
Induces the expression of cytokine genes in T-cells, such as IL-2, IL-3, IL-4, TNF-
alpha or GM-CSF 
0.02516 1.84 
Q15477 SKIV2 Helicase SKI2W  Involved in exosome-mediated RNA decay through forming part of the SKI 
complex  
0.01723 1.8 
Q9NUB1 ACS2L Acetyl-coenzyme A 
synthetase 2-like, 
mitochondrial 
Converts acetate to acetyl-CoA so that it can be used for oxidation in ketogenic 
conditions through the tricarboxylic cycle 
5.72E-
07 
1.79 
P20962 PTMS Parathymosin Blocks the effects of prothymosin alpha which confers resistance to certain 
opportunistic infections  
0.00192 1.79 
Q5JTJ3 COA6 Cytochrome c oxidase 
assembly factor 6 
homolog 
Involved in the maturation of the mitochondrial respiratory chain complex IV 
subunit MT-CO2/COX2. This complex is part of the respiratory chain that 
catalyses the transfer of electrons from intermembrane space to molecular 
oxygen in the matrix and contributes to the proton gradient in ATP synthesis 
0.0046 1.79 
O75323 NIPS2 Protein NipSnap 
homolog 2 
May act as a positive regulator of L-type calcium channels 0.00659 1.78 
Q2T9J0 TYSD1 Peroxisomal leader 
peptide-processing 
protease  
Catalyses the processing of PTS1-proteins involved in the peroxisomal beta-
oxidation of fatty acids 
0.03505 1.77 
P04179 SODM Superoxide dismutase 
[Mn], mitochondrial 
Destroys toxic superoxide anion radicals normally produced within the cells 0.00071 1.76 
P28799 GRN Granulins  Thought to have cytokine-like activity and thus are potentially are involved in 
inflammation, wound repair, and tissue remodelling 
0.00735 1.75 
O14617 AP3D1 AP-3 complex subunit 
delta-1  
Facilitates the budding of vesicles from the Golgi membrane as part of the AP-3 
adaptor-related complex. 
0.01847 1.74 
Q7Z4V5 HDGR2 Hepatoma-derived 
growth factor-related 
protein 2  
Involved in cellular growth control through the regulation of cyclin D1 
expression 
0.03126 1.73 
Q9Y624 JAM1 Junctional adhesion 
molecule A 
Involved in the early stages of epithelial tight junction formation 0.00032 1.72 
Q15853 USF2 Upstream stimulatory 
factor 2 
Functions as a transcription factor that binds to a symmetrical DNA sequence 
(E-boxes) (5'-CACGTG-3') found in several viral and cellular promoter sequences 
0.01757 1.72 
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O75208 COQ9 Ubiquinone 
biosynthesis protein 
COQ9, mitochondrial  
Involved in the biosynthesis of coenzyme Q, a lipid-soluble electron transporter 
for aerobic cellular respiration 
0.00436 1.69 
P07305 H10 Histone H1.0 Assists in condensing nucleosome chains into higher-order structures. Found in 
cells in terminal stages of differentiation or with low cell division rates 
2.49E-
06 
1.68 
Q12959 DLG1 Disks large homolog 1  Recruits channels, receptors and signalling molecules to discrete plasma 
membrane domains in polarized cells. As such, this protein is involved in a 
number of cellular processes such as adheren junction assembly, signal 
transduction, cell proliferation, synaptogenesis and lymphocyte activation 
0.04402 1.68 
Q9Y5K8 VATD V-type proton ATPase 
subunit D 
Acidifies a variety of intracellular compartments in eukaryotic cells to provide 
energy for transport processes in the vacuolar system 
0.00132 1.66 
Q9BZ29 DOCK9 Dedicator of 
cytokinesis protein 9  
Activates CDC42 by exchanging bound GDP for free GTP due to its role as a 
guanine nucleotide-exchange factor 
0.00729 1.66 
Q4G176 ACSF3 Acyl-CoA synthetase 
family member 3, 
mitochondrial 
Activates malonate and methylmalonate into their respective CoA thioester 
during the first step of intramitochondrial fatty acid synthesis 
4.20E-
05 
1.65 
Q14643 ITPR1 Inositol 1,4,5-
trisphosphate receptor 
type 1  
Regulates epithelial secretion of electrolytes and fluid by influencing calcium 
release from the ER following stimulation by inositol 1,4,5-trisphosphate 
0.03223 1.65 
P13716 HEM2 Delta-aminolevulinic 
acid dehydratase  
Catalyses an early step in the biosynthesis of tetrapyrroles 0.00274 1.64 
P22830 HEMH Ferrochelatase, 
mitochondrial 
Catalyses the ferrous insertion into protoporphyrin IX 0.00016 1.63 
Q9HAN9 NMNA1 Nicotinamide/nicotinic 
acid mononucleotide 
adenylyltransferase 1 
Works with PARP1, PARG and NUDT5 to synthesise ATP in the nucleus, essential 
for extensive chromatin remodelling events 
0.00349 1.63 
P80365 DHI2 Corticosteroid 11-beta-
dehydrogenase 
isozyme 2  
Catalyses the conversion of cortisol to the inactive metabolite cortisone. 
Modulates intracellular glucocorticoid levels 
0.0283 1.63 
P31323 KAP3 cAMP-dependent 
protein kinase type II-
beta regulatory subunit  
Involved in cAMP signalling 0.04013 1.63 
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Q96Q05 TPPC9 Trafficking protein 
particle complex 
subunit 9  
Functions as an activator of NF-kappa-B through increased phosphorylation of 
the IKK complex 
0.00518 1.61 
P50336 PPOX Protoporphyrinogen 
oxidase  
Catalyses the 6-electron oxidation of protoporphyrinogen-IX to form 
protoporphyrin-IX 
0.00689 1.61 
O94927 HAUS5 HAUS augmin-like 
complex subunit 5  
Involved in mitotic spindle assembly, cytokinesis and centrosome integrity 
maintenance 
0.02284 1.61 
P06703 S10A6 Protein S100-A6  May function as calcium sensor and modulator. Indirectly plays a role in many 
physiological processes such as the reorganization of the actin cytoskeleton and 
in cell motility 
0.00194 1.6 
Q9Y6M7 S4A7 Sodium bicarbonate 
cotransporter 3  
Functions as an electroneutral sodium- and bicarbonate-dependent 
cotransporter to regulate the intracellular pH 
0.00791 1.6 
Q15018 F175B BRISC complex subunit 
Abro1 
Involved in a number of cellular processes including: regulation of the onset of 
apoptosis via modulation of Lys-63-linked ubiquitination of target proteins; 
required for normal mitotic spindle assembly and microtubule attachment to 
kinetochores via deubiquitinating NUMA1; acts as a central scaffold protein in 
the BRISK complex of protein degradation 
0.0096 1.6 
Q9UH99 SUN2 SUN domain-
containing protein 2 
Involved in the connection between the nuclear lamina and the cytoskeleton 
(part of the LINC complex) 
0.01153 1.6 
Q92620 PRP16 Pre-mRNA-splicing 
factor ATP-dependent 
RNA helicase PRP16  
Probable ATP-binding RNA helicase involved in pre-mRNA splicing 0.01522 1.6 
Q05209 PTN12 Tyrosine-protein 
phosphatase non-
receptor type 12 
Dephosphorylates a range of proteins, and thereby regulates cellular signalling 
cascades via ERBB2 and PTK2B/PYK2 
0.02853 1.6 
Q5VVQ6 OTU1 Ubiquitin thioesterase 
OTU1 
Removes conjugated ubiquitin from misfolded lumenal proteins in the 
endoplasmic reticulum-associated degradation (ERAD) via its hydrolase actvity 
0.03342 1.6 
Q02252 MMSA Methylmalonate-
semialdehyde 
dehydrogenase 
[acylating], 
mitochondrial 
Plays a role in valine and pyrimidine metabolism. Binds fatty acyl-CoA 1.59E-
05 
1.59 
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P17900 SAP3 Ganglioside GM2 
activator  
Binds gangliosides and stimulates ganglioside GM2 degradation 0.001 1.59 
Q99541 PLIN2 Perilipin-2  May be involved in development and maintenance of adipose tissue 0.00532 1.59 
P49902 5NTC Cytosolic purine 5'-
nucleotidase  
Co-operates with other nucleotidases to maintain a constant composition of 
purine/pyrimidine nucleotides within the cell 
0.02014 1.59 
P07858 CATB Cathepsin B  Believed to participate in intracellular degradation and turnover of proteins. 
Has also been implicated in tumour invasion and metastasis 
3.09E-
05 
1.58 
Q9UEY8 ADDG Gamma-adducin Promotes the assembly of the spectrin-actin network and promotes actin 
filament capping by associating with the membrane cytoskeleton  
0.00566 1.57 
O14497 ARI1A AT-rich interactive 
domain-containing 
protein 1A 
Involved in transcriptional activation and repression of select genes by 
chromatin remodelling (alteration of DNA-nucleosome topology) 
0.04257 1.57 
Q9UIJ7 KAD3 GTP:AMP 
phosphotransferase 
AK3, mitochondrial 
Involved in maintaining the homeostasis of cellular nucleotides by catalysing 
the interconversion of nucleoside phosphates 
9.94E-
05 
1.56 
P69905 HBA Haemoglobin subunit 
alpha 
Involved in oxygen transport from the lung to the various peripheral tissues 0.00047 1.56 
O00115 DNS2A Deoxyribonuclease-2-
alpha  
Involved in the degradation of nuclear DNA in cellular apoptosis during 
development and hydrolyses DNA under acidic conditions 
0.00025 1.55 
Q9H9H4 VP37B Vacuolar protein 
sorting-associated 
protein 37B 
Regulates vesicular trafficking and sorting of endocytic ubiquitinated cargos in 
multivesicular bodies as part of the ESCRT-I complex. May also be involved in 
cell growth and differentiation 
0.00026 1.54 
P10909 CLUS Clusterin Acts as an extracellular chaperone, preventing aggregation of non-native 
proteins and blood plasma protein aggregation induced by cellular stress. Also 
maintains partially unfolded proteins in a state of subsequent refolding by 
other chaperonins 
0.02161 1.54 
P0CG12 CTF8A Chromosome 
transmission fidelity 
protein 8 homolog 
isoform 2 
Potential tumour suppressor 0.04628 1.54 
Q7Z434 MAVS Mitochondrial 
antiviral-signalling 
protein  
May protect cells from apoptosis. Required for innate immune defence against 
viruses 
0.00029 1.53 
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P35611 ADDA Alpha-adducin Membrane-cytoskeleton-associated protein that promotes the assembly of the 
spectrin-actin network 
0.00045 1.53 
P07108 ACBP Acyl-CoA-binding 
protein  
Binds and carries medium- and long-chain acyl-CoA esters (binds with very high 
affinity). 
0.00176 1.53 
P60468 SC61B Protein transport 
protein Sec61 subunit 
beta 
Necessary for protein translocation in the endoplasmic reticulum 0.00245 1.53 
Q8IWS0 PHF6 PHD finger protein 6  Transcriptional regulator that suppresses rRNA transcription through 
associations with rRNA promoters 
0.00373 1.53 
P07942 LAMB1 Laminin subunit beta-1 Thought to mediate the attachment, migration and organization of cells into 
tissues during embryonic development by interacting with other extracellular 
matrix components 
0.05486 1.53 
Q96RQ3 MCCA Methylcrotonoyl-CoA 
carboxylase subunit 
alpha, mitochondrial 
Biotin-attachment subunit of the 3-methylcrotonyl-CoA carboxylase involved in 
leucine and isovaleric acid catabolism.  
0.00106 1.52 
P15144 AMPN Aminopeptidase N Broad specificity aminopeptidase which may be involved the cleavage of 
peptides bound to major histocompatibility complex class II molecules of 
antigen presenting cells 
0.00175 1.52 
O95182 NDUA7 NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 7  
Accessory subunit of the mitochondrial membrane respiratory chain NADH 
dehydrogenase (Complex 1) which transfers electrons from NADH to the 
respiratory chain 
0.00361 1.52 
Q86UV5 UBP48 Ubiquitin carboxyl-
terminal hydrolase 48 
Involved in processing poly-ubiquitin precursors and ubiquitinated proteins by 
recognising and hydrolysing the peptide bond at the C-terminal Gly of ubiquitin 
0.00463 1.52 
P02008 HBAZ Haemoglobin subunit 
zeta  
An alpha-type chain of mammalian embryonic haemoglobin 0.03035 1.52 
Q5SSJ5 HP1B3 Heterochromatin 
protein 1-binding 
protein 3 
Maintains heterochromatin integrity during G1/S progression. Also regulates 
the duration of G1 phase to critically influence the cell’s proliferative capacity 
4.13E-
07 
1.51 
P29590 PML Protein PML  Associates with PML-nuclear bodies (PML-NBs) in various intracellular 
processes such as tumour suppression, transcriptional regulation, apoptosis, 
senescence and DNA damage response 
0.00025 1.51 
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P32019 I5P2 Type II inositol 1,4,5-
trisphosphate 5-
phosphatase 
Modulates cellular signalling events by hydrolysing phosphatidylinositol 4,5-
bisphosphate (PtIns(4,5)P2) and phosphatidylinositol 1,4,5-trisphosphate 
(PtIns(1,4,5)P3) 
0.0306 1.51 
Q8IXM2 BAP18 Chromatin complexes 
subunit BAP18 
Component of chromatin complexes such as the MLL1/MLL and NURF 
complexes 
0.00065 1.5 
P35914 HMGCL Hydroxymethylglutaryl-
CoA lyase, 
mitochondrial 
Key enzyme in ketogenesis. Also involved in the terminal step of leucine 
catabolism 
0.01721 1.5 
Q9BUT1 BDH2 3-hydroxybutyrate 
dehydrogenase type 2  
Plays a key role in iron homeostasis and transport by mediating the formation 
of 2,5-dihydrobenzoic acid 
0.02237 1.5 
Q9UKL0 RCOR1 REST corepressor 1  Controls hematopoietic differentiation and suppresses several genes involved 
in multilineage blood cell development by recruiting histone deacetylases 
(HDAC) 
0.03752 1.5 
 
As in Figure 12, all significantly upregulated proteins were also mapped using STRING-DB and are shown in Figure 13.  
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Figure 13: Protein network showing the proteins significantly upregulated (fold change >1.5) in response to 1 µM RUX in SET2 cells cultured for 24 hours and detected by SWATH-MS analysis. 
Proteins were mapped using STRING database at high confidence. 129 UNIPROT identification numbers of significantly downregulated proteins were input into the database. From this network, the 
medium interaction score parameter was set to high confidence (0.7000) and at this point, nodes with no interactions were removed from the protein network, leaving a total of 52 nodes within the 
protein map. Protein clusters indicated: Red = cytoskeleton proteins, blue = ubiquitination, green = fatty acid synthesis, orange = platelet activation  
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The protein map shown in Figure 13 shows clusters of upregulated proteins involved in several cellular 
pathways including: platelet aggregation, lipid metabolism, lysosomal proteins, intrinsic apoptotic 
signalling, negative regulation of calcium-mediated signalling.  
 
STRING-DB uses many different techniques to assess the interactions between proteins, be that physical 
or functional associations, and each one gives a relative observation of protein interactions. Amending 
the confidence settings on the STRING-DB resulted in over half of the significantly upregulated proteins 
identified through SWATH-MS to be discounted from the final figure, indicating that there is a low 
probability that the interactions between these proteins exist. Proteins lost during analysis therefore 
may not have any relation to other proteins identified during SWATH and therefore are not associated 
with any clustering of protein families with similar structures and biological functions. The results in 
Figure 13 show that RUX significantly affects platelet activation and aggregation (orange cluster), which 
compliments the overall activation of the immune response. Membrane integrity is also affected by RUX 
treatment (red cluster), which could be because of intracellular stress or decreases transcription of 
membrane-associated proteins. Conversely, there was a significant increase in the expression of 
proteins involved in fatty acid synthesis (green cluster). Translation of ubiquitinating proteins was also 
significantly upregulated in response to 24-hour treatment with 1 µM RUX (blue cluster), leading to an 
increase in ubiquitination and subsequent degradation of intracellular molecules.   
 
Once proteins of interest had been identified through SWATH-MS and through evaluation of the current 
literature, conformational studies using Q-RT-PCR and Western Blots were performed to support 
previous findings and elucidate the functional significance of these target molecules and how they 
support the role of aberrant JAK2 signalling in the pathogenesis of ET. 
 
3.3. The effect of 1µM ruxolitinib on target gene transcription in ET 
Mass spectrum analysis results from Section 3.2 and a review of the current literature has highlighted 
various downstream JAK/STAT targets thought to be differentially expressed in ET, including STAT and 
SOCS proteins, molecular chaperones and members of the antigen presentation pathway. Analysis of 
these gene transcripts by Q-RT-PCR was performed in SET2 cells cultured in the presence and absence of 
1 µM RUX throughout a 72-hour period.  
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Figure 14: Relative gene expression of selected downstream JAK2/STAT targets in SET2 cells upon treatment with 1 µM RUX for 24, 48 and 72 hours, with fold change relative 
to untreated cells at 24 hours. STAT3, STAT5B, CALR (n=3). HSP90AB1, CANX, (n=2). Each bar and point represent the mean of the biological repeats with error bars indicating the 
standard deviation. Two-way ANOVA: STAT3 p=0.7074, STAT5B p=0.4566, HSP90AB1 p=0.1066, CALR p=0.1947, CANX p=0.4999.  
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Gene expression of selected downstream JAK2 targets upon treatment with RUX for up to 72 hours was 
determined by Q-RT-PCR. Two-way ANOVA analysis was performed to determine the statistical 
significance of results using GraphPad Prism. With respect to signal transducers, STAT3 (Figure 14A) and 
STAT5B (14B) show differing responses to RUX in SET2 cells. STAT3 mRNA expression is downregulated 
after 24 hours and gradually increases over time to a similar level as untreated cells at 48 and 72 hours.  
In contrast, the expression of STAT5B is slightly upregulated in response to RUX at all 3 time-points, with 
a gradual increase in expression over time. Chaperone proteins HSP90AB1 (Figure 14C) and CALR (14D) 
are both consistently downregulated in response to 1 µM RUX at all time points assessed. CANX mRNA 
expression (Figure 14E) showed the same pattern of expression as STAT3 and appeared to be 
downregulated in response to RUX after 24 hours and a gradual increase in expression up to 72 hours 
can be seen. None of the downstream JAK2/STAT targets investigated in SET2 cells showed any 
significant changes in RNA expression upon treatment with ruxolitinib, as analysed by two-way ANOVA. 
The absence of significant statistical results may be due to large error bars within the biological repeats 
analysed and significance may have been reached had the number of biological samples been increased. 
 
In addition, Q-RT-PCR analysis has been performed on SET2 cells cultured in 1 µM RUX for 24 hours only. 
48 and 72hr mRNA expression was not investigated in the following genes shown below in Figure 15. 
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Figure 15: Relative gene expression of selected downstream JAK2/STAT targets in SET2 cells upon treatment with 1 µM RUX for 24 hours, with fold change relative to 
untreated cells (n=3). Each bar and point represent the mean of the biological repeats with error bars indicating the standard deviation. Unpaired T-test; SOCS1 p=0.9820. SOCS3 
p<0.0001, HSPA5B p=0.0783, HSPA8 p=0.1101, TAP1 p=0.0014, MCL1 p<0.0001, IRF1 p=0.0052, DDX3X p=0.0660, ISG15 p=0.3516, HLA-A p=0.0302.  
 
Figure 15 shows the gene expression of selected downstream JAK2 targets upon treatment with RUX for 24 hours, as determined by Q-RT-PCR. 
Unpaired T-Tests were performed to determine the statistical significance of results using GraphPad Prism. Considering suppressors of cytokine 
signals, there was a significant decrease in the expression of SOCS3 after 24-hour RUX treatment (Figure 15B, p<0.0001) while there was no 
change in SOCS1 expression (15A). HSPA5 and HSPA8 transcription was decreased upon RUX treatment but not significantly (Figure 15C and 
15D). TAP-1 (Figure 15E) mRNA was significantly decreased in cells treated with 1 µM RUX compared to untreated cells (p=0.0014 respectively). 
In contrast, MCL1, IRF1 and HLA-A (Figure 15F, 15GF and 15J respectively) were all significantly upregulated in RUX-treated SET2 cells (p<0.0001, 
p=0.0052 p=0.0302 respectively). Transcription of DDX3X (Figure 15H) and ISG15 (15I) was also upregulated upon RUX treatment in SET2 cells.  
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3.4. The effect of 1µM ruxolitinib on target protein translation in ET 
Heat shock proteins are members of the chaperone family and can be constitutively expressed or 
induced upon cellular stress (Jindal, 1996). Their expression has been shown to be upregulated in 
various malignancies (Lancet, et al., 2010) (Rajan, et al., 2011). Consequently, HSP70 translational 
expression was investigated in this report.  
 
Figure 16: A) Western Blot images for HSP70 protein expression in SET2 cells grown in the presence or absence of 1 µM RUX 
for 24 hours (n=3). Western blot analysis of HSP70 (70 kDa) and α-tubulin (50 kDa) proteins in SET2 cells cultured in the 
presence or absence of 1 µM RUX (n=3). For this report, only one blot has been shown which is representative of all 3 biological 
repeats. B) Densitometry of HSP70 protein expression in SET2 cells treated with 1 µM RUX for 24 hours, showing fold change 
against respective control cells (n=3).  Relative protein expression of HSP70 upon 24-hour treatment with 1µM RUX in SET2 
cells, relative to untreated control. All samples were normalized to expression levels of α-tubulin (loading control) and analysis 
performed using ImageLab software. Each bar represents the mean of three biological repeats with error bars indicating the 
standard deviation between replicates. Unpaired T-test: p=0.0467 
 
Figure 16A shows nitrocellulose Western Blot membranes incubated with primary antibodies against 
HSP70 and α-tubulin housekeeping (for loading control). The blot images show a qualitative decrease in 
the expression of HSP70. Quantitative analysis using ImageLab allowed for densitometry to determine if 
any statistical significance in HSP70 protein expression was observed between treated and untreated 
SET2 cells after 24 hours. Figure 16B shows the quantitative expression of HSP70 within SET2 cells gown 
in the presence or absence of RUX for 24 hours. Densitometry analysis indicates the expression of HSP70 
was significantly decreased upon ruxolitinib treatment. 
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Previous literature describes a critical role of STAT5 in the development of a PV-like phenotype in mice 
models and explains how loss of STAT5 prevents the development of JAK2V617F MPNs (Yan, et al., 
2012). STAT5 phosphorylation is strongly associated with JAK2 activation and signal transduction 
therefore the expression of STAT5 was explored in SET2 cells treated with RUX. Figure 10 shows 
Western Blot membranes incubated with primary antibodies against STAT5 and α-tubulin housekeeping 
(for loading control) in SET2 cells treated with 1 M RUX for 24 hours.  
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
Figure 17: A) Western Blot images for STAT5 protein expression in SET2 cells grown in the presence or absence of 1 µM RUX 
for 24 hours (n=3). Western blot analysis of STAT5 (90 kDa) and α-tubulin (50 kDa) proteins in SET2 cells cultured in the presence 
or absence of 1 µM RUX (n=3). For this report, only one blot has been shown which is representative of all 3 biological repeats. 
B) Densitometry of STAT5A and STAT5B protein expression in SET2 cells treated with 1 µM RUX for 24 hours, showing fold 
change against respective control cells (n=3).  Relative protein expression of STAT5A and STAT5B upon 24-hour treatment with 
1µM RUX in SET2 cells, relative to untreated control. All samples were normalized to expression levels of α-tubulin (loading 
control) and analysis performed using ImageLab software. Each bar represents the mean of three biological repeats with error 
bars indicating the standard deviation between replicates. Unpaired T-test: STAT5A p=0.3026. STAT5B p=0.1381. 
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Use of the STAT5 antibody detected two bands around 90kDa (Figure 10). From the molecular weights 
of both isoforms, it was understood that the heavier molecular weight band indicated STAT5A while the 
lighter molecular band was STAT5B (MW = 90.6 kDa and 89.9 kDa respectively). Densitometry analysis 
was also performed to obtain a quantitative evaluation of protein expression. For quantitative 
densitometry analysis, both isoforms were analysed separately. Figure 17 shows the densitometry 
analysis of STAT5A and STAT5B in response to 1 µM RUX after 24 hours, with results normalized to the 
expression in untreated cells. Unpaired T-test analysis shows no difference in the expression of either 
isoform in response to RUX. 
 
3.5. The effect of 1µM RUX on STAT1 expression in ET and PV 
Since STAT1 is thought to be the driver of the ET phenotype (Chen, et al., 2010), its expression was 
investigated on a transcriptional and translational level using mass spectrometry, Western Blotting and 
Q-RT-PCR. Mass spectrometry results demonstrated a significant downregulation of STAT1 upon 24-hour 
ruxolitinib treatment in SET2 cells, with a fold change of 0.582. Expression of STAT1 and phosphorylated 
STAT1 (pSTAT1) protein was investigated along with the effect of short and long-term treatment with 1 
µM RUX on STAT1 mRNA expression. Figure 18 shows the relative protein expression of STAT1 and 
pSTAT1 via Western Blot analysis in SET2 and HEL cells 24-hours post-treatment with ruxolitinib. 
 
 
 
 
 
 
Figure 18: Western Blot images of STAT1 and pSTAT1 target proteins expressed in SET2 and HEL cells grown in the presence 
or absence of 1 µM RUX for 24 hours (n=3 and n=2 respectively). Western blot analysis of total STAT1 and phosphorylated 
STAT1 (91 kDa), and α-tubulin (50 kDa) proteins in SET2 and HEL cells cultured in the presence or absence of 1 µM RUX. For this 
report, only one blot has been shown which is representative of all biological repeats in each cell line.  
Figure 18 shows western blot nitrocellulose membranes incubated with antibodies against STAT1, 
phosphorylated STAT1 and the housekeeping protein α-tubulin, for loading control purposes. A 
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qualitative decrease in expression of both total STAT1 and phosphorylated STAT1 (pSTAT1) protein can 
be seen in SET2 cells in response to 1 µM RUX after 24 hours. Densitometry analysis was also performed 
to obtain a quantitative evaluation of protein expression, as shown below. 
 
Figure 19: Densitometry of STAT1 and pSTAT1 protein expression in SET2 cells upon 24-hour treatment with 1 µM RUX, 
showing fold change against respective control cells (n=3). Relative protein expression of A) STAT1 and B) pSTAT1 upon 24-
hour treatment with 1µM RUX in SET2 cells, relative to untreated control. All samples were normalized to expression levels of α-
tubulin (loading control) and analysis performed using ImageLab software. Each bar represents the mean of three biological 
repeats with error bars indicating the standard deviation between replicates. Unpaired T-test: STAT1: p<0.0001. pSTAT1 
p<0.0001. 
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Figure 20: Densitometry of STAT1 and pSTAT1 protein expression in HEL cells upon 24-hour treatment with 1 µM RUX, 
showing fold change against respective control cells (n=2). Relative protein expression of A) STAT1 and B) pSTAT1 upon 24-
hour treatment with 1µM RUX in HEL cells, relative to untreated controls. All samples were normalized to expression levels of α-
tubulin (loading control) and analysis performed using ImageLab software. Each bar represents the mean of two biological 
repeats with error bars indicating the standard deviation between replicates. Unpaired T-test: STAT1 p=0.0001, pSTAT1 
p=0.0001).  
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Densitometry analysis displayed in Figure 19 shows the protein expression of total STAT1 (Figure 19A) 
and pSTAT1 (Figure 19B) and indicates a significant decreased expression of both active and inactive 
STAT1 after 24-hour treatment of SET2 cells with 1 µM RUX (unpaired T-test: STAT1 p=0.0001, pSTAT1 
p=0.0001). In contrast, HEL cell densitometry analysis shown in Figure 20 indicates the protein 
expression of total STAT1 (Figure 20A) and pSTAT1 (Figure 20B) is not significant altered after 1 µM RUX 
treatment after 24 hours.  
 
To further confirm that the expression of STAT1 protein is downregulated in SET2 cells upon RUX 
treatment, results from the mass spectrometry analysis explained in Section 3.2 were further analysed 
to look specifically at the expression of STAT1 (Uniprot ID: P42224). The resulting box plot was drawn 
illustrating the intensity of STAT1 ions detected in untreated SET2 cells and cells treated with 1 µM RUX 
for 24 hours.  
Figure 21: Box plot of STAT1 protein expression in RUX-treated and untreated SET2 cells, as determined by mass 
spectrometry. Each point indicates the expression of STAT1 protein in each sample injection (n=3 biological repeats, n=3 
injections per sample). Box ends are indicative of Q1 (25th percentile) and Q3 (75th percentile) while the band inside the box 
indicates the Q2 (median) value. Whiskers represent the minimum and maximum values of the sample sets. Welch’s T-test p= 
7.359x10-8 
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The box plot in Figure 21 shows the expression of STAT1 protein in SET2 cells is significantly 
downregulated in response to 24-hour RUX treatment, as detected by mass spectrometry analysis. A 
Welch’s t-test was performed and showed that the expression of STAT1 protein is significantly 
downregulated in response to 1 µM RUX (p=7.359x10-8). 
 
To investigate the short and long-term effects of RUX on STAT1 mRNA expression in ET, SET2 cells were 
cultured with RUX for up to 6 hours and harvested every 2 hours. Another experiment investigated the 
effect of RUX at 24-hour intervals for up to 72 hours. Isolated mRNA was converted to cDNA and Q-RT-
PCR performed on the samples to examine the expression of STAT1. Figure 22 shows the expression of 
STAT1 in treated SET2 cells, relative to the mRNA expression in untreated cells. 
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Figure 22: Relative gene expression of STAT1 upon treatment with 1 µM RUX in SET2 cells. A) 1 µM RUX treatment of SET2 
cells for up to 72 hours, with cells harvested every 24 hours (n=3). B) SET2 cells treated with 1 µM RUX for a total of 6 hours, 
with cells harvested at 2-hour time points (n=2). Each bar in A) and point in B) represents the mean of the biological repeats 
with error bars indicating standard deviation. In A), fold change plotted against untreated cells at 24 hours. Two-way ANOVA: 
p=0.0076. In B), fold change plotted relative to untreated cells at 0hr time point. Two-way ANOVA: p= 0.2759.  
 
The results in Figure 22A indicate the relative expression of STAT1 mRNA after 24, 48 and 72 hours in 
SET2 cells cultured in the presence and absence of 1 µM RUX, with two-way ANOVA performed for 
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significance between treated and untreated samples over 72 hours. The graph shows a significant 
decrease in STAT1 expression in treated SET2 cells compared to untreated cells (p=0.0076).  
 
In comparison, Figure 22B shows the relative fold change of STAT1 expression in SET2 cells upon RUX 
treatment, compared to STAT1 levels within untreated cells harvested at 0hrs. Two-way ANOVA analysis 
of Figure 14A shows that STAT1 expression in SET2 cells upon treatment with 1 µM RUX was not 
significantly affected within the first 6 hours post-treatment (p=0.2759). A trend of decreasing 
expression can be seen however, more biological repeats of this experiment may be needed, and time 
point extended to observe at what point a significant decrease in STAT1 expression in SET2 cells is 
reached.  
 
3.6. The effect of 1 µM ruxolitinib and 1 µg/ml IFN-α on proliferation in ET and PV 
To investigate the role of STAT1 in the pathogenesis of PV and ET, both cell lines were treated with RUX, 
IFN-α (a STAT1 activator) and a combination of the two drugs. For growth curves involving a 
combination of RUX and IFN-α, cells were seeded at a density of 5x10⁴ cells/ml. Cells were treated with 
1 µM RUX and/or 1 µg/ml IFN-α and cultured at 37°C 5% CO₂ for a total of 72 hours. At 24-hour 
intervals, a single cell suspension was made and 50 µL cell suspension was removed. Cells were counted, 
and Trypan Blue exclusion assay performed as per Section 2.1.3. 
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Figure 23: 72-hour growth curve of A) SET2 and B) HEL cells treated with 1 µM RUX, 1 µg/ml IFNα or a combination of the two 
treatments, with cells counted every 24 hours (n=3). Each point represents the mean of the biological repeats with error bars 
indicating the standard deviation. Two-way ANOVA results: SET2 p=0.2037. HEL p<0.0001.  
 
Figure 23 shows the density of SET2 and HEL cells every 24 hours for a total of 72 hours when treated 
with 1 µM RUX, 1 µg/µL IFN-α, a combination of RUX and IFN-α, or VC (DMSO). The graphs illustrate that 
cellular proliferation is negatively affected by IFN-α and RUX as single agents and in combination as a 
A 
B 
98 
 
dual treatment after 72 hours in both cell lines. Figure 23A shows the greatest effect on SET2 cell 
proliferation was seen in cells subject to a combination of RUX and IFN-α treatment after 72 hours. Two-
way ANOVA repeated measures analysis shows no overall significant difference in cell proliferation 
between the 3 treatment sets (p=0.2037). Bonferroni multiple comparisons analysis showed that the 
significant differences observed were after 72 hours when comparing untreated SET2 cells to cells 
treated 1 µM RUX (p<0.05) and with a combination of 1 µM RUX and 1 µg/ml IFN-α (p<0.05).  
 
In the HEL cell line shown in Figure 23B, two-way ANOVA repeated measures analysis indicated a 
significant difference in cellular proliferation across the different treatment options (p=0.0001). 
Bonferroni multiple comparisons analysis indicated a significant difference in proliferation in RUX-
treated cells at 48 and 72 hours compared to untreated control cells (p<0.01 and p<0.0001 respectively). 
When comparing control cells to IFN-α treatment, a significant decrease in proliferation was observed at 
48 and 72 hours (p<0.05 and p<0.0001 respectively). The combination of RUX and IFN-α showed a 
similar pattern with respect to decreasing proliferative capacity as the HEL cells treated with RUX alone 
as significance was observed at 48- and 72- hours post-treatment (p<0.01 and p<0.0001). Comparison of 
IFN-α and RUX as single therapeutic agents showed a significant difference in proliferation after 72 
hours (p<0.0001) while comparison of IFN-α with the dual treatment (RUX + IFN-α) showed a significant 
difference in these two treatments at 72 hours (p<0.001). There was no significant difference in 
proliferative capacity in HEL cells treated with RUX alone compared to cells treated with a combined 
therapy of RUX and IFN-α over the 72 hours observed.  
 
During cell counts in the production of growth curves shown in Figure 16, cell viability was also assessed 
by Trypan Blue exclusion assay. The Trypan Blue assay data shown below in Figure 24 is associated with 
samples taken for growth curve analysis in Figure 23.  
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Figure 24: A) SET2 and B) HEL cells grown in the presence or absence of 1 µM RUX, 1 µg/ml IFN-α or a combination of the two 
treatments. Cell viability was assessed over 72 hours and determined by Trypan Blue every 24 hours (n=3). Each bar 
represents the mean of the biological repeats with error bars indicating the standard deviation. Two-way ANOVA: SET2 
p=0.0009. HEL p=0.0002.  
 
Figure 24 shows the assessment of cell viability by Trypan Blue exclusion assay in SET2 and HEL cells 
assessed every 24 hours for a total of 72 hours. Cells were treated with 1 µM RUX, 1 µg/ml IFN-α or a 
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combination of these two treatments. SET2 cell viability over 72 hours is shown in Figure 24A and 
demonstrates how all treatments negatively affect the viability of SET2 cells in comparison to untreated 
cells. Two-way ANOVA repeated measures and Bonferroni multiple comparisons analysis showed no 
significant decrease in cell viability in RUX-treated cells at any time point. With respect to IFN-α 
treatment, no significant difference in viability was seen over the 72-hour period observed when 
compared to untreated cells. This may be due to large error bars in the RUX and IFN single treatment 
groups. Dual treatment with RUX and IFN-α showed a significant difference in viability only after 72 
hours (p<0.05). There was also no significant difference observed when comparing RUX-treated cells to 
IFN-α alone or cells treated with a combination of RUX and IFN-α.   
 
Treatment of HEL cells with RUX, IFN-α or a combination of the two show a different pattern to the SET2 
cells (Figure 24B). Bonferroni multiple comparisons analysis showed a significant difference in RUX-
treated cells compared to control cells after 48 and 72 hours (p<0.05 and p<0.0001). Dual treatment 
with RUX and IFN-α showed significant decrease compared to control cells after 72 hours (p<0.0001) 
while IFN-α treatment did not affect cell viability across the 72 hours observed in comparison to 
untreated cells. There was a significant difference in HEL cell viability when comparing RUX and IFN-α as 
single treatments at 72 hours (p<0.001) and when comparing IFN-α single treatment to the combined 
treatment of RUX and IFN-α (p<0.0001). 
 
Cellular proliferation was also assessed by MTS assay. As described previously, 1x10⁴ cells were grown in 
a 96-well plate in the presence or absence of 1 µM RUX and cultured for 72 hours at 37°C 5% CO₂. 
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Figure 25: Cell proliferation in A) SET2 and B) HEL cells determined by MTS assay 72 hours post-treatment with 1 µM RUX, 1 µg/ml IFN-α or a combination of the two drugs 
for 72 hours, normalised to untreated control cells (n=3 and n=4 respectively). Each bar represents the mean of the biological repeats with error bars indicating the standard 
deviation. One-way ANOVA: SET2 p<0.0001. HEL p<0.0001. 
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The results of the MTS assay in Figure 25 show the percentage proliferation of SET2 and HEL cells 
treated with 1 µM RUX, 1 µg/ml IFN-α, a combination of the two treatments or VC (DMSO), with results 
normalized to the VC. One-way ANOVA shows that for both cell lines, there is a significant difference in 
the proliferation of both SET2 and HEL cell lines when cultured with all treatment options (p<0.0001). 
This experiment shows that cellular proliferation is negatively affected by RUX and IFN-α treatment in 
both SET2 and HEL cells after 72 hours. Tukey’s multiple comparisons test was performed to compare 
between treatment groups. In SET2 cells, shown in Figure 25A, the proliferation of cells treated with 
RUX was significantly decreased compared to untreated cells 72 hours post-treatment (p<0.0001). This 
effect was the same when comparing untreated cells to cells treated with a combination of RUX and IFN-
α (p<0.0001). There was also a significant difference in proliferation in cells treated with IFN-α as a 
single agent compared to both other treatments containing RUX (single and dual agent with IFN-α 
(p<0.0001)). No significant difference was seen when comparing untreated cells to those treated with 
IFN-α alone. There was also no significant difference in response comparing RUX alone to the 
combination of RUX and IFN-α. This pattern was mirrored in HEL cells, as Figure 25B shows the MTS 
assay results of HEL cells treated with RUX and IFN-α or a combination of the two drugs. 
 
3.7. The effect of 1 µM ruxolitinib and 5 or 10 µM fludarabine on proliferation 
Fludarabine, a selective STAT1 inhibitor, was also used as a single and dual treatment to investigate the 
role of STAT1 in the pathogenesis of PV and ET. For growth curves involving a combination of RUX and 
FLU, cells were seeded at a density of 5x10⁴ cells/ml. Cells were treated with 1 µM RUX and/or 5 µM or 
10 µM FLU and cultured at 37°C 5% CO₂ for a total of 72 hours. At 24-hour intervals, a single cell 
suspension was made and 50 µL cell suspension was removed. Cells were counted, and Trypan Blue 
exclusion assay performed as per Section 2.1.3. 
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Figure 26: 72-hour growth curve of A) SET2 and B) HEL cells treated with 1 µM RUX, 5 or 10 µM FLU or a combination of the 
treatments, with cells counted every 24 hours (n=3). Each point represents the mean of the biological repeats with error bars 
indicating the standard deviation. Two-way ANOVA: SET2 p<0.0001. HEL p<0.0001.  
 
Two-way ANOVA and Bonferroni multiple comparisons tests were performed to investigate the effect of 
different single and dual treatments on the proliferation of both SET2 and HEL cells over a period of 72 
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hours. In the SET2 cell line shown in Figure 26A, Bonferroni multiple comparisons test showed no 
significant difference in cellular proliferation when comparing untreated cells to any of the treatment 
options except when untreated cells were compared to cells under RUX + 10 µM FLU treatment after 72 
hours (p<0.01). When comparing RUX alone to 5 µM FLU, a significant increase in expression was seen 
after 72 hours (p<0.05). No significance was seen at any time point when comparing RUX alone to 10 µM 
FLU. With the combination therapies, a significant decrease in proliferation was only seen when 
comparing RUX alone to RUX + 10 µM FLU (p<0.05).  
  
With respect to HEL cells in Figure 26B, Bonferroni comparisons following two-way ANOVA analysis 
shows that there was a significant decrease in cellular proliferation in HEL cells under any treatment 
condition after 48 and 72 hours (p<0.0001 for both) but not at the 24-hour time point. Significance was 
achieved after 72 hours when comparing RUX and both concentrations of FLU (RUX vs 5 µM FLU p<0.05: 
RUX vs 10 µM FLU p<0.0001). When using a combination of RUX and FLU, significance was achieved at 
48 hours and continued to 72 hours with both concentrations of FLU when compared to RUX treatment 
alone (RUX vs RUX + 5 µM FLU: 48hr p<0.05, 72hr p<0.0001; RUX vs RUX + 10 µM FLU: 48 and 72hr 
p<0.0001). 
 
During cell counts in the production of growth curves shown in Figure 20, cell viability was also assessed 
by Trypan Blue exclusion assay. The Trypan Blue assay data shown below in Figure 27 is associated with 
samples taken for growth curve analysis in Figure 26.  
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Figure 27: A) SET2 and B) HEL cells grown in the presence or absence of 1 µM RUX, 5 or 10 µM FLU or a combination of the 
treatments. Cell viability was assessed over 72 hours and determined by Trypan Blue every 24 hours (n=3). Each bar 
represents the mean of the biological repeats with error bars indicating the standard deviation. Two-way ANOVA: SET p<0.0001. 
HEL p<0.0001  
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As before in Figure 26, two-way ANOVA and Bonferroni multiple comparisons tests were performed on 
the treatments in each cell line. With respect to SET2 cells in Figure 27A, no significant decrease in cell 
viability was seen in any of the single treatments or in the combination treatment with a low FLU 
concentration. In the cells treated with RUX + 10 µM FLU, a significant decrease in viability was only 
seen at the 72-hour time point (p<0.001). When comparing treatments to RUX-treated cells, the only 
significant difference in cell viability was seen when compared against the RUX + 10 µM FLU group after 
72 hours (p<0.01).  
 
In the HEL cell line shown in Figure 27B, there was a significant decrease in cell viability in RUX-treated 
cells after 48 and 72 hours compared to untreated cells (p<0.001 for both). Single agent treatment with 
5 µM FLU resulted in a significant drop in viability after 72 hours (p<0.0001) and in the 10 µM FLU 
treatment group, cell viability was decreased significantly after 48 hours and further decreased after 72 
hours (p<0.001 and p<0.0001 respectively. Both dual treatment groups (RUX + 5 µM FLU and RUX + 10 
µM FLU) resulted in the same significant decrease in cell viability after 48 and 72 hours when compared 
to the control group (p<0.0001). In comparison to RUX treatment alone, no significant difference was 
seen when comparing cell viability within the 5 µM FLU treatment group. At 10 µM FLU, a significant 
difference in cell viability was seen after 72 hours (p<0.01). Cell viability levels with the dual treatment 
of RUX + 5 µM FLU was statistically significant at 72 hours when compared to RUX alone (p<0.001). 
There was also a significant difference in viability by Trypan Blue assay when comparing RUX alone and 
RUX + 10 µM FLU 48-hours and 72-hours post-treatment (p<0.0001 for both).
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Figure 28: Cell proliferation in A) SET2 and B) HEL cells determined by MTS assay 072 hours post-treatment with 1 µM RUX, 1 µg/ml IFN-α or a combination of the two drugs 
for 72 hours, normalised to untreated control cells (n=3 and n=4 respectively). Each bar represents the mean of the biological repeats with error bars indicating the standard 
deviation. One-way ANOVA: SET2 p<0.0001. HEL p<0.0001. 
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The MTS assay in Figure 28 shows that the percentage proliferation of SET2 (28A) and HEL (28B) cells 
treated with 1 µM RUX, 5 µM and 10 µM FLU and a combination of the treatments or VC (DMSO), with 
results normalized to the VC. One-way ANOVA shows that there is a significant difference in cell viability 
with each of the single and combinations of treatments in both cell lines (p<0.0001). Bonferroni post-
hoc test shows that cellular proliferation is significantly negatively affected by RUX and FLU treatment in 
both SET2 and HEL cells after 72 hours, and a combination of the two treatments at both concentrations 
of FLU when compared to untreated cells (p<0.001). There is a significant difference in the effect of 
ruxolitinib alone compared to the combination of RUX and 5 µM FLU and with RUX and 10 µM FLU in 
both cell lines (p<0.05 for SET2 and p<0.01 for HEL cells). There is also a significant difference in cellular 
viability when comparing 5 µM and 10 µM FLU as single agents, as 10 µM performs better at decreasing 
viability in both cell lines (p<0.01).  
By looking at the trend of the two graphs, FLU treatment appears to have more of a negative affect HEL 
cells compared to SET2 cells, as RUX treatment alone has a greater effect on cell viability in SET2 cells 
whereas 5 µM FLU treatment is more effective than RUX treatment alone in HEL cells.  
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4. Discussion 
4.1. Ruxolitinib significantly decreases proliferation and viability of SET2 and HEL cells  
Previous studies have shown that the introduction of ruxolitinib into cell culture medium decreases 
cellular proliferation in HEL and SET2 cells (Xu, et al., 2016) (Liang, et al., 2016) (Quintás-Cardama, et al., 
2010) (Szymańska, et al., 2015) and this is also reflected in the ability of ruxolitinib to reduce the 
haematocrit and platelet count in PV and ET patients respectively (Verstovsek, et al., 2014) (Verstovsek, 
et al., 2014). The results in this report align with current literature and show a significant decrease in cell 
proliferation in both SET2 and HEL cells upon treatment with 1 µM ruxolitinib after 72 hours. 
Considering growth curve patterns, no significant effect on proliferative capacity was seen after 24 
hours in either cell line but significance was achieved at 48 hours and maintained at 72 hours. 
Furthermore, RUX is known to be cytotoxic to JAK-STAT activated cells (Wen, et al., 2015) (Quintás-
Cardama, et al., 2010).  
 
Cell viability upon treatment with ruxolitinib was investigated and shown to be significantly decreased 
over the 72-hour period, confirmed by Trypan Blue assay. Statistical analysis showed that HEL cell 
proliferation was significantly affected by RUX after 24 hours, whereas a significant reduction in viability 
in SET2 cells was observed after 48 hours, suggesting that the HEL cell line may be more sensitive to 
JAK2 inhibition by ruxolitinib. Previous researchers have demonstrated a dose-dependent reduction in 
viability in HEL cells treated with RUX 48-hours post treatment. The group report that HEL proliferation 
was not completely inhibited by RUX at 4 nM in comparison to BA/F3 cells expressing JAK2V617F that 
exhibited complete inhibition of proliferation, suggesting that proliferation in HEL cells is not entirely 
JAK2V617F-dependent (Quintás-Cardama, et al., 2010). It is worth noting that the study used a much 
lower concentration of RUX than the concentration used in this report which may explain the 
differences in results. In contrast, after 72 hours, both cell lines showed a similar level of reduced 
proliferative capability upon treatment with ruxolitinib, as determined by Trypan Blue exclusion assay. 
In relation to MTS results, both cell lines treated with ruxolitinib showed the same reduced proliferative 
capacity after 72 hours, with the same statistical significance. Overall, a similar pattern was described in 
both SET2 and HEL cells with respect to cell proliferation and viability, suggesting both cell types have a 
similar dependence on JAK2 signalling to maintain their hyperproliferative disease state.  
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In this study, both Trypan Blue exclusion assay and MTS assay were used to assess cell viability and 
proliferation. Trypan blue is a negatively-charged azo dye that is routinely used to assess cell viability by 
exclusively staining dead cells with a blue dye. Trypan blue exclusion method is one of the earliest and 
simplest viability assays and is based on the principle that live cells possess an intact cell membrane of 
which the impermeable dye cannot penetrate. In contrast, dead cells have a porous cell membrane and 
therefore the dye is able to enter the cytoplasm and stain the cells a blue colour which can be visualised 
under a microscope (Tran, et al., 2011). For the purpose of this study, use of trypan blue exclusion assay 
to determine cell viability was convenient as it can be performed using a light microscope and 
haemocytometer, so does not need particularly specialised equipment, and can determine cell viability 
quickly and accurately.  
 
MTT assay is commonly used as colorimetric assay to investigate cell viability and proliferation based on 
detecting cellular metabolic activity. The assay uses a yellow tetrazolium salt known as 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), which is positively charged and readily 
penetrates cells. Viable cells with active metabolism use mitochondrial dehydrogenases to reduce MTT 
to an insoluble purple formazan product (Liu, et al., 1997). This product is then trapped inside living cells 
and can be detected by spectrophotometric analysis. The absorbance at 570nm correlates to the 
amount of formazan within the cells which subsequently correlates to the metabolic activity within the 
cells, as determined by the activity of mitochondrial dehydrogenase enzymes. Dead cells have lost their 
ability to convert MTT to a formazan and therefore, the purple colour formed is an indicator of the 
metabolic activity in viable cells.  
 
In this study, the MTS assay is used. This assay was developed after the MTT assay but uses the same 
general principle of conversion of a tetrazolium salt into a coloured formazan product. Unlike MTT, MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt) is 
negatively charged and does not readily penetrate cells. This compound uses an intermediate electron 
acceptor, known as PMF (phenazine methosulfate), to facilitate the reduction of the tetrazolium salt 
into the purple formazan product (Riss, et al., 2013). MTS assay is commonly described as a ‘one-step 
MTT assay’, as the reagent can be added straight to the cell culture without the intermittent steps 
required in the MTT assay needed to solubilize the formazan product. Furthermore, Alamar Blue uses 
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cellular metabolism to investigate cell proliferation and viability and is similar in principle to the MTT 
and MTS assays, in which a non-toxic permeable dye is reduced to a pink fluorescent product which is 
then measured by a spectrophotometer (Hamid, et al., 2004). Advantages of using Alamar Blue over 
MTS would be the nontoxic nature of the dye, allowing for the monitoring of cells in culture over time 
and providing somewhat more accurate information with respect to both proliferative rates and viability 
in comparison to MTT/MTS assays (O'Brien, et al., 2000).  
 
One of the most informative viability assays available is named the live/dead assay, for its ability to 
present information relating to the number of viable cells, cellular morphology and cell distribution and 
metabolic activity. Instead of a traditional colour change assay as described above, this assay utilizes 
dual-colour fluorescent signals to discriminate between viable, proliferating cells and non-viable cells 
based on intracellular esterase activity (Periasamy, 2013). The two dyes present in this assay are calcein 
acetoxymethyl ester (AM) and ethidium homodimer. The former is a non-fluorescent based dye that 
enters both viable and non-viable cells by permeating the cell membrane. It is then hydrolysed by 
intracellular esterases and emits a green fluorescent signal, detectable under a fluorescent microscope 
which is used to determine the overall cell number and metabolic activity. In contrast, ethidium 
homodimer is a non-permeable red fluorescent dye that only penetrates compromised cell membranes, 
therefore entering non-viable cells and binding to DNA to emit red fluorescence (Maltaris, et al., 2006).  
 
Cell enumeration and assessment of viability and proliferation in this study was important in providing 
information about drug efficacy and toxicity in cancerous cell lines. Through evaluation and 
consideration of different assays, it may have been more appropriate to use the Alamar Blue assay in 
this study for the investigation of cell viability over 72 hours in the long-term experiments, due to its 
non-toxicity in cell culture. Live/dead stain would have also been beneficial for investigating cell viability 
and proliferation over time and would provide a more accurate measure of viability and overall cell 
count due to its dual colour nature, however would require use of a fluorescent microscope and 
accompanying software, making this method more technically challenging but more reliable.  
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4.2. Ruxolitinib treatment decreases the expression of JAK2 downstream targets  
Liquid-chromatography with tandem mass spectrometry (LC-MS/MS) is often the preferred method for 
identifying and quantifying proteins in a biological sample (Walther & Mann, 2010) (Han, et al., 2008). 
There are two main types of LC-MS/MS methods commonly used, both of which utilize proteolysis to 
convert proteins into peptides before separation by the LC system. The most widely used method is 
shotgun proteomics. In this method, the MS system is operated in a data-dependent acquisition 
method, where selected precursor ions from MS1 are selected for fragmentation in MS2 and the 
resulting fragment ion spectra is assigned to the corresponding peptide sequence by sequence database 
searching  (Kapp & Schütz, 2007) (Nesvizhskii, 2007). The second method, targeted proteomics, uses the 
MS in a selected reaction monitoring (SRM) mode, whereby a sample is queried for the presence and 
quantity of a set of peptides specified prior to data acquisition. During this analysis, the acquisition of 
predefined pairs of precursor and product ion masses are analysed to detect peptides of interest in a 
biological sample as oppose to detecting targeted precursors, as in shotgun proteomics (Lange, et al., 
2008). Both methods have their advantages and disadvantages: shotgun proteomics is superior for 
detecting the maximum number of proteins from one or few samples but suffers with irreproducible 
precursor ion selection and under-sampling with larger samples sets (Liu, et al., 2004) (Michalski, et al., 
2011); targeted proteomics is more reproducible and accurate for the detection of sets of specific 
proteins in complex samples however this method cannot routinely quantify large peptide fractions 
(Kiyonami, et al., 2011).  
 
To overcome these limitations, data independent acquisition (DIA) methods have been developed which 
consist of consecutive scans of fragment ion spectra of all precursors in predetermined isolation 
windows. SWATH-MS is a DIA method that combines targeted data extraction proteomics and the use of 
predetermined fragment ion spectra to obtain a complete record of all detectable peptide precursors in 
a sample. This data is then permanently stored and can be accessed at any time for cross-reference 
analysis. SWATH, as the name suggests, utilizes sequential isolation windows of a known m/z range of 
precursor ion spectra detected in MS1 and fractionates all peptides in that specific m/z window in MS2 
(Ludwig, et al., 2018). SWATH-MS is now commonly used for the quantitative analysis of complex 
biological samples for the identification of potential biomarkers of disease (Guo, et al., 2018) (Harrison, 
et al., 2018) (Sajic, et al., 2018) (Miyauchi, et al., 2018). In this report, SWATH-MS was used to 
investigate the effect of ruxolitinib on downstream JAK2 targets in SET2 cells, a cell line representative 
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of ET. The results show several pathways that were differentially affected by ruxolitinib treatment, with 
the most affected pathways being associated with cell cycle progression, apoptosis and post-
translational processing. 
 
Signal Transducers and Activators of Transcription (STATs) 
STAT1 is thought to be the driver of the ET phenotype, with increased STAT1 activity promoting 
megakaryocytic development and producing an ET-like phenotype, whereas lower STAT1 activity 
produces a PV-like phenotype (Chen, et al., 2010) (Shi, et al., 2016) (Duek, et al., 2014). Aberrant 
signalling through STAT1 has also been documented in both acute and chronic leukaemia subtypes (Lin, 
et al., 2000) (Weber-Nordt, et al., 1996). It has been shown that decreases in STAT1 correlate with a 
defective ability to initiate an innate immune response to viral infection (Durbin, et al., 1996) and since 
JAK2 activity is strongly associated with STAT1 phosphorylation (Briscoe, et al., 1996), inhibition of 
STAT1 is likely to induce compromised immunity in ruxolitinib-treated patients. Gene expression via 
microarray study in CD34+ cells from MPN peripheral blood shows that STAT1 is upregulated in 
JAK2V617F-positive ET patients (Čokić, et al., 2015). In this study, STAT1 expression was significantly 
decreased at a transcriptional level with ruxolitinib treatment after 24 hours and was still significantly 
decreased 72 hours after treatment in SET2 cells. Q-RT-PCR results from pellets harvested within 6 hours 
post-RUX treatment show no initial significant change in STAT1 expression, therefore indicating it may 
take over 6 hours for RUX to have a significant effect on STAT1 expression in SET2 cells. More 
experimental repeats are needed to confirm these results and the time points extended to investigate at 
what time point ruxolitinib significantly decreases the mRNA expression of STAT1. STAT1 protein 
expression was also significantly decreased with 24-hour ruxolitinib treatment, as shown by Western 
Blot and mass spectrometry analysis. In addition, the expression of phosphorylated STAT1 protein was 
also shown to be significantly decreased in ruxolitinib-treated SET2 cells 24 hours after treatment. This 
finding supports previous literature where ruxolitinib was shown to inhibit the phosphorylation of STAT1 
in SET2 cells (Nitulescu, et al., 2017). The decrease in STAT1 and phosphorylated STAT1 can be explained 
through direct inhibition of JAK2 via ruxolitinib, with inhibition of JAK2 leading to inactivation of JAK2 
monomers and no recruitment of STAT proteins. In contrast, the protein expression of STAT1 and 
phosphorylated STAT1 in HEL cells was not significantly altered. This is most likely due to the large error 
bars, particularly in the case of phosphorylated STAT1 and more biological repeats may be necessary to 
indicate significance in this experiment.  
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MPN cells are known to rely on STAT3 and STAT5 for survival and proliferation (Yan, et al., 2012) 
(Friedbichler, et al., 2010) (Walz, et al., 2012) (Funakoshi-Tago, et al., 2010) (Jedidi, et al., 2009) (Röder, 
et al., 2001) (Kleppe, et al., 2015). Furthermore, STAT5 activation is necessary for tumourigenesis 
induced by the JAK5V617F and is a critical signalling molecule for JAK2V617F (Funakoshi-Tago, et al., 
2010). Increased protein expression of STAT5 and phosphorylated STAT5 has previously been associated 
with JAK2V617F-positive cells (James, et al., 2005) however, studies have shown no significant 
difference in total STAT5 expression in JAK2V617F-positive cells upon treatment with ruxolitinib 
(Sahasrabuddhe, et al., 2015) (Quintás-Cardama, et al., 2010) (Fridman, et al., 2007). In this report, the 
expression of both isomers of STAT5 were examined. STAT5A and STAT5B protein expression was not 
significantly altered in treated SET2 cells compared to untreated controls, as determined by Western 
Blot analysis. In previous studies, STAT5 phosphorylation was inhibited by ruxolitinib in JAK2V617F 
positive cells (Quintás-Cardama, et al., 2010) (Sahasrabuddhe, et al., 2015) (Ma, et al., 2013) (Fridman, 
et al., 2007). To confirm the findings of these studies, phosphorylated STAT5 antibody must be 
examined via western blot analysis. With regards to mRNA expression, STAT5B was unaffected by 
ruxolitinib treatment in SET2 cells while STAT5A expression has not yet been determined. 
 
There is additional evidence showing STAT3 expression is consistently upregulated in ET and this is 
independent of the presence of a JAK2 mutation (Čokić, et al., 2015) (Hui, et al., 2013) (Senyuk, et al., 
2009). STAT3 is activated through interferon and interleukin signals and is also activated through MAPK 
and c-src kinase (Silva, 2004) (Lim & Cao, 2006). Albeit a slight decrease in STAT3 protein expression was 
detected in SET2 cells treated with ruxolitinib after 24 hours, this change was not significant. STAT3 
expression gradually increased over time in treated cells and was upregulated compared to untreated 
cells after 72 hours however RNA expression was never significantly affected by RUX. This could be 
explained by STAT3 activation occurring through an alternate pathway, such as MAPK or c-src. 
Alternatively, it has been in reported that STAT3 has a role in tumour suppression, depending on the 
mutational background of tumour cells (de la Iglesia, et al., 2008) (Musteanu, et al., 2010). By this 
theory, an increase in transcription of STAT3 may be due to an increase in tumour suppression upon 
ruxolitinib treatment. Considering phosphorylation of STAT3, it is known that JAK2-specific inhibition 
blocks STAT3 phosphorylation (Colomiere, et al., 2009), so the expression of STAT3 protein may not alter 
significantly, but the phosphorylation status may change significantly under ruxolitinib treatment. The 
phosphorylation status of STAT3 should be investigated through western blot analysis.  
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Suppressors of Cytokine Signals (SOCS) 
SOCS1 and SOCS3 are both powerful regulators of JAK2 signalling (Greenhalgh & Hilton, 2001) and 
directly inhibit the kinase activity of JAK2 through association with the JH1 catalytic domain (Ungureanu, 
et al., 2002) (Nicholson, et al., 1999). SOCS1 RNA expression is not significantly altered by ruxolitinib 
treatment in this study however, due to large error bars, PCR should be repeated. Purchase of a new 
primer set may be necessary due to melt curve analysis showing multiple curves (data not shown). 
SOCS3 is regulated by DNA methylation and was shown to be increased in MPN granulocytes 
independent of JAK2 mutational status (Čokić, et al., 2015). SOCS3 mRNA expression was significantly 
downregulated after 24-hour treatment with ruxolitinib in SET2 cells. This is because SOCS3 is a known 
downstream target of JAK2/STAT signalling and constituent activation of JAK2/STAT through the 
JAK2V617F mutation activates SOCS3 through tyrosine phosphorylation. SOCS3 mRNA expression is 
significantly downregulated in response to 1 µM ruxolitinib treatment due to decreased STAT signalling 
through JAK2 as a result of JAK2 inhibition. The decrease in STAT signalling subsequently decreases the 
transcription of the SOCS negative regulators of JAK-STAT signalling.  
 
Cell Cycle Progression 
P53 is a tumour suppressor protein involved in cell cycle regulation through growth arrest, DNA repair 
and apoptosis (Harris, 1996). PSME3 is a negative regulator of p53 and functions by promoting its 
nuclear export and targets cell cycle inhibitors for degradation in a ubiquitin-independent manner 
(Chen, et al., 2007). If the expression of PSME3 is downregulated, as it is in RUX-treated SET2 cells, the 
intracellular levels of p53 and other cell cycle inhibitors will increase, halting cell cycle progression. 
Conversely, cytoskeleton-associated protein 2 (CKAP2) is a p53 target gene which is known to enhance 
p53 activity (Tsuchihara, et al., 2005) and this protein is downregulated in SET2 cells treated with RUX, 
leading to the attenuation of p53. PLK1 is essential during the M-phase of the cell cycle, as it regulates 
centrosome maturation and segregation, and spindle assembly and orientation (van de Weerdt & 
Medema, 2006). CDK2 is required for the transition between G1/S while M-phase inducer phosphatase 2 
(MPIP2) allows G2/M progression (Elledge, 1996) (Sur & Agrawal, 2016). Both proteins are significantly 
decreased upon RUX treatment, as determined by mass spectrometry analysis, providing more evidence 
of cell cycle inhibition under RUX treatment.  
 
116 
 
Interferon Regulatory Factor 1, abbreviated to IRF1, is a transcription factor able to activate the 
expression of various cytokines such as IFN-β (Miyamoto, et al., 1988). Deletion of IRF-1 has been 
associated with the development of both solid tumours and leukaemia subtypes (Willman, et al., 1993) 
(Nozawa, et al., 1998) and has thus been associated with tumour suppressive functions. In addition, it 
has been reported that IRF1 assists in the activation of p53 cell cycle regulator by recruitment of p300 
(Dornan, et al., 2004). Results of this report show that IRF1 mRNA expression is significantly upregulated 
in response to ruxolitinib in SET2 cells after 24 hours, suggesting that RUX treatment negatively affects 
the progression of the cell cycle and thus inhibits proliferation of SET2 cells. This is supported by 
previous growth curve results and examining cellular viability and proliferation. Conversely, DDX3X is a 
multifunctional ATP-dependent RNA helicase and is also involved in gene transcription, mRNA splicing, 
maturation and export (Leitão, et al., 2015) (Merz, et al., 2006) (Lai, et al., 2008). Increased expression of 
DDX3X has been associated with poor prognosis in both colorectal and breast carcinomas (Heerma van 
Voss, et al., 2017). DDX3X transcription was not significantly affected by treatment with ruxolitinib. 
ISG15 is a ubiquitin-like modifier known to have antiviral activity (Morales & Lenschow, 2013). 
Upregulation of ISG15 has been shown to decrease levels of oncogenic c-Myc which plays a role in cell 
cycle progression (Yoo, et al., 2018). ISG15 is upregulated, but not significantly, in RUX-treated SET2 
cells, therefore aiding cell cycle arrest. 
 
Heat Shock Proteins and other Molecular Chaperones 
With respect to chaperone proteins, CALR is a ubiquitous calcium-binding protein chaperone that is 
responsible for the quality control of N-glycosylated protein and in calcium storage in the ER (Michalak, 
et al., 2009). Mutations within CALR are the second most prevalent mutation in ET patients following the 
JAK2V617F mutation, and have been identified in 15-25% of ET patients (Imai, et al., 2017) (Nangalia, et 
al., 2013) (Rotunno, et al., 2014). It has been previously shown that CALR mutants activate the 
thrombopoietin receptor (MPL) after binding to its N-glycosylated residues in the ER (Chachoua, et al., 
2016) (Marty, et al., 2016). Moreover, MPL mutations have been identified in 3% of ET patients 
(Pardanani, et al., 2006), suggesting this chaperone may be of significance in ET. Expression of the CALR 
gene in treated cells increased over time up to 72 hours post-treatment. At 72 hours, expression of CALR 
had normalized to the levels observed in untreated cells but was not significantly affected by ruxolitinib 
treatment.  
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Heat shock proteins (HSP) are highly-conserved molecular chaperones that assist in the covalent folding 
or unfolding of newly synthesized polypeptides, the assembly/disassembly of macromolecular structures 
and transport of proteins across cellular membranes (Garrido, et al., 2001). Membrane-bound or 
extracellular HSPs are known to regulate apoptosis pathways (Gupta, et al., 2010) while intracellular 
HSPs show increased expression in the presence of cellular stress such as hypoxia, temperature changes, 
inflammation and infection (Jindal, 1996). HSPs are upregulated in a multitude of human cancers and 
are associated with increased proliferation and evasion of apoptosis (Lanneau, et al., 2008). Heat shock 
proteins are named according to their molecular weight, with HSP70 and HSP90 both being required for 
the differentiation of monocytes (Didelot, et al., 2008) (Jego, et al., 2014).  
 
HSP90 chaperones are ATP-dependent and are involved in the activation and stabalisation of proteins in 
cellular signalling pathways, such as JAK2, and regulates the progression of the cell cycle (Reed, 1999) 
(Burrows, et al., 2004). HSP90 is a key signalling molecule in malignancies (Pearl, et al., 2008) and has 
been shown to be upregulated in AML and in several solid tumours (Lancet, et al., 2010) (Rajan, et al., 
2011) (de Bono, et al., 2008). It has been shown that JAK2V617F-positive MPNs are dependent on 
HSP90, with enough evidence to develop HSP90 inhibitors for the treatment of JAKV617F+ MPNs 
(Marubayashi, et al., 2010) (Fiskus, et al., 2011). In this study, HSP90 was downregulated in SET2 cells in 
response to 1 µM ruxolitinib at a transcriptional level at 24, 48 and 72 hours, as determined by Q-RT-
PCR. This decreased expression was not significant, possibly due to large statistical error. Co-chaperones 
of HSP90 were shown to be downregulated in response to RUX, as detected by mass spectrometry. 
CHRD1, DNJC7 and TTI1 were all shown to be downregulated after 24-hour RUX treatment.  
 
HSP70 is an anti-apoptotic chaperone that regulates the function of NFkB. HSP70 is essential for the 
differentiation of primary erythroblasts (Ribeil, et al., 2007) has been shown to have a significant role in 
the pathogenesis of PV (Gallardo, et al., 2013). CML patients also show elevated levels of HSP70 (Ray, et 
al., 2004). In this study, HSP70 protein expression was significantly downregulated upon introduction of 
ruxolitinib into SET2 cell culture medium, as determined by both Western Blot and mass spectrometry, 
indicating a decrease in the cell’s anti-apoptotic mechanism required to prolong cell survival. HSPA8 is a 
constitutively expressed chaperone protein that forms part of the spliceosome and is required for the 
activation of a pre-mRNA splicing complex. HSPA8 is a member of the HSP70 family and is significantly 
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overexpressed in breast and endometrial cancer and is currently being investigated as a potential 
biomarker of disease (Hou, et al., 2016) (Shan, et al., 2016). CML patients also express high levels of 
HSPA8 and the upregulation of HSPA8 was partially dependent on STAT5-dependent transcriptional 
activation and results in cell cycle progression (José-Enériz, et al., 2008). In addition, HSPA5, also known 
as binding immunoglobulin protein (BiP), is also a highly-conserved member of the HSP70 chaperone 
protein family and is involved in the unfolded protein response (UPR), ER-associated degradation and 
calcium homeostasis (Wang, et al., 2017) and its overexpression has been noted in advanced breast 
cancer (Chen, et al., 2015) and even been the target of a new melanoma treatment (Cerezo & Rocchi, 
2017). mRNA expression of both HSPA8 and HSPA5B was downregulated, but not significantly, in SET2 
cells treated with 1 µM ruxolitinib for 24 hours, suggesting that RUX affects post-transcriptional and 
post-translational patterns in cells through interfering with the spliceosome function and degradation of 
misfolded proteins.  
 
Antigen Presentation  
The progression of PV and ET to MF has been correlated with chronic inflammation (Hasselbalch, 2012) 
and an imbalance in the regulation of immune and inflammatory genes (Skov, et al., 2012) (Skov, et al., 
2012). This is thought to impair the immune surveillance with respect to tumour cells and aid in the 
evasion of tumour cells from immune attack (Hasselbalch, 2012). It has been shown that defects in the 
expression of HLA class I on clonal myeloid cells may contribute to the aberrant tumour immune 
surveillance (Brodsky & Guagliardi, 1991) (Garrido, et al., 1997) (Garcia-Lora, et al., 2003) (Bukur, et al., 
2012) (Seliger, 2012). Downregulation of antigen presentation genes may lead to defects in T-cell 
recognition of foreign antigens and therefore a dampened immune response to malignant cells. The 
dysregulation of HLA and associated genes within malignant cells has been previously investigated in 
many different tumour types and MPNs and reports show a significant downregulation of several HLA-
related genes in MPN patients (Ferris, et al., 2006) (Meidenbauer, et al., 2004) (Seliger, et al., 2002) 
(Garrido, et al., 1997) (Pellagatti, et al., 2010) (Skov, et al., 2013). In addition, significant downregulation 
of members of the antigen presentation pathway have been demonstrated in CML progenitor cells, with 
antigen presentation pathway being the top downregulated pathway in CML (Tarafdar, et al., 2017). 
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MHC Class II downregulation has been associated with diffuse large B-cell lymphoma and is related to 
poor patient survival (Rimsza, et al., 2004). HLA-A was shown to be significantly downregulated in ET 
patients (Skov, et al., 2013). In this report, HLA-A was significantly upregulated in response to ruxolitinib 
treatment in the ET-representative SET2 cell line, suggesting an increased expression in antigen 
presentation genes. TAP-1 facilitates the transport of processed peptides to the ER (Nijenhuis & 
Hämmerling, 1996) before peptides associate with the MHC class I heavy chain and β2-microglobulin to 
form a functional MCH complex on the cell surface (Satler & Creswell, 1986). Cells with TAP mutations 
have decreased MHC class I expression and defective antigen presentation (Townsend, et al., 1989).  
Downregulation of TAP has been noted in various malignancies (Ren, et al., 2014) (Vambutas, et al., 
2000) (Ling, et al., 2017) while TAP-1 has also been shown to be significantly downregulated in MF 
patients (Skov, et al., 2013).  The results show that TAP-1 was significantly decreased in ruxolitinib-
treated SET2 cells. This may explain why patients treated with ruxolitinib experience an increased risk of 
opportunistic infections as a decrease in antigen presentation in response to RUX may lead to defective 
immune response to pathogens, despite an increase in HLA-A expression. 
 
Regulation of Apoptosis 
Apoptosis signalling in response to DNA damage was also significantly affected by RUX. This has been 
previously shown in a number of haematological cell lines, analysed by flow cytometry using Annexin V 
(Civallero, et al., 2017). This study also confirms the induction of caspase activation with ruxolitinib, 
which aligns with the findings in this report which show an upregulation of caspases under RUX 
treatment. In this report, BCL2-like protein 1 (B2CL1) and Ankyrin repeat and KH domain-containing 
protein 1 (ANKH1) are both significantly downregulated in response to RUX, as determined by mass 
spectrometry. Isoform 2 of ANKH1 has been shown to have anti-apoptotic effects by regulating caspase 
activation (Miles, et al., 2005) and its downregulation in RUX-treated SET2 cells suggests that RUX 
induces apoptosis. Similarly, the downregulation of B2CL1, which functions to inhibit caspase activation 
(Chao & Korsmeyer, 1988) also supports the role of RUX as an apoptosis-inducing compound. Other 
proteins involved in apoptosis inhibition were also significantly downregulated by SWATH-MS analysis, 
including DNAJA1 and PSME3. In contrast, some activators of apoptosis were also significantly 
downregulated in RUX-treated SET2 cells, such as DDX5, TPX2, NDK3 and FAK1. All these proteins 
contribute to the initiation and regulation of apoptosis but were seen to be downregulated in RUX-
treated cells. This finding is controversial and more research into the function of these genes in SET2 
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cells may be required. Conversely, proteins involved in promoting apoptosis were shown to be 
significantly upregulated upon RUX treatment, such as DDCD4, DNS2A, PML, F175B, IR3IPM, RN5A and 
HIP1. An increase in pro-apoptotic gene expression would be expected, as previous studies have 
confirmed the pro-apoptotic activity of RUX in JAK2-positive cell lines (Szymańska, et al., 2015). 
MCL1 is an anti-apoptotic gene which is activated by STAT3 (Guo, et al., 2015). It has been shown that 
JAK2V617F increases MCL1 activation and inhibition of JAK2 by ruxolitinib reduces MCL1 expression in 
SET2 cells (Guo, et al., 2015). Since there was no significant change in the RNA expression of STAT3, it 
would be expected that the expression of MCL1 is also unaffected by RUX treatment. In this report, 
MCL1 expression was significantly upregulated in response to ruxolitinib. This result is contrary to 
current literature however, it has been previously reported that alternative splicing of the MCL1 gene 
results in two transcripts with opposing function. The longer transcript has been shown to have anti-
apoptotic functions while the shorter transcript has pro-apoptotic properties (Bae, et al., 2000). Since it 
cannot be discerned which transcript is upregulated, the consequence of MCL1 upregulation in response 
to RUX cannot be fully elucidated.  
 
As mentioned previously, HEL cell samples were not analysed by SWATH-MS due to problems with cell 
viability. Experiments were only conducted on cells with a viability of 90% of greater and during culture 
of HEL cells, viability when expanding cell numbers for proteomic and translational analysis never 
exceeded 90% so cells were not harvested for this purpose. In addition, the added time constraints for 
this study meant that this cell line could not be analysed to the same degree as the SET2 cell line. 
Furthermore, data on the differential changes in protein and RNA expression in SET2 and HEL cells 72-
hours post-treatment would have complimented the analysis of growth curves and cell viability at these 
time points. Reflecting on these weaknesses within the study, the collection of both protein and RNA 
expression data by mass spectrometry and Q-RT-PCR for the both cell lines at multiple time points 
would have been exceptionally useful for a more extensive investigation into the molecular and genetic 
pathogenesis of each disease phenotype and the differentiating elements that define each of these 
hyperproliferative MPNs.  Given more time, this analysis would have been performed and a more 
complete comparison between the effects of each treatment on the different phenotypes would have 
been conducted. 
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4.3. IFN-α and ruxolitinib dual treatment shows little synergy compared to ruxolitinib alone 
The ability of IFN-α to reduce clonal burden and successfully initiate haematological and molecular 
responses makes this therapy attractive for combinational treatment in association with ruxolitinib. IFN-
α treatment alone shows little effect on cell proliferation and viability in SET2 and HEL cells. This may be 
due to the absence of other immune cells in culture as one role of IFN-α is to stimulate immune cells 
which have a direct apoptotic effect on transformed cells, such as NK and T-cells. Still, a slight decrease 
in proliferation and viability is observed which could be explained by IFN-α’s intracellular pro-apoptotic 
mechanism, as mentioned previously. The combination of RUX and IFN-α has shown little synergy 
compared to RUX treatment alone, with respect to decreasing proliferation and viability of both MPN 
representative cell lines. Growth curves, Trypan Blue exclusion assay and MTS assay all show a similar 
pattern with respect to both RUX and IFN-α therapy, indicating that both cell types behave in a similar 
manner in response to JAK2 inhibition and IFN-α treatment.  
 
4.4. Combination of fludarabine and ruxolitinib is more effective than ruxolitinib alone 
The use of fludarabine in the treatment of MPNs has mainly been restricted to conditioning regiments in 
preparation for stem cell transplantation in myelofibrosis patients (idiopathic or post-PV or -ET MF) 
(Kerbauy, et al., 2007) (Slot, et al., 2015) (Ito, et al., 2012). This has been effective for decreasing 
splenomegaly and increasing success of graft transplantation. There is a very small pool of literature 
relating the use of fludarabine in PV and ET treatment. One small study noted its use in post-PV AML 
patients, comparing the use of fludarabine to cytarabine and cytarabine-plus-idarubicin. Results 
indicated all induction chemotherapies had no superiority to palliative care options and stem cell 
transplantation conferred the best survival outcome (Passamonti, et al., 2005).  
 
This report illustrates that fludarabine is able to decrease cell viability to less than 50% over a 72-hour 
period (when used at 10 µM). This finding compliments previous research that shows a decrease in cell 
viability of leukaemic cells with the use of fludarabine treatment (Opydo-Chanek, et al., 2012) (Bellosillo, 
et al., 1999). In these studies, 1 µM fludarabine was able to decrease cell viability to between 60 and 
10% over 48 hours, depending on the cell line treated. No studies to date have investigated the effects 
of a combination of ruxolitinib and fludarabine on the proliferation and viability of MPN cells. In this 
study, the combination of ruxolitinib and fludarabine was able to further decrease the viability of HEL 
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cells from 61% with ruxolitinib alone to 34% and 14% with the combination treatments at both 5 and 10 
µM fludarabine respectively, 72-hours post-treatment. A similar pattern was seen in SET2 cells (1 µM 
RUX: 70%; 1 µM RUX + 5 µM FLU: 59%; 1 µM RUX + 10 µM FLU: 33%).  
 
Proliferation is also negatively affected by a combination of ruxolitinib and fludarabine in both cell lines, 
with the greatest decrease in cellular proliferation seen after 72 hours in the combination group 
containing of 1 µM ruxolitinib and 10 µM fludarabine. MTS assay results show that HEL cell proliferation 
was more negatively affected by 10 µM fludarabine alone than 1 µM ruxolitinib alone, demonstrating 
that fludarabine may have a greater effect on HEL cells and that STAT1 inhibition in this cell line has a 
greater effect on cell survival. A similar pattern was observed when examining the effect of a 
combination of ruxolitinib and fludarabine on the proliferation of SET2 and HEL cells, again with a 
slightly greater decrease in proliferation seen in HEL cells (SET2: 1 µM RUX + 5 µM FLU: 11.9%. 1 µM RUX 
+ 10 µM FLU: 8.0%. HEL: 1 µM RUX + 5 µM FLU: 7.9&. 1 µM RUX + 10 µM FLU: 6.2%). In the HEL growth 
curve, cellular proliferation is most negatively affected by a combination of ruxolitinib and 10 µM 
fludarabine after 72 hours, which correlates with the results of the MTS assay. Growth curve analysis for 
the SET2 cell line could be considered inaccurate due to the large error bars seen in all treatment 
groups. More experimental repeats are required to gain an accurate insight into the proliferative 
capacity of SET2 cells treated with a combination of ruxolitinib and fludarabine.  
 
With respect to both cell proliferation and viability, fludarabine appears to affect HEL cells more than 
SET2 cells, indicating a preference of the combination therapy in the treatment of PV rather than ET. 
Nevertheless, is important to note the large variation between experiments in the SET2 growth curve 
and Trypan Blue viability graphs may distort the experimental results of treating SET2 cells with a 
combination of ruxolitinib and fludarabine.   
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5. Conclusion 
With respect to the hypotheses stated at the beginning of this report, the results show that ruxolitinib 
significantly affected the proliferative rate and viability of both SET2 and HEL cells over 72 hours as 
shown by growth curve analysis, Trypan Blue exclusion assay and MTS assays. Considering these results, 
the expression of a number of downstream JAK2 targets were also shown to be downregulated by 
ruxolitinib treatment in SET2 cells 24 hours post-treatment. The expression of downstream targets 
showed mixed results, with some known downstream targets, such as STAT5 and HSP90 shown to be 
not significantly altered by the presence of ruxolitinib in SET2 cells, whereas STAT1, SOCS3 and HSP70 
are all significantly downregulated in response to ruxolitinib. In this case, the first null hypothesis, 
stating that ruxolitinib will have no effect on proliferation, viability and expression of downstream JAK2 
targets, cannot be rejected completely due to the varying results with respect to expression of 
downstream targets. In addition, the analysis of JAK2/STAT targets was only investigated in SET2 cells 
and a more complete analysis, including examination of target expression in HEL cells, needs to be 
performed for this null hypothesis to be confidently rejected.  
 
The second null hypothesis states that ruxolitinib in combination with IFN-α or fludarabine will have no 
effect on SET2 and HEL cells and changes with respect to cell proliferation and viability will not be 
superior to ruxolitinib treatment alone. This study found that, although ruxolitinib and the combination 
of ruxolitinib and IFN-α did significantly decrease proliferation and viability of SET2 and HEL cells, there 
was no significant difference in the extent to which this decrease was seen. Therefore, there was no 
synergistic effect on decreasing cell proliferation and viability when combining ruxolitinib with IFN-α. 
There is a failure to reject the null hypothesis in the case of ruxolitinib and IFN-α.  
In contrast, there was a significant difference in response of SET2 and HEL cells to ruxolitinib alone 
compared to ruxolitinib combined with 10 µM fludarabine with respect to cell proliferation in both cell 
lines after 72 hours. The same pattern was also seen with respect to cell viability as assessed by Trypan 
Blue assay, suggesting a synergistic effect is seen when ruxolitinib is combined with fludarabine. With 
respect to MTS assay, there was a significant difference in proliferative capacity of both cell lines under 
ruxolitinib treatment alone compared to ruxolitinib in combination with both 5 µM and 10 µM 
fludarabine. Reflecting on the results when combining ruxolitinib with fludarabine, the second null 
hypothesis can be rejected on the basis that a statistically significant difference was observed in both 
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cell lines when comparing both viability and proliferation of cells treated with ruxolitinib alone and in 
combination with fludarabine over a 72-hour period. 
 
The final null hypothesis states that there will be no difference in responses between the two cell lines 
when investigating the effect of ruxolitinib or a combination of ruxolitinib and IFN-α or fludarabine on 
cell proliferation and viability. With respect to the effects of ruxolitinib treatment as a single agent on 
both cell lines, there seems to be no difference in response. Two-way ANOVA shows that both cell lines 
are significantly affected by 1 µM ruxolitinib treatment however the p-value is smaller in SET2 cells 
(p<0.0001) compared to HEL cells (p=0.0135). In contrast, by Trypan Blue assay, HEL cells seem to be 
more sensitive to ruxolitinib as a significant decrease in cell viability is observed at 24 hours in HEL cells 
compared to significance reached at 48 hours in SET2 cells. Considering MTS assay, both cell lines show 
the same decrease in viability at 72 hours post-ruxolitinib treatment. In this case, there is a failure to 
reject the null hypothesis as both cell lines appear to respond in the same way in the presence of 
ruxolitinib alone.  
 
In the case of ruxolitinib combined with IFN-α, two-way ANOVA of growth curve analysis shows HEL cells 
are significantly affected by ruxolitinib alone, IFN-α alone and the combination of the two at 48 and 72 
hours. In contrast, the proliferation of the SET2 cell line is only significantly affected by ruxolitinib and 
the combination treatment after 72 hours. This difference between responses in each cell line could be 
due to the large error bars between biological repeats in the SET2 cell line. With respect to cell viability, 
both cell lines are significantly altered by the treatments, however the p-value for HEL cells is still 
smaller than the p-value for SET2 cells using two-way ANOVA. Since the growth curve analysis and 
Trypan Blue assay were performed on the same biological samples, the samples may still be providing a 
lot of variance as opposed to the treatment being the reasoning behind the differences seen in response 
between both cell lines. With respect to the MTS assay, the proliferation of both cell lines is decreased 
to the same extent, therefore the responses of each disease phenotype are similar and 
indistinguishable. Repeated analysis of SET2 cells for growth curve analysis and Trypan Blue exclusion 
assay should be performed to decrease variability between biological repeats and obtain a more 
accurate result of the effects of ruxolitinib on each cell line. In this case, the null hypothesis cannot be 
confidently rejected due to the presence of large error bars in the SET2 cell line.  
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Observing growth curve analysis of the combination of ruxolitinib and fludarabine, SET2 cell 
proliferation is only significantly affected after 72 hours by ruxolitinib and 10 µM fludarabine. 
Conversely, HEL cells are affected by all treatment conditions after 48 and 72 hours. Trypan blue 
exclusion assay gives a similar pattern in SET2 cells as proliferation by growth curve analysis, with 
viability only being significantly affected after 72 hours and only by a combination of ruxolitinib and 
fludarabine. HEL cells also show a similar pattern to the growth curve analysis, as viability is significantly 
decreased in all treatments at 48 and 72 hours. As with the combination experiments with ruxolitinib 
and IFN-α, the large error bars in the SET2 cell line for growth curve analysis and Trypan Blue exclusion 
assay could explain the difference in response observed between SET2 and HEL cell lines and phenotypic 
differences may not actually be the reason behind the difference in responses. The SET2 growth curve 
and Trypan blue experiments should be repeated to decrease the variability between biological repeats. 
Only then can the potential difference in response of both cell lines to ruxolitinib and fludarabine be 
elucidated. On the contrary, the MTS assay illustrates that HEL cells may be more sensitive to the 
presence of fludarabine than SET2 cells, as fludarabine alone at 5 µM decreases the proliferation of HEL 
cells more than 1 µM ruxolitinib alone, whereas in SET2 cells, treatment with 1 µM ruxolitinib decreases 
the proliferation more than 5 µM fludarabine. Furthermore, fludarabine treatment at 5 and 10 µM in 
HEL cells decreases the proliferation greater than fludarabine treatment in SET2 cells at 5 and 10 µM.   
 
JAK2 inhibition by ruxolitinib has shown great clinical potential for the alleviation of disease-related 
symptoms in Philadelphia-chromosome-negative MPNs and use of JAK2 inhibitors are able to support 
research into disease aetiology, drug discovery and personalized medicine. Ruxolitinib has shown great 
ability to decrease the proliferation and viability of PV and ET-representative cell lines in vitro, with no 
substantial difference in response to JAK2 inhibition between the two diseases. SWATH-MS analysis 
identified several proteins and associated signalling pathways significantly downregulated in response to 
JAK2 inhibition in ET however this work should be extended to include the PV-associated HEL cell line for 
a more comprehensive analysis of JAK2 signalling in each phenotype. Further conformational studies by 
Q-PCR and Western Blot highlighted potential novel therapeutic targets for the treatment of PV and ET. 
Dual treatment of SET2 and HEL cells with IFN-α and ruxolitinib does not seem to have a synergistic 
effect on decreasing cell proliferation and viability in SET2 and HEL cells, however a combination of 
ruxolitinib and 10 µM fludarabine seems to have a greater effect on inhibiting cellular proliferation and 
decreasing cell viability in both cell lines compared to ruxolitinib alone. More experimental repeats may 
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be needed for growth curve analysis and Trypan Blue exclusion assay for the combination experiments 
including both IFN-α and fludarabine, as the biological repeats in this report show great variability in 
results. A more detailed investigation into the expression of proliferative genes and proteins is required 
to gain a more complete insight into whether IFNα or fludarabine therapy is a suitable complimentary 
agent for the treatment of PV and ET. Transcriptional and translational analysis by Q-RT-PCR and 
Western Blots should be performed to continue to investigate the changes in expression of anti-
apoptotic, proliferative and antigen presentation genes in IFN-α- and fludarabine-supplemented 
treatments and results compared to ruxolitinib treatment alone, in hopes to ascertain the most effective 
treatment combination for Ph-MPNs that overcome some of limitations of current treatments.  
 
In conclusion, ruxolitinib at 1 µM concentration has shown great ability in decreasing the proliferation 
and viability of SET2 and HEL cells, representative of ET and PV, two hyperproliferative 
myeloproliferative neoplasms.  Downstream targets of JAK2 are significantly affected by the presence of 
1 µM ruxolitinib in SET2 cells but further investigation is needed into the effect of ruxolitinib on 
downstream targets in HEL cells to distinguish different biological mechanisms involved in each disease 
phenotype. In addition, the combination of ruxolitinib and IFN-α does not seem to have a synergistic 
effect on decreasing cell viability or proliferation however, the combination of ruxolitinib and 
fludarabine has potential to be a synergistic combination of treatments, as demonstrated by their ability 
to further decrease the proliferation and viability of SET2 and HEL cells over 72 hours compared to 
ruxolitinib alone. Further exploration into the exact mechanisms underlying the pathogenesis of PV and 
ET could be facilitated by more experiments investigating the effects of ruxolitinib and fludarabine on 
mRNA and protein expression of downstream JAK2 targets, and on cell viability and proliferation in 
these cell lines.  
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